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Abstract 
Enteroendocrine hormones released from the intestine following food intake have several roles in the 
control of metabolism, some of which are exploited therapeutically for the treatment of type 2 
diabetes. Within this thesis, focus has been on the receptors of the gut hormones glucagon-like 
peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-2 
(GLP-2).  
In recent years there has been a surge of interest in the enteroendocrine hormones particularly due 
to the success of GLP-1 mimetics in the treatment of type 2 diabetes. GLP-1 is an incretin hormone, 
which enhances glucose induced insulin secretion by binding GLP-1 receptors (GLP1R) on pancreatic 
β-cells. Despite the therapeutic success, several extra-pancreatic clinical effects of GLP-1 remain 
unexplained. Here, a GLP1R monoclonal antagonistic antibody that can block GLP1R signalling in vivo 
has been developed and characterised, providing a new tool for the study of GLP1R physiology. 
GIP is the second incretin hormone, initially referred to as the ‘ugly duckling’ incretin hormone due to 
it’s ineffectiveness in inducing insulin secretion in type 2 diabetic patients. Aside from the incretin 
actions, GIP is thought to be involved in the regulation of high-fat diet (HFD) induced obesity. A new 
transgenic mouse model expressing a fluorescent reporter under the control of the Gipr promoter has 
been used here to identify GIPR expressing cells. This model showed GIPR expression in the pancreas, 
adipose tissue, duodenum and nodose ganglia. Surprisingly GIPR expressing cells were found centrally, 
in areas of the hypothalamus involved in the regulation of food intake and energy expenditure. We 
consequently sought to investigate the function of GIPR expressing hypothalamic cells. 
GLP-2, unlike GLP-1 and GIP, is not an incretin hormone. Rather, GLP-2 has been implicated in the 
regulation of epithelial cell proliferation and apoptosis within the intestine. Therapeutically, an 
analogue of GLP-2 is used for the treatment of short bowel syndrome. A common missense mutation 
in the GLP-2 receptor (GLP2R), D470N, has been found to be associated with type 2 diabetes, and here 
we sought to understand the mechanism underlying this association. The D470N mutant has 
decreased β-arrestin recruitment, though the significance of this finding will need further research. 
Overall; the new monoclonal antagonistic GLP1R antibody will help to further understand GLP1R 
physiology, the new transgenic GIPR mouse model has contributed to the understanding of GIPR 
localisation, and cell based assays have identified functional implications of a polymorphism in the 
GLP2R associated with an increased risk of diabetes. It is hoped that further understanding of the 
physiology of these gut hormone receptors will be critical in the development of new therapeutics for 
diabetes and obesity.   
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Chapter 1. Introduction 
1.1 Metabolic Physiology 
Metabolism is defined as the chemical reactions which occur within cells of all living organisms 
essential for maintaining normal function. In this section, the metabolic physiology of key organs 
involved in nutrient digestion and energy storage have been described separately, however it is 
important to point out that metabolic physiology is an integrated whole-body process.  
1.1.1 Physiology of the Gastrointestinal Tract 
When considering nutrient metabolism following food intake, the gastrointestinal tract is the first 
organ which nutrients reach. The acidic environment of the stomach, together with the presence of 
digestive enzymes such as gastric lipases and pepsin lead to initial digestion of food into the composite 
nutrients, which is aided by trituration driven by circular contractions of the gastric antrum. The rate 
at which these nutrients are absorbed is then determined by a range of factors which govern the 
nutrient delivery rate to the proximal small intestine via gastric emptying [1]. The process of gastric 
emptying is highly regulated, with the caloric delivery rate to the duodenum remaining almost 
constant at ~200 kcal/hour [2]. However, it appears that this rate is not affected by the macronutrient 
composition of food [2-4]. The vagus nerve is important for controlling the rate of gastric emptying; 
with bilateral truncal vagotomy (surgical resection of the vagus nerve) causing delayed gastric 
emptying [5], and vagus nerve stimulation promoting gastric emptying [6]. Blood glucose 
concentrations also have a small effect on the regulation of gastric emptying, with hyperglycaemia 
delaying gastric emptying, and hypoglycaemia accelerating gastric emptying [1].      
Following gastric emptying, once nutrients reach the small intestine they can begin to be absorbed as 
they traverse the intestine. Additionally, these nutrients stimulate gut hormone secretion which is a 
function of particular interest. These gut hormones have a range of downstream actions, including the 
regulation of glucose homeostasis and gastric emptying. Research within this thesis has focused upon 
a handful of these gut hormones, and as such the enteroendocrine system will be detailed in more 
depth in Section 1.2.   
1.1.2 Physiology of the gut-brain axis  
The gastrointestinal tract alone is not solely responsible for regulating appetite, rather signals sent 
from the gastrointestinal tract to the brain via the vagus nerve are important for appetite regulation. 
There are two main regions within the brain that are involved in the control of food intake and energy 
expenditure; the brainstem and the hypothalamus [7].  
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The vagus nerve predominantly terminates in the thoracic and abdominal cavities, with the 
gastrointestinal tract being of particular interest when considering metabolic physiology. Within the 
gastrointestinal tract, the vagus nerve terminals are found in three distinct locations; the external 
muscle layers, the myenteric plexus, and the mucosal lamina propria. The neuronal cell bodies are 
located within the nodose ganglia, and the central neuronal projections innervate the nucleus of the 
solitary tract (NTS) [8].  
The NTS within the caudal brainstem, is essential for co-ordinating peripheral and central appetite 
regulation signals. Projections from the hypothalamus extend to this region and vice versa, meaning 
neuronal signals can be transmitted from the NTS to the hypothalamus, the second main brain region 
involved in appetite regulation [9]. The area postrema (AP) is located within the caudal brainstem, 
which is a circumventricular organ, meaning peripheral factors can also cross the blood-brain barrier 
here, and signal within the NTS [10]. The main function of the brainstem in appetite regulation appears 
to be negative-feedback control of ingestion [11].  
Within the hypothalamus, the arcuate nucleus (Arc) is particularly important for regulating appetite 
[12]. This nucleus of cells is located directly next to the median eminence, which is a circumventricular 
organ with a highly fenestrated capillary network, providing an incomplete blood-brain barrier [13, 
14]. Consequently, this means that peripheral factors, such as circulating gut hormones, have access 
to this area of the central nervous system. Within the Arc there are two main populations of neurons 
which are involved in appetite regulation; the agouti-related peptide (AgRP) neurons and the pro-
opiomelanocortin (POMC) neurons. Activation of the AgRP neurons leads to an orexigenic response 
(the stimulation of appetite), whereas activation of the POMC neurons gives an anorexigenic response 
(inhibition of food intake/loss of appetite) [15]. These neuronal populations do not act independently, 
rather the neurons project and signal to other hypothalamic nuclei including the paraventricular 
nucleus, dorsomedial nucleus, lateral hypothalamus and ventromedial nucleus [16, 17].  
1.1.3 Pancreatic Physiology 
Aside from the gastrointestinal tract, pancreas function is also important to consider in metabolic 
physiology, with roles in digestion and glucose homeostasis. The pancreas can be divided into two 
physiological components; the exocrine and the endocrine pancreas. The acinar tissue, which makes 
up the majority of the pancreas, is exocrine in nature and responsible for secreting digestive enzymes 
such as amylase and pancreatic lipase into pancreatic ducts [18].  
The endocrine cells are located in clusters, named the islets of Langerhans. These cells respond to a 
range of signals and regulate the release of pancreatic hormones [19, 20]. There are at least five 
different endocrine cell types within the pancreas: α-cells which secrete glucagon [21], β-cells which 
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secrete insulin [22], δ-cells which secrete somatostatin [23], γ-cells which secrete pancreatic 
polypeptide [24], and ε-cells which are a small population of cells which secrete ghrelin [25]. Together, 
these hormones are responsible for the regulation of glucose homeostasis. Glucagon increases blood 
glucose, insulin decreases blood glucose, somatostatin inhibits the secretion of both glucagon and 
insulin, with pancreatic polypeptide also regulating hormone secretion [20].  
The β-cells make up the highest proportion of endocrine cells within the islets of Langerhans. β-cells 
secrete insulin in response to glucose via a canonical glucose sensing mechanism. GLUT transporters 
on the surface of pancreatic β-cells are responsible for glucose uptake into the cell. Upon entering the 
cell glucose is phosphorylated by glucokinase, a hexokinase which controls the flux of glucose in 
glycolysis [26]. The metabolism of glucose leads to increased ATP, together with decreased ADP, giving 
an overall increased ATP:MgADP ratio. This increased ATP:MgADP ratio closes the KATP channels on 
the β-cell membrane, leading to membrane depolarisation. Consequently, voltage-gated calcium 
channels are opened, and the resultant increased calcium influx stimulates exocytosis of insulin-
containing vesicles [27, 28]. Following secretion, insulin increases glucose absorbance from the 
bloodstream into insulin-sensitive tissues, such as muscle and fat, via increasing translocation of the 
glucose transporter GLUT4 onto the plasma membrane of these cells [29].  
1.1.4 Physiology of Adipose Tissue 
For a more complete understanding of metabolic physiology, one must also consider the storage of 
nutrients following digestion. Adipose tissue is a depot for storage of lipids, which is split into 3 
subsets: white, brown and beige adipose tissue.  
White adipose tissue is the main tissue in which lipids are stored as triacylglycerols (TAG), in unilocular 
adipocytes [30]. Two processes are involved in controlling the amount of TAG stored in the white 
adipocytes; lipogenesis which is the synthesis and storage of TAG, and lipolysis which is the hydrolysis 
of TAG using enzymes such as lipoprotein lipase (LPL) [31, 32]. When food is scarce, or there is a high 
energy demand, lipolysis is increased to provide fatty acids and glycerol as alternative energy 
substrates. On the other hand, when food intake outweighs energy demand, lipogenesis leads to 
increased storage of lipids in adipocytes, increasing adiposity [30]. 
In contrast to white adipose tissue, brown adipose tissue contains brown adipocytes which are 
multilocular, and dissipate the energy in lipids as heat in non-shivering thermogenesis [33, 34]. The 
process underlying this non-shivering thermogenesis is uncoupled respiration, which is mediated by 
uncoupling protein 1 (UCP1) expressed specifically within brown adipose tissue. This results in 
increased fatty acid oxidation and heat production [33, 35, 36].   
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The white adipose depots and brown adipose depots are normally located in distinct regions. 
However, ‘beige adipose tissue’ is the presence of brown adipocytes within white adipose tissue 
depots [36]. One stimulus of this ‘beiging’ process is prolonged cold exposure [37-39]. The ‘beige’ 
adipocytes have variable characteristics dependent upon the stimulus and are able to adopt either 
white or brown adipocyte functions [36].  
1.2 The Enteroendocrine System 
The enteroendocrine system responsible for secretion of gut hormones is essential for maintaining 
metabolic physiology. The gut has been described as ‘the largest endocrine organ in the body’ [40], 
hence research into this enteroendocrine system is vital for understanding the control of metabolism. 
1902 marked the discovery of the first gut hormone, secretin, a chemical substance released from the 
duodenum in acidic conditions causing pancreatic exocrine secretions [41]. Closely following this, it 
was hypothesised that chemical substances or ‘hormones’ in the gut can regulate endocrine secretions 
from the pancreas, and could be used to treat patients with diabetes [42]. These hormones were later 
described as incretins, however their function wasn’t defined until 1964 when two groups showed 
oral glucose elevates insulin secretion substantially more than an equivalent dose of intravenous 
glucose [43, 44]. This effect has been coined the ‘incretin effect’ and can be explained by the secretion 
of incretin hormones following nutrient ingestion, which enhance glucose stimulated insulin secretion 
from pancreatic beta cells.  
Two incretin hormones have been described; glucagon-like peptide 1 (GLP-1) and glucose-dependent 
insulinotropic peptide (GIP) [45, 46]. Since their discovery, interest in this field has increased due to 
the therapeutic relevance of targeting incretin hormones for treatment of type 2 diabetes. 
Analogues/mimetics of GLP-1 are now used for the treatment of type 2 diabetes, and new drugs are 
being designed which target both incretin hormones simultaneously [47, 48].  
Aside from incretin hormones, there are a plethora of different enteroendocrine hormones produced 
and secreted from specialised enteroendocrine cells in the gut [49] (Figure 1.1). These 
enteroendocrine hormones have a wide range of roles involved in regulation of metabolism. For 
example; somatostatin (Sst) is secreted from D-cells in the stomach and intestine, where it functions 
to inhibit gastric acid secretion, gastric emptying and intestinal motility [50, 51]. Enteroendocrine L-
cells secrete both glucagon-like peptides (GLP-1 and GLP-2), peptide-YY (PYY), and insulin-like peptide 
5 (Insl5), each of which has differing roles in the regulation of metabolism [52]. GLP-1 and GLP-2 wil 
be described in detail in further sections, PYY is thought to inhibit food intake and insulin secretion 
[53, 54]. Insl5 is a relatively newly defined gut hormone, in contrast to GLP-1 and PYY, production of 
Insl5 is increased by calorie restriction and the peptide has orexigenic effects [55]. I-cells primarily 
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secrete cholecystokinin (CCK) which reduces appetite and slows gastric emptying [56-58]. K-cells 
secrete the incretin hormone GIP, to be described in detail in a later section. Enterochromaffin (EC) 
cells secrete serotonin (5-HT), a multifunctional bioamine which is involved in peristalsis, nausea and 
possibly the regulation of metabolism [59-62]. These metabolic effects include, regulation of glucose 
homeostasis, hepatic gluconeogenesis, mobilisation of hepatic free fatty acids, and browning of white 
adipose tissue [63]. Other gut hormones include motilin which is secreted from D1 cells and regulates 
interdigestive migrating contractions which are the fasted motor pattern in the gastrointestinal tract 
[64], and secretin which is secreted from S cells and stimulates secretions from the exocrine pancreas 
[65]. Initially this classification of hormones and cell-types was thought to be strictly defined, however 
recent research has indicated there is more hormonal overlap than that originally described [66, 67]. 
Within this thesis, research has been performed on the GLP-1 receptor (GLP1R), GIP receptor (GIPR), 
and GLP-2 receptor (GLP2R), consequently the comprehensive literature review will focus on GLP-1, 
GIP and GLP-2. 
 
Figure 1.1 Schematic representation of enteroendocrine hormone distribution and cell-type. 
Enteroendocrine hormones are secreted from specialised cell-types, with varying densities along 
the intestine as indicated. Figure was adapted by F. Reimann, based on an immunohistochemical 
study by Sjolund et al. (1983)[68] and updated to include Insl5 using data from Grosse et al. 
(2014)[55]. 
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1.3 Physiology of Glucagon-like peptide 1 (GLP-1) 
1.3.1 Production of GLP-1 
GLP-1 is derived from the proglucagon gene, expressed in small intestinal and colonic enteroendocrine 
L-cells, pancreatic α-cells and specific subsets of neurons within the brainstem [69]. Transcription of 
proglucagon is activated by the transcription factor Pax6 in rodent intestinal endocrine cells [70]. In 
human intestinal cells, this transcription is regulated by factors including β-catenin and transcription 
factor-4 (TCF-4) [71].  
Following transcription and translation of the proglucagon gene, the proglucagon product is cleaved 
by prohormone convertases (PC) to yield a number of peptides. In pancreatic α-cells PC2 is expressed, 
leading to the cleavage of proglucagon into glucagon, glicentin related pancreatic polypeptide (GRPP), 
and the larger major proglucagon fragment [72]. In contrast, the intestinal L-cells and proglucagon 
expressing cells in the central nervous system (CNS) express PC1/3, leading to differential processing 
of proglucagon. PC1/3 cleavage of proglucagon leads to the production of GLP-1, GLP-2, glicentin and 
oxyntomodulin (Figure 1.2) [73].   
Biologically active GLP-1 exists in two isoforms, GLP-17-36 amide and GLP-17-37, with the main circulating 
form in humans being GLP-17-36 amide [74, 75]. The circulating levels of biologically active GLP-1 are only 
within the picomolar range, due to rapid degradation by dipeptidyl peptidase 4 (DPP-4) giving GLP-1 
an extremely short half-life of 1-2 minutes, together with rapid clearance of both DPP-4 cleaved and 
full-length GLP-1 [76-78].  
DPP-4 cleaves the agonistic GLP-17-36 amide to GLP-19-36 amide which is often thought to be inactive. 
However, GLP-19-36 amide binding to the GLP1R has been observed, with a much lower binding affinity 
than GLP-17-36 amide [79]. In addition to this, some studies suggest that GLP-19-36 amide has antagonistic, 
inhibitory properties, inhibiting hepatic glucose production in obese mice [80]. 
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Figure 1.2 Differential processing of proglucagon. Prohormone convertase (PC) isoforms PC1/3 
and PC2 differentially cleave proglucagon in the intestinal L-cells/CNS and pancreatic α-cells 
respectively. Figure based upon Holst (2007) review [73].  
 
1.3.2 Regulation of GLP-1 secretion 
GLP-1 is secreted from enteroendocrine L-cells distributed along the epithelial layer of the intestine, 
increasing in density towards the ileum and colon [73].  These enteroendocrine cells are often ‘open-
type’, with microvilli covered apical surfaces, and the base residing on the basal lamina. Following 
consumption of a meal, the enteroendocrine L-cells ‘sense’ nutrients which stimulate secretion of GLP-
1. A wide-range of nutrients and metabolites lead to the secretion of GLP-1, including derivatives from 
carbohydrates, protein and fat in the forms of glucose, amino acids, bile acids, fatty acids and 
monoacylglycerols [81]. Briefly, the underlying molecular mechanism for secretion relies either upon 
stimulation of membrane depolarisation, increased concentrations of cyclic adenosine 
monophosphate (cAMP), or increased concentrations of intracellular Ca2+ (Figure 1.3).  
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Figure 1.3 Overview of nutrient sensing for GLP-1 secretion. A wide-range of nutrients and 
metabolites stimulate GLP-1 secretion through a variety of mechanisms. A selection of 
transporters, channels and GPCRs involved in ‘sensing’ these metabolites are depicted [81]. 
Abbreviations: sodium-dependent glucose transporter 1 (SGLT1), proton-coupled peptide 
transporter (PEPT1), free fatty acid receptors 1 and 3 (FFAR1, FFAR3), G-protein-coupled bile acid 
receptor 1 (GPBAR1), phospholipase C (PLC), phosphatidylinositol-4,5-bisphosphate (PIP2), 
inositol-1,4,5-triphosphate (IP3), diacylglycerol (DAG), protein kinase C (PKC), exchange protein 
directly activated by cAMP (Epac) and protein kinase A (PKA).   
 
1.3.3 GLP-1 Receptor (GLP1R) Structure and Signalling 
Following secretion of GLP-1, the biologically active circulating form binds to and activates the GLP1R 
located in a number of distinct cell-types throughout the body. When considering the mechanism of 
how GLP-1 binds to and activates the GLP1R, the structure of GLP1R has revealed where GLP-1 binds. 
The GLP1R is a G protein coupled receptor (GPCR) with a large N terminal extracellular domain, in the 
‘Class B’ or ‘secretin’ family of GPCRs [82]. Up until recently, only the X-ray crystal structure of the 
extracellular domain (ECD) was available, showing the ECD is responsible for binding the C-terminal 
part of GLP-1 [83, 84]. Now, X-ray crystal structures and structures derived from cryo-electron 
microscopy are available for the full GLP1R in complex with agonist peptides or Gαs proteins [85-87]. 
Overall, this structural data has revealed that the seven transmembrane domains of the GLP1R are 
arranged in a similar manner to that of other ‘Class B’ GPCR’s, with a V-shaped central cavity. In 
contrast to the structure of the glucagon receptor, no helical stalk is found linking the transmembrane 
domains to the ECD, rather the extracellular loop 1 (ECL1) and second transmembrane domain (TM2) 
extend well beyond the membrane plane, and contact the ECD [85]. Despite this, evidence suggests 
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that the ECD is flexible in the absence of ligand, aiding the initial binding of the ECD to GLP-1 [88]. 
Aside from ECL1 which has a short helix-turn-helix secondary structure, all other connecting loops lack 
a secondary structure and are flexible in their nature. From the X-ray crystallography structural data, 
a simulation model of the molecular dynamics of GLP-1 binding has been made [86]. This is in line with 
what was previously known regarding the 2-domain binding mechanism, and matches the mechanistic 
proposals of GLP1R activation made from cryo-electron microscopy [87]. Briefly, agonist binding 
appears to cause a conformational change within helix V and VI of the GLP1R transmembrane domain, 
which then disrupts an intracellular ionic lock, opening a cavity for G-protein interactions [86, 87].   
The GLP1R signals primarily via Gαs coupling leading to increased cAMP [89]. Downstream of cAMP, 
protein kinase A (PKA) is activated along with ‘exchange protein directly activated by cAMP’ (Epac). 
PKA and Epac have several downstream effects in the cell [90]. Both signalling proteins increase the 
ATP sensitivity of ATP sensitive potassium channels (KATP) leading to membrane depolarisation and 
Ca2+ influx. In pancreatic β-cells, this triggers insulin granule exocytosis. PKA and Epac also alter the 
dynamics of proteins that regulate insulin secretion, and in part increase insulin gene expression. 
Overall, this results in increased glucose stimulated insulin secretion (GSIS) from the pancreatic β-cells 
[91]. Aside from the main Gαs coupled signalling pathway, there are also indications that GLP1R may 
signal via Gαq and β-arrestin (described further in chapter 3).  
1.3.4 GLP1R Localisation 
The GLP1R is not solely located within pancreatic islets; expression is much more widespread. Studies 
using antibodies to determine GLP1R localisation have been limited due to the lack of antibodies that 
specifically detect GLP1R [92].  
Use of a transgenic mouse model, expressing Cre downstream of the glp1r promoter and crossed with 
fluorescent reporters, has enabled detailed characterisation of GLP1R localisation, without the use of 
GLP1R antibodies with limited specificity. This glp1r-Cre mouse model revealed GLP1R expression in 
the pancreatic β- and δ-cells, vascular smooth muscle, cardiac atrium, gastric antrum/pylorus, enteric 
neurons and vagal/dorsal root ganglia [93]. A subsequent study has also used this model to reveal 
GLP1R expression in a number of distinct areas in the central nervous system [94], which has since 
been confirmed using in situ hybridisation with a newly generated GLP1R antibody specific for mouse 
tissue [95].  
1.3.5 Actions of GLP-1  
The widespread localisation of the GLP1R results in GLP-1 having a wide range of actions.  As described 
earlier, the main role of GLP-1 exploited therapeutically is the ability to enhance glucose stimulated 
insulin secretion, known as the ‘incretin effect’. This effect is clearly mediated by GLP1R in the 
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pancreas, however functions of GLP-1 mediated by extra-pancreatic GLP1R are also important in the 
regulation of metabolism (Figure 1.4). 
 
 
Figure 1.4 Schematic representation of GLP-1 functions. Aside from the well-known incretin 
actions of GLP-1 on insulin secretion, GLP-1 also exerts a wide-range of other functions depicted 
above. Figure is based on review from Meier (2012)[47]. Images downloaded from Servier Medical 
Art. 
 
1.3.5.1 Actions of GLP-1 in the pancreas 
Aside from GLP1R in pancreatic β-cells mediating insulin secretion, GLP-1 also increases β-cell 
proliferation possibly involving the epidermal growth factor receptor [96] and decreases β-cell 
apoptosis, in part due to protein kinase C (PKC) activation [97, 98]. Together, this results in GLP-1 
increasing total β-cell mass, leading to further increased insulin secretion. Additionally, GLP-1 has been 
shown to effect the biosynthesis of insulin; increasing insulin gene transcription, and enhancing insulin 
mRNA stability via interactions with pancreatic duodenal homeobox 1 (Pdx1) transcription factor [89, 
99].  
In the pancreatic α-cells GLP-1 inhibits glucagon secretion, therefore regulating glucose control via 
two complementary mechanisms. Whether this inhibition is a direct or indirect effect is unknown. As 
GLP1R is found in a subset of α-cells this indicates the possibility of a direct GLP-1 effect [93], which 
↓ Gastric Emptying 
GLP-1 
↓ Appetite 
↑ Neuroprotection 
↑ Natriuresis 
↑ Cardiac Function  
↑ Cardioprotection 
  
↑ Insulin synthesis and secretion  
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has been demonstrated by GLP-1 inhibition of voltage gated Ca2+ channels in α-cells [100]. On the 
other hand, GLP-1 stimulation of somatostatin secretion from δ-cells has been observed, which would 
have an indirect effect on the inhibition of glucagon secretion [101].   
1.3.5.2 Extra-pancreatic actions of GLP-1 
Locally, following GLP-1 secretion from the enteroendocrine L-cells, GLP-1 reduces gastric emptying 
[102]. This has been observed in both humans and rodents, the slowing or reduction of gastric 
emptying means decreased nutrient absorption in the intestine, and consequently decreased post-
prandial glucose excursions [102, 103]. This regulation of gastrointestinal motility by GLP-1 is thought 
to be mediated by GLP1R expressing vagal afferents, as both the denervation of vagal afferents in rats, 
and truncal vagotomy in humans abolishes the GLP-1 induced effects [103, 104]. Other local effects of 
GLP-1 include decreasing gut motility [105] and decreasing gastric acid secretion [106].   
GLP-1 has several effects in extra-pancreatic tissue, not limited to the location of GLP-1 secretion. For 
example, renal effects of GLP-1 include increased natriuresis and diuresis [107], along with increased 
glomerular filtration rate [108]. Although the mechanism of these renal effects are not fully 
characterised, direct mechanisms involving the inhibition of sodium-hydrogen exchanger isoform 3 
(NHE3) have been proposed [109-111].  On the other hand, there are also suggestions that the renal 
effects are indirect effects of GLP-1 influencing feeding and drinking behaviour [112]. GLP-1 regulation 
of food intake is thought to be mediated by central GLP1R, and will be described in section 1.2.5.3. 
GLP-1 also has a range of actions in the cardiovascular system which were brought to light in the use 
of GLP-1 mimetics for the treatment of type 2 diabetic patients. To name a few physiological effects; 
GLP-1 modulates heart rate and blood pressure, and protects the heart from ischemia and reperfusion 
injury. With regards to clinical studies using GLP-1 mimetics, the cardiovascular beneficial effects 
appear to differ dependent on the agonist used [113-115]. As GLP-1 mimetics are now widely used for 
the treatment of type 2 diabetes, the long-term effects of GLP-1 mimetics on cardiovascular 
parameters will be critical to define any additional beneficial cardiovascular effects. 
The exact location of GLP1R in the cardiovascular system remains uncertain. The glp1r-cre reporter 
mice found GLP1R in the aorta, arteries, arterioles and atrium myocardium however not in the 
ventricular myocardium [93]. Within the primate heart, GLP1R is detected within myocytes in the 
sinoatrial node, and smooth muscle cells or arteries and arterioles [116]. Most recently, analysis of 
human cardiovascular tissue has detected GLP1R mRNA in the heart, however the exact location 
within the heart remains to be determined by immunostaining [117].  
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The molecular mechanisms of GLP-1 induced cardiovascular effects remain fairly unclear, with debate 
surrounding whether the effects are direct or indirect. Regarding possible direct mechanisms, there 
are several studies that suggest effects are mediated directly via GLP1R mediated signalling in the 
affected tissue. For example, experiments with cardiomyocytes demonstrated Epac2 translocation to 
the cell membrane, and downstream secretion of vasodilatory atrial natriuretic peptide in response 
to a GLP1R agonist [118]. Further supporting evidence for a direct GLP1R mediated effect, is that 
GLP1R knock-out mice have altered cardiovascular properties compared to wild-type mice [119]. On 
the other hand, GLP-1 administration to GLP1R knock-out mice still exerts many of its cardiovascular 
effects [120]. There are also a number of studies which show the ‘inactive’ form of GLP-1, GLP-19-36 
amide has similar cardiovascular effects to the biologically active form GLP-17-36 amide [120-122]. Together, 
this supports the theory that GLP-1 exerts its cardiovascular actions independently of the GLP1R. A 
further proposal is that GLP-1 indirectly causes changes in cardiovascular parameters via the 
autonomic nervous system. Supporting evidence for this hypothesis is that intracerebroventricular 
administration of GLP-1 alters heart rate and blood pressure in rodents, which is blocked by 
antagonism of central cholinergic receptors [123]. Additionally, ex vivo studies using isolated perfused 
mouse hearts show GLP1R agonists cannot induce the chronotropic effects showing these effects 
require the neural inputs [124]. Most likely, both direct and indirect effects mediate the GLP-1 induced 
effects on cardiovascular parameters, however more research is required to clearly define the 
molecular mechanism.  
1.3.5.3 Centrally mediated actions of GLP-1 
Aside from the peripheral extra-pancreatic actions of GLP-1, GLP-1 also controls appetite partly via 
centrally expressed GLP1R in the hypothalamus. Early studies showed that intracerebroventricular 
injection of GLP-1 reduced acute food and water intake in fasted rats in a dose-dependent fashion 
[107, 125]. Central injection of the small molecule GLP1R antagonist, exendin 9-39, prevented this 
GLP-1 mediated inhibition, thus showing central GLP1R is involved in the GLP-1 control of appetite 
[125]. Daily central administration of GLP-1 to rats even reduces body weight alongside food intake, 
suggesting GLP-1 may play a physiological role in regulating body weight [126]. This activity makes 
GLP-1 mimetics particularly attractive for treatment of type 2 diabetes, which often occurs in 
overweight patients.   
GLP1R activating therapeutic peptides, such as liraglutide, are also able to control appetite alongside 
glucose levels, even when given peripherally. Whether centrally expressed GLP1R is necessary or 
sufficient for these anorectic effects of GLP1R agonists has recently been investigated. A number of 
studies, including the early intracerebroventricular GLP-1 injection experiments show that central 
GLP1R is sufficient for GLP-1 mediated effects on appetite control [107, 125]. Indeed, subsets of 
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neurons such as the paraventricular nucleus of the hypothalamus, nucleus of the solitary tract, and 
central amygdala are activated following peripheral injection of GLP1R agonists [125, 127]. Knock-out 
of central GLP1R using nestin-Cre reduced the effects of liraglutide on food intake both acutely and 
chronically, showing these effects are mediated primarily via the central nervous system [128]. Other 
studies, using fluorescently labelled liraglutide have shown that it is specifically neurons within the 
arcuate nucleus (ARC) which are involved in centrally regulating liraglutide effects on appetite. In 
particular, neurons expressing the proopiomelanocortin (POMC) peptide and cocaine- and 
amphetamine-regulated transcript (CART) were stimulated by liraglutide, which have an impact on 
inhibiting food intake [129]. These studies suggest that GLP1R agonists require hypothalamic GLP1R 
for the appetite regulating effects, however experiments using hypothalamic specific knock-out and 
knock-down mouse models suggest the hypothalamic GLP1R is in fact not required for appetite 
regulation. Both GLP1R agonists, exendin-4 and liraglutide, retain anorectic actions in hypothalamic 
GLP1R knock-down mice, paraventricular nucleus GLP1R knock-out mice, and POMC specific GLP1R 
knock-out mice [130]. If the central GLP1R is not necessary for GLP1R agonist effects on regulating 
appetite, one would suggest these effects are mediated either via alternative GLP1R neurons in other 
locations such as the area postrema, or the GLP1R on vagal afferents which can transmit signals 
centrally via the nodose ganglia terminating in the nucleus of the solitary tract[131, 132].  
1.4 Physiology of Glucose-dependent insulinotropic peptide (GIP) 
1.4.1 Production of GIP 
GIP is encoded by the ProGIP gene, comprising 6 exons, with exon 3 encoding the majority of the 
active GIP sequence [133]. Unlike GLP-1, GIP-expressing cells are the enteroendocrine K-cells 
predominantly found in the proximal small intestine, with expression also found in the submandibular 
salivary gland of rats [134, 135]. The factors which regulate transcription of GIP have not been defined, 
however binding sites exist for several transcription factors [136, 137]. Translation produces the 
proGIP prohormone precursor, which is subsequently cleaved at single arginine residues by PC1/3 to 
yield the incretin hormone, GIP [138]. The other peptides encoded by the proGIP precursor seem to 
have no known function.  
Similar to GLP-1, GIP is inactivated by DPP-4 mediated cleavage at position 2 [139, 140]. This means 
GIP also has a short half-life, of 7 minutes in healthy human subjects, and the maximal circulating 
levels are in the range of 100 picomolar following meal consumption [141, 142]. Although this half-life 
is short, it is not equivalent to the GLP-1 half-life, and there are suggestions that GIP is less susceptible 
to DPP-4 cleavage in vivo when compared to GLP-1 [139, 140].  
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1.4.2 Regulation of GIP secretion 
GIP is secreted from enteroendocrine K cells lining the intestinal wall, with increased density at the 
proximal end of the intestine in the duodenum and jejunum. This secretion is nutrient-dependent, 
primarily driven by the ingestion of dietary fat and carbohydrates [143-145]. The cellular structure of 
K-cells is similar to that of L-cells, with the apical surface being covered in microvilli at the luminal wall, 
meaning K-cells can directly sense the presence of nutrients. When considering the molecular 
mechanism responsible for this sensing, it is thought that the sodium-dependent sugar uptake 
pathway is involved in detection of luminal carbohydrates [146, 147], and free fatty-acid receptors are 
involved in the detection of fat in the form of fatty acids [147, 148].  
1.4.3 GIP receptor (GIPR) Structure and Signalling 
GIP binds to and activates the GIPR on a number of cell-types throughout the body. The GIPR, like the 
GLP1R is a member of the ‘Class B’ family of GPCRs [82], with a large extracellular N terminal domain, 
a core domain consisting of seven transmembrane helices, and an intracellular C terminal tail which 
interacts with associated G proteins [149-151]. Although the complete structure of the GIPR is not yet 
available, a crystal structure of the N terminal ECD responsible for binding GIP has been produced. 
This structure indicates that GIP binds to the N terminal ECD within a surface groove using mainly 
hydrophobic interactions, with the N terminal residues of GIP being free from interactions [152]. This 
suggests that GIP interacts both with the ECD, and the core domain which fits with the proposed 2-
step mechanism for ‘Class B’ GPCR activation. Briefly, within this mechanism of activation the ligand 
first binds the N terminal domain of the receptor locking the ligand in place, and bringing it into contact 
with the core transmembrane domain of the receptor for a second interaction, resulting in a 
conformational change of the receptor which causes activation [153]. 
As with the GLP1R, and other members of the ‘Class B’ GPCR family, the GIPR signals primarily via the 
Gαs  coupled protein which causes accumulation of cAMP, and downstream activation of PKA and Epac 
[154, 155]. Molecularly, in the pancreatic β-cell, these signalling molecules lead to a variety of 
downstream effects such as closure of KATP channels, opening of voltage-dependent calcium channels 
(VDCC) leading to Ca2+ influx, and possible direct actions on granule movement and exocytosis [155]. 
In comparison to GLP-1, the GIP effects on insulin secretion appear to be more dependent upon KATP 
channel closure [156]. A further comparison using transfected cell lines has suggested that the GIPR 
has a higher basal activity than the GLP1R, which may be because unlike the GLP1R, the GIPR shows 
decreased β-arrestin 2 binding which could be extrapolated to the other β-arrestins which regulate 
receptor desensitisation [157].  
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GIP activation of the GIPR also leads to signalling via alternative downstream pathways. For example, 
extracellular signal-regulated kinase (ERK) phosphorylation is stimulated in a PKA-dependent manner 
[158]. Downstream of this, it has been observed that GIP promotes expression of transcription factor-
7 (Tcf7) gene in pancreatic β-cells, which is thought to be important for the cytoprotective effects of 
GIP [159]. Additionally, GIP mediates anti-apoptotic signalling, reducing the effects of B-cell 
lymphoma-2 (Bcl-2) family members on pancreatic β-cell apoptosis [160].  
1.4.4 GIPR Localisation 
Similar to the GLP1R, when considering GIPR localisation, it is not limited to pancreatic β-cells where 
GIP exerts its insulinotropic actions. Rather GIPR localisation is more widespread; early in situ 
hybridisation studies showed that the GIPR is also found in adipose tissue, the heart, gut, pituitary 
glands, and inner layers of the adrenal cortex [149]. There are also indications that the GIPR is found 
in the central nervous system in addition to these peripheral organs [149, 161]. However, the data 
from these studies has limited resolution. Very little further work has been completed in the study of 
GIPR localisation due to a lack of antibodies verified for use in immunostaining [162-164].  
1.4.5 Actions of GIP  
The main described actions of GIP, of interest therapeutically, are its ability to stimulate insulin 
secretion from pancreatic β-cells in the presence of glucose, and to increase nutrient storage and 
therefore lipogenesis in adipose tissue. These actions will be described in detail below. Other functions 
also include a role in bone formation [165], inhibition of gastric acid secretion from the stomach at 
supraphysiological concentrations [166], and possibly a role in memory formation [167, 168] (Figure 
1.5). 
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Figure 1.5 Schematic representation of GIP functions. GIP also has a number of roles aside from 
stimulating insulin secretion from the pancreas, these are depicted above.  Figure is based on review 
from Baggio and Drucker (2007) [78]. Images downloaded from Servier Medical Art. 
 
1.4.5.1 Pancreatic actions of GIP  
The insulinotropic actions of GIP on pancreatic β-cells are analogous to those of GLP-1. However, 
targeting of the GIPR for treatment of type 2 diabetic patients has not yet been successfully exploited 
therapeutically without also targeting the GLP1R [48, 169].  
Aside from the insulinotropic effect of GIP, there are also indications that GIP exerts anti-apoptotic 
and proliferative actions on the pancreatic β-cells. Regarding the anti-apoptotic actions at a molecular 
level, PKA activated upon GIPR stimulation causes phosphorylation of cAMP response element binding 
protein (CREB), which in the nucleus promotes transcription of the anti-apoptotic factor Bcl2 [170]. 
Regarding the proliferative actions, GIP causes signalling via ERK phosphorylation which leads to 
proliferation [158]. Additionally, in terms of cell-cycle regulating proteins, GIP causes transcription of 
cyclin D1 which is essential for cells to progress through the G1 phase [171].  
↓ Gastric Acid Secretion 
GIP 
↑ Memory formation 
↑ Lipogenesis   
↑ Insulin synthesis and secretion  
↑ β-cell proliferation 
↓ β-cell apoptosis 
↑ Bone formation 
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In contrast to GLP-1, there are suggestions that GIP is able to enhance glucagon secretion from 
pancreatic α-cells [172]. This would appear to counteract it’s glucose lowering actions induced by 
stimulation of insulin secretion, and may be an explanation for the lack of GIPR agonists in the clinic 
for treatment of type 2 diabetes. 
1.4.5.2 Actions of GIP in adipose tissue 
The second aspect of GIP physiology most described is the ability to increase nutrient storage in the 
adipose tissue. Early indications that GIP may play a role in nutrient uptake to adipose tissue came 
from studies using rat epididymal fat pads. GIP in the presence of insulin increased fatty acid 
incorporation into these fat pads [173]. Additionally, in vivo studies demonstrated a role of GIP in 
clearing chylomicron-associated triglycerides from circulation in rats and dogs [174, 175].  
One of the direct roles of GIP on adipocytes is the enhancement of lipoprotein lipase (LPL) activity 
[176-179], which is involved in the hydrolysis of triacylglycerols [180]. Regarding the mechanism 
responsible for this, GIP has been shown to alter the transcription of LPL. In human adipocytes, a GIP 
dependent increase in LPL gene expression is observed in the presence of insulin. This appears to be 
due to GIP inducing phosphorylation of CREB, together with nuclear localisation of cAMP-responsive 
CREB coactivator 2 (TORC2) which both bind to the LPL promoter and increase transcription [181]. 
This may not be the only way in which GIP increases LPL activity, post-transcriptional events could also 
contribute. For example, the time-dependent manner in which GIP increases LPL activity suggests GIP 
may mediate it’s actions on LPL via an intermediate signalling molecule. One suggestion is that GIP 
increases secretion of adipokine resistin which then signals to increase LPL activity [177].   
A further role of GIP in adipose tissue is the regulation of adipocyte glucose metabolism. Although in 
the past there has been controversy surrounding this function of GIP, there is some evidence to 
suggest GIP potentiates adipocyte insulin sensitivity, increasing glucose uptake [182, 183]. At the 
intracellular level, GIP in the presence of insulin increases the membrane translocation of the Glut4 
glucose transporter, and increases nuclear exclusion of the Fox01 transcription factor. Molecularly, 
this relies upon activation of CREB and the p110β isoform of phosphoinositide 3-kinase (PI3K), 
however the complete molecular mechanism remains to be elucidated [184].  
GIPR knock-out mouse models also show the importance of adipose tissue GIPR. Both a global GIPR 
knock-out, and GIPR knock-out restricted to adipose tissue using a mouse adipocyte protein 2 (aP2)-
Cre line, provide protection from HFD induced obesity [182, 185]. The reason for this protection is not 
fully understood. In the global GIPR knock-out model, the investigators suggested the explanation was 
due to decreased triglyceride in adipocytes resulting in less nutrient storage [182]. Whereas the 
adipose specific GIPR knock-out investigators showed the differences in body weight were due to 
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decreased lean mass rather than fat mass [185]. Clearly more investigation is required to fully 
understand the role of GIP in adipose tissue.  
1.5 Physiology of Glucagon-like peptide 2 (GLP-2) 
1.5.1 Production of GLP-2 and regulation of secretion 
GLP-2, along with GLP-1 described earlier, is derived from the proglucagon gene [69]. For the 
production of GLP-2, PC1 cleaves the proglucagon product in intestinal L cells and proglucagon 
expressing cells in the central nervous system, yielding the 33 amino-acid peptide (Figure 1.2) [73, 
186].   
The secretion of GLP-2 from the enteroendocrine L-cells occurs simultaneously with GLP-1, thus as 
described earlier a wide range of nutrients and metabolites stimulate secretion. In addition to nutrient 
sensing being responsible for GLP-2 secretion, intestinal injury also causes GLP-2 secretion [187]. 
Again, like GLP-1 and GIP, GLP-2 is a target for degradation by DPP-4. Within minutes of GLP-2 
secretion, intact biologically active GLP-21-33 is cleaved to GLP-23-33 [188].  
1.5.2 GLP-2 Receptor (GLP2R) Structure and Signalling 
As with the GLP1R and GIPR, the GLP2R is a member of the ‘Class B’ GPCR’s primarily coupled to Gαs. 
In contrast to the previously described receptors, structural data for the GLP2R does not exist. Rather, 
structural models have been generated computationally for the human GLP2R extracellular domain 
(ECD) based upon the GLP1R, with which the GLP2R shares the highest sequence similarity [189, 190]. 
Nuclear magnetic resonance (NMR) studies have revealed the GLP-2 structure containing a central α-
helical region along with a loose helical region at the C-terminal end. This has enabled the modelling 
of GLP2 binding to the GLP2R ECD; only the C-terminal portion of GLP-2 binds to the GLP2R ECD, sitting 
within the hydrophobic binding cavity of the ECD [189].  
Studies using primary cultures and transfected cell lines have shown GLP-2 binding to the GLP2R leads 
to signalling primarily via Gαs and the generation of cAMP [191]. Aside from this, GLP-2 activation of 
the GLP2R leads to phosphorylation of protein kinase B (known as Akt) and phosphorylation of ERK1/2 
in a PI3K dependent manner, as observed in primary cultures of enteric neurons [192]. There is also 
evidence indicating that β-arrestin 2 is recruited to the GLP2R upon activation, which may then cause 
downstream signalling [193].  
1.5.3 GLP2R Localisation 
Unlike the GLP1R and GIPR, the main described location of the GLP2R is the gastrointestinal tract, 
encompassing the stomach, small and large intestine. However, the precise cellular location of the 
GLP2R in these areas is debatable, with two main schools of thought. On one hand, 
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immunocytochemistry studies using human, rat or pig tissue have observed the GLP2R in 
enteroendocrine cells within the epithelial lining of the intestine [194-196]. On the other hand, a 
number of studies using a combination of in situ hybridisation, immunocytochemistry and receptor 
autoradiography localise the GLP2R to cells outside of the epithelial layer including enteric neurons, 
subepithelial myofibroblasts and submucosal glial cells neurons [192, 197-200]. One likely reason for 
the debate surrounding GLP2R localisation is a low abundance of GLP2R positive cells, combined with 
the available GLP2R antibodies lacking sensitivity and specificity [201].  
1.5.4 Actions of GLP-2  
GLP-2 is known to be an intestinotrophic factor, initially found to increase small bowel weight due to 
increased length of the intestinal villi, when injected into mice twice daily for 10 days [202]. Other 
gastrointestinal functions of GLP-2 include the increase of nutrient absorption [203-205], a possible 
inhibitory effect on gut motility [206], decreased gut permeability and increased intestinal barrier 
function [207, 208]. Aside from the intestinal effects, GLP-2 also increases visceral blood flow [209, 
210], inhibits bone resorption [211, 212] and may stimulate glucagon secretion from pancreatic α-
cells [205, 213] (Figure 1.6).  
 
 
Figure 1.6 Schematic representation of GLP-2 functions. The main functions of GLP-2 are in the 
gastrointestinal tract, with some functions in other tissues depicted above. Images downloaded 
from Servier Medical Art. 
 
↑ Visceral blood flow 
GLP-2 
↑ Glucagon secretion?   
↑ Intestinal growth  
↑ Nutrient absorption 
↓ Permeability 
↓ Bone resorption 
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1.5.4.1 Gastrointestinal actions of GLP-2  
The intestinotrophic actions of GLP-2 are due to an increase in crypt cell proliferation together with a 
decrease in epithelial cell apoptosis, however the molecular mechanism resulting in these changes are 
not completely explained. Morphologically, electron microscopy has shown GLP-2 treatment in mice 
makes epithelial cells narrower and longer, with longer microvilli [207]. The increased length of 
intestinal villi is linked to a change in nutrient transport, and changes in gut permeability.  
The effects of GLP-2 on nutrient transport were first detected in 1997 when it was observed that the 
intestinal growth stimulated by GLP-2 also leads to increased intestinal RNA and protein content, 
which is synonymous with an increase in brush border disaccharidase and peptidase enzymes. To 
assess nutrient transport and absorbance of carbohydrates, amino acids, or triglycerides respectively 
either glucose, maltose or a mixture of leucine and triolein were administered by oral gavage or 
directly to the duodenum. No GLP-2 mediated effects on nutrient absorbance were detected when 
nutrients were administered orally, possibly due to GLP-2 effects on gastric emptying. In contrast, GLP-
2 increased absorbance of leucine and triolein in the duodenal nutrient tolerance test.  However, GLP-
2 did not increase carbohydrate absorbance in this setting [214]. In a separate set of experiments 
using in vivo perfusions in the rat, fructose absorbance was increased in the presence of GLP-2, 
however whether this represents a physiological setting is debatable [215].  
The GLP-2 mediated increase in lipid absorption is associated with increased triglyceride (TG) 
incorporation into TG rich lipoproteins (TRL) also known as chylomicrons, which upon secretion lead 
to increased plasma TG. An increase in secretion of chylomicrons has been observed upon GLP-2 
treatment in mice and hamsters. It is thought that CD36 glycosylation is required for this process, as 
CD36 knock-out animals fail to show GLP-2 mediated increases in lipid absorption [204]. It should be 
noted that these effects on lipid absorption have also been observed in humans [205, 216]. 
The GLP-2 mediated effects on amino acid absorbance have recently been confirmed in mice. The use 
of GLP2R knock-out mice gave confidence that the GLP-2 mediated increase in basal amino acid 
absorbance was dependent upon the GLP2R. Mechanistically, GLP-2 appears to increase the 
expression of the cationic amino acid transporter slc7a9 and increase 4F2hc which is required for the 
function of light-chain amino acid transporters [217].  
Regarding gut permeability, GLP-2 administration to mice reduces paracellular transport of Na+ ions 
and small molecules in the intercellular space. GLP-2 also reduces transcellular transport of larger 
molecules through the epithelial cells. These decreases in flux were observed at as little as 4 hours 
after GLP-2 treatment, suggesting that the GLP-2 mediated effects on flux are not completely 
dependent upon changes in morphology. Overall, the increased epithelial barrier function indicates 
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therapeutics based on GLP-2 may be useful for treating enteropathies related to increased epithelial 
permeability and resultant inflammatory responses [207]. Molecularly, there are some observations 
indicating that GLP-2 increases expression of the tight junction proteins zonula occludens-1, occudin, 
and claudin-1 in pig jejunal tissue, which is reduced by inhibition of mitogen-activated protein kinase 
(MAPK) [218]. However, this does not provide a full molecular explanation for how GLP-2 reduces gut 
permeability.  
1.5.4.2 Actions of GLP-2 outside of the gastrointestinal tract 
Aside from the direct gastrointestinal effects, GLP-2 also increases mesenteric blood flow in humans, 
as measured in the superior mesenteric artery which supplies the gastrointestinal tract with 
oxygenated blood [210]. The mechanism by which GLP-2 exerts this action is not understood, though 
studies in pigs suggest nitric oxide is essential for the increased intestinal blood flow as demonstrated 
by the use of a nitric oxide synthase inhibitor [209].  
In the pancreas, there is debate surrounding whether GLP-2 can stimulate glucagon secretion. Infusion 
of supra-physiological concentrations GLP-2 to humans increases plasma glucagon levels, however 
there are no effects on plasma glucose [205]. Additionally, the perfused rat pancreas secretes 
glucagon in response to high concentrations of GLP-2. In pancreas tissue from human and rat the 
GLP2R is colocalised with glucagon in islet α-cells, suggesting effects on glucagon secretion are 
mediated directly by the GLP2R [213]. However, there are inter-species differences, in the mouse no 
effects of GLP-2 on glucagon have been found, nor is there expression of GLP2R in the pancreatic α-
cells [194, 219].  
1.6 Clinical Abnormalities in Metabolic Physiology 
Defects in metabolic physiology cause a whole range of diseases; two of which that are increasing in 
prevalence are obesity and type 2 diabetes. Patients with obesity are extremely overweight with 
excessive body fat. Patients with type 2 diabetes have insufficient insulin secretion for their level of 
insulin resistance, meaning blood glucose levels are not controlled, and patients have high levels of 
blood glucose, known as hyperglycaemia [220]. Increased insulin resistance associated obesity results 
in a high risk of type 2 diabetes in obese people [221-223].  
Severe obesity is increasingly managed by surgical approaches, most commonly either by roux-en-Y 
gastric bypass surgery or sleeve gastrectomy. Briefly, roux-en-Y gastric bypass surgery is a procedure 
whereby the stomach is divided; a small pouch of the proximal stomach is connected to the distal 
portion of the jejenum, the other part of the stomach remains connected to the duodenum, and is 
anastomosed lower down the jejenum [224]. Sleeve gastrectomy on the other hand is a procedure 
whereby approximately 75% of the stomach is removed, leaving a tubularised stomach with reduced 
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capacity [224]. These metabolic surgeries are highly efficacious in treating obesity and are also the 
single most effective treatment for type 2 diabetes, however the reason for this is not clear [220, 225].        
A further clinical abnormality in metabolic physiology, of relevance for this thesis, is short bowel 
syndrome (SBS). This syndrome is often caused by extensive intestinal resection surgery, resulting in 
a short small intestinal length which is inadequate for optimal absorption. This insufficient intestinal 
function means that patients on a normal diet are unable to maintain protein-energy, fluid, electrolyte 
and micronutrient balances [226]. The consequences of this mean that patients are often using 
parenteral nutrition, being fed intravenously, giving a reduced quality of life. Not only this, but SBS is 
also associated with significant morbidity and mortality [227, 228]. 
1.6.1 Therapeutic Targeting of the Gut Hormones GLP-1, GIP and GLP-2 
Studies on the physiology of the gut hormones GLP-1, GIP and GLP-2 revealed possibilities for targeting 
these hormones therapeutically; either using the incretin properties of GLP-1 and GIP for the 
treatment of type 2 diabetes, or using the intestinotrophic properties of GLP-2 for the treatment of 
short bowel syndrome (SBS).  
Patients with type 2 diabetes suffer from hyperglycaemia due to ineffective regulation of blood 
glucose levels, this results in a number of symptoms including increased risk of developing 
cardiovascular disease [229]. For the treatment of type 2 diabetes there are two main therapeutic 
strategies focused on gut hormones; the use of GLP-1 mimetics which are resistant to degradation by 
DPP-4 [47], and the use of DPP-4 inhibitors which prevent the degradation of incretin hormones [230]. 
More recently, focus has shifted to the development of unimolecular agonists that target multiple gut 
hormone pathways simultaneously. This arose from the observation that upon comparison of all 
treatments for type 2 diabetes, gastric bypass surgery is the most effective [225]. Clearly, this efficacy 
is not the result of targeting one molecular pathway, rather a whole host of metabolic and physical 
changes are induced after surgery, one of which is a differing pattern of gut hormone secretion leading 
to increased levels of several gut hormones [231]. This new therapeutic strategy of targeting multiple 
gut hormones simultaneously with a unimolecular agonist aims to mimic the effects of gastric bypass 
surgery. Many of these agonists are centred on GLP-1, which is already known to exert beneficial 
therapeutic effects of patients with type 2 diabetes [232]. One such dual agonist is the GLP-1/GIP dual 
peptide, targeting both axes of the incretin effect which allows for a lower dose of GLP-1 to be used 
reducing gastrointestinal side effects [48]. 
Patients with SBS have decreased capacity to absorb nutrients via the intestine, and thus can suffer 
from malabsorption, dehydration and malnutrition [233]. For the treatment of SBS, the 
intestinotrophic activity of GLP-2 makes it an attractive therapeutic target [234]. Indeed, teduglutide, 
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a GLP2R agonist with an extended half-life compared to GLP-2, improves intestinal absorption in these 
patients likely due to increasing intestinal mucosal growth [235, 236]. 
1.7 Aims of Thesis 
As described above, enteroendocrine hormones have a wide range of roles in the control of 
metabolism, and can be targeted therapeutically. A detailed understanding of the physiology of these 
gut hormones and their receptors is therefore particularly useful for further development of 
therapeutics. With this in mind, the aims of this thesis were three-fold.  
Firstly, I focused on the receptor to GLP-1, the incretin hormone which is the most widely targeted gut 
hormone for the treatment of type 2 diabetes. However, therapeutic targeting of GLP-1 also leads to 
a number of extra-pancreatic effects which have not yet been fully explained at the molecular level. 
For the study of GLP1R physiology, antibodies to the GLP1R are limited. The first aim of my thesis was 
to generate a GLP1R monoclonal antagonistic antibody using naïve phage display (Chapter 2). 
Subsequently the specificity of this antibody was assessed, along with the ability to block GLP1R 
mediated signalling pathways and downstream effects in a range of in vitro and in vivo experiments 
(Chapter 3).  
Secondly, I focused on GIPR, the receptor for the second incretin hormone (GIP) which also regulates 
nutrient storage in adipose tissue. Due to a lack of GIPR antibodies for use in immunostaining there is 
limited information surrounding GIPR localisation. The second aim of my thesis was to identify and 
characterise cells containing the GIPR using a newly generated mouse model expressing fluorescent 
reporters downstream of the Gipr promoter (generated by F. Reimann). I used immunohistochemistry 
to identify GIPR expressing cells in peripheral organs and the central nervous system. The function of 
hypothalamic GIPR expressing cells in the regulation of food intake was then investigated (Chapter 4).  
Finally, I focused on the GLP2R, the receptor for GLP-2 which is an intestinotrophic gut hormone 
secreted simultaneously with GLP-1. Collaborators raised interest in a common missense mutation in 
the GLP2R (D470N) which they found to be associated with increased citrulline levels, and increased 
risk of type 2 diabetes (L. Lotta, C. Langenberg and colleagues). As the final aim of my thesis I sought 
to characterise the effects of this GLP2R polymorphism on GLP-2 signalling pathways, including cAMP 
stimulation, β-arrestin recruitment and phosphorylation of ERK1/2 (Chapter 5). 
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Chapter 2. Generation of a GLP1R antagonistic antibody 
2.1 Introduction 
2.1.1 Therapeutic Targeting of GLP1R 
The endogenous incretin actions of GLP-1, as described in chapter 1, are now utilised for the treatment 
of type 2 diabetes. Two forms of therapeutics are available; long-lasting GLP-1 mimetics such as 
liraglutide, and DPP-4 inhibitors such as sitagliptin which prevent the degradation of endogenous GLP-
1 [237]. The success of these treatments is primarily due to the regulation of glycaemic control, 
however other beneficial effects are also observed including weight loss, and decreased 
cardiovascular risk.  
It should be noted that the beneficial effects of GLP-1 mimetics appear to differ between studies, and 
may depend on the agonist used. For example, the LEADER trial showed liraglutide reduced the 
number of major cardiovascular events in patients with a high risk of a cardiovascular event. A time-
to-event analysis showed the occurrence of cardiovascular death, nonfatal myocardial infarction, or 
nonfatal stroke was less in type 2 diabetes patients treated with liraglutide [113]. A similar result was 
seen in the SUSTAIN-6 trial, in which semaglutide also decreased these major cardiovascular events in 
type 2 diabetes patients with a high risk of cardiovascular disease [114]. In contrast, the ELIXA trial 
showed lixisenatide, the shorter-acting GLP-1 mimetic, had no beneficial effects on these major 
cardiovascular events in type 2 diabetic patients who had recently had an acute coronary event [115].   
Combined, these trials have increased interest of GLP-1 actions in the cardiovascular system. At a 
mechanistic level, uncertainty surrounds whether the effects are mediated directly via GLP1R in the 
affected tissue, indirectly via GLP1R activation in neurons, or via alternative receptors in GLP1R-
independent pathways [238]. Further research is required to underpin the cardiovascular and other 
extra-pancreatic effects of GLP-1. Pharmacologically this could be investigated using GLP1R selective 
antagonists.  
2.1.2 Use of antagonists to study the GLP1R 
Antagonism of GLP1R is widely achieved using the peptide antagonist exendin 9-39, a truncated form 
of exendin-4, originally derived from Heloderma suspectum [239]. Recently, 18F-labeled derivatives of 
exendin9-39 have been developed for imaging and downstream quantification of beta-cell mass, 
showing an alternative use of the antagonist [240].  Interestingly, the use of exendin9-39 for treatment 
of congenital hyperinsulinism and post-bariatric hypoglycaemia is being investigated, raising the 
potential to use GLP1R antagonists therapeutically [241, 242].  
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However, exendin 9-39 off-target effects have been observed in preclinical studies using 
cardiomyocytes from Glp1r-/- mice [121]. Alongside this, exendin 9-39 has also been shown to inhibit 
the other incretin receptor, GIPR [243, 244]. Combined, these studies raise questions about the 
specificity of exendin 9-39. One solution that we propose is the use of an antagonistic antibody that 
specifically targets GLP1R, which would also provide the advantage of having an extended half-life 
when compared to exendin 9-39.  
2.1.3 Specificity of GLP1R antibodies 
Although some GLP1R antibodies were available at the start of this PhD project, their usefulness and 
specificity were questionable. In 2013, the specificity of commercially available antibodies was 
investigated by immunoprecipitation and western blot of Glp1r+/+ and Glp1r-/- tissue extract. All of the 
tested antibodies reacted unspecifically with both tissue extracts [92]. As a result, alternative methods 
have since been sought for studying receptor expression, including the generation of a transgenic 
mouse model expressing fluorescent reporters downstream of the Glp1r promoter [93].  
As described in chapter 1, the GLP1R is a GPCR, and as such the generation of antibodies to the 
receptor is inherently difficult for several reasons. For example, the extracellular exposed domains 
within GPCRs provide limited epitopes, the extracellular region of GPCRs is often highly variable, and 
it is difficult to prepare functional GPCR antigens [245]. Despite these difficulties, at the beginning of 
this PhD, a new antibody with specificity for the human and monkey GLP1R, mAb3F52, had just been 
produced by Novo Nordisk using a hybridoma strategy, and extensively validated for use in 
immunostaining [116].  
The most straight forward strategy for production of GPCR antibodies is to generate antibodies 
targeting the extracellular domain (ECD), which gives the added benefit of modifying ligand binding. 
No GLP1R antibodies targeting the mouse GLP1R were available at the outset of this project, thus we 
sought to produce a new GLP1R antibody targeting both the mouse and human GLP1R. Antagonistic 
activity of the antibody was also desired to provide an alternative tool to exendin 9-39 for studying 
GLP1R pharmacology.   
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2.2 Aims 
To generate a novel monoclonal antagonistic antibody for GLP1R with cross-reactivity for the mouse 
and human GLP1R by: 
a) Naïve phage display using the biotinylated human GLP1R ECD and CHO cells overexpressing 
mouse GLP1R. 
 
b) Screening the clones of interest in agonistic and antagonistic cAMP assays in GLP1R 
overexpressing cell lines. 
 
c) Affinity maturation of the lead clone of interest to improve affinity for GLP1R. 
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2.3 Methods 
2.3.1 Solutions and Compounds 
Assay buffer for the cAMP homogenous time-resolved fluorescence (HTRF) assay was Hanks’ balanced 
salt solution supplemented with 25 mmol/l HEPES, 0.1% (w/v) bovine serum albumin (BSA) (pH 7.4) 
and 0.5 mmol/l 3-isobutyl-1-methylxanthine (IBMX). 
The GLP1R extracellular domain (ECD) was produced in Escherichia coli, purified as described 
previously [246], and biotinylated in-house at MedImmune using EZ-link Sulfo-NHS-LC-Biotin 
(ThermoFisher Scientific, Loughborough, UK). Unless stated otherwise, chemicals were obtained from 
Sigma-Aldrich (Poole, UK), and peptides were purchased from Bachem (Bubendorf, Switzerland). The 
exendin (9-39) acetate salt stock was dissolved in dimethyl sulfoxide (DMSO) to 136 µmol/l. GLP-1 (7-
36) was diluted in water to 100 µmol/l.  
2.3.2 Bacterial Strains 
TG1 cells, CJ236 cells, and DH5α cells were cultured in 2xTY media (Bactotryptone 16 g/L, Bactoyeast 
extract 10 g/L, NaCl 5g/L, pH adjusted to 7.0), supplemented according to experimental requirements. 
pCantab6 was used as the expression vector for single chain variable fragments (Appendix 1).  
2.3.3 Cell Culture 
All cell lines were maintained at 37°C with 5% CO2. G22 cells (MedImmune) were maintained in CCM8 
media (SAFC) supplemented with 100 mg/l hygromycin B, and 25 mg/l L-methionine sulfoximine 
(MSX).  
Chinese Hamster Ovary (CHO) K1 cells were maintained in Nutrient Mixture F-12 Ham supplemented 
with 10% FBS, 0.1 units/l penicillin, 0.1 µg/l streptomycin and 2 mmol/l L-glutamine. Stably transfected 
cell lines overexpressing GPCRs of interest were generated at AstraZeneca (Gothenburg, Sweden) or 
MedImmune (Cambridge, UK). For experimental use these overexpressing cell lines were thawed from 
liquid nitrogen stocks directly into assay buffer. 
2.3.4 Phage Display Selections 
2.3.4.1 Soluble selections 
Selections were performed against biotinylated human GLP1R extracellular domain (ECD). For each 
round of selection, input and output titres of phage were calculated. Phage and magnetic streptavidin 
beads were blocked for 1 hour in 3% (w/v) skimmed milk powder in PBS (MPBS), rotating at 20 rpm at 
room temperature. The phage libraries were then deselected against streptavidin beads, following 
which biotinylated GLP1R ECD was incubated with the phage library for 1 hour. 50 µl of blocked beads 
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were then mixed with the selection, and equilibrated in a deep well 96 well plate. Beads were washed 
in 0.1% (v/v) PBS-Tween using the Kingfisher 96, and released into 10 µg/ml trypsin in 0.1 M sodium 
phosphate buffer. The plates were then incubated for 30 minutes at 37°C, 300 rpm. Eluted phage was 
used to infect 1-5 ml of TG1 cells in the logarithmic phase of growth, at 37°C and 150 rpm for 1 hour. 
Selection outputs were plated onto 2xTYAG (100 µg/ml ampicillin, 2% (w/v) glucose) bioassay plates, 
and incubated overnight at 30°C. Finally, TG1 cells were harvested in 2xTY with 17% (w/v) glycerol, 
and stored at -80°C.  
2.3.4.2 Cell surface selections 
Selections were performed on Chinese Hamster Ovary (CHO) cells overexpressing mouse GLP1R 
(mGLP1R), using 1 x 107 cells per selection blocked in 3% (w/v) MPBS, and 50 µl phage also blocked in 
3% (w/v) MPBS. In the washing stage cells were pelleted at 400 g for 1 minute, supernatant removed, 
and resuspended in 1 ml PBS. This was repeated 8 times. Phage were eluted in 200 µl of 100 µg/ml 
trypsin in 0.1 M sodium phosphate buffer. Eluted phage were used to infect TG1 cells, as described 
above. 88 colonies from each selection output were picked for sequencing.  
2.3.4.3 Selection Rescue 
2xTYAG (100 µg/ml ampicillin, 2% (w/v) glucose) media was inoculated with TG1 cells from selection 
outputs to a starting OD600 of 0.1. Cells were then grown to logarithmic phase, and infected with WT 
K07 M13 helper phage using a multiplicity of infection (m.o.i) of 10, for one hour at 37°C, 150 rpm. 
After infection, media was changed to 2xTYAK (100 µg/ml ampicillin, 50 µg/ml kanamycin), and cells 
were cultured overnight at 25°C, 280rpm. To prepare bacteriophage for further rounds of selection, 1 
ml of overnight cultures was centrifuged at max g in a table top centrifuge, and supernatant containing 
bacteriophage was kept on ice until use. 
2.3.4.4 Phage ELISA 
Bacteriophage was prepared from 88 individual colonies of selection output, according to the 
selection rescue protocol, in 96 deep-well plates containing 500 µl appropriate media. In addition, 
nunc maxisorp plates were coated with 50 µl GLP1R ECD either at 1µg/ml or 10µg/ml overnight at 4°C.  
The following day plates were rinsed 3 x in PBS, the plates and phage were then blocked in 3% (w/v) 
MPBS at room temperature for 1 hour. After a further 3 x wash of antigen plates in PBS, 50 µl phage 
was added per well for 1 hour. Plates were then washed 3 x with PBS + 0.1% (v/v) Tween20, and phage 
binding was detected by addition of 50 µl anti-M13-HRP (1:5000 dilution in 3% MPBS) incubated at 
room temperature for 1 hour. Finally, the plate was washed 3 x with PBS + 0.1% (v/v) Tween20, and 
developed by addition of 50 µl 3,3',5,5'-tetramethylbenzidine (TMB) substrate. The reaction was 
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stopped after 20 minutes by addition of 50 µl 0.5 M H2SO4. Absorbance at 450nm was measured on 
the 2104 EnVision® Multilabel Reader.  
For the cell based ELISA assays, cells were seeded into 96 well flat bottom plates (Costar), and 
incubated overnight at 37°C with 5% CO2. CHO K1, and CHO human GLP1R (hGLP1R) cells were seeded 
at 10,000 cells/well. CHO mGLP1R cells were seeded at 7,500 cells/well. Prior to use in the ELISA, cells 
were centrifuged at 485 g for 5 minutes, then washed with PBS, and blocked for 1 hour with 3% (w/v) 
MPBS. Following blocking, cells were washed once with PBS, and 100 µl of phage also blocked in 3% 
(w/v) MPBS was added for 1 hour. The plates were then washed twice with PBS, and anti-M13-
horseradish peroxidase (HRP) was added to wells as described above. The final wash step was 3 x PBS 
washes, and the reaction was developed as above.  
2.3.4.5 Antibody expression and purification 
Variable genes from antibodies of interest were amplified using PCR (primers defined in Appendix 2) 
and cloned into pEU expression vectors. The heavy chain variable genes were digested with BssHII and 
BstEII, then inserted into pEU1.4. Light chain variable genes were digested with ApaL1 and Pac1, then 
inserted into pEU4.4. DNA quick ligase (New England Biolabs, Hitchin, UK) was used for ligation 
reactions, and Z competent DH5α cells were transformed. Successful cloning was confirmed using PCR 
with primers in the pEU backbone, products were loaded in a 1% agarose gel, which was ran at 120V 
for 30 minutes to check for the presence of an insertion.  The insert sequence was then checked using 
DNA sequencing, and DNA was harvested from successful clones using the QIAgen Midi Prep Plus Kit. 
For antibody expression, DNA from the heavy and light chain variable genes was transfected into G22 
cells using polyethylenimine (PEI) Max (Polysciences Inc, Warrington, USA). The transfected cells were 
then incubated for 5-16 hours at 37°C with shaking at 140 rpm, 5% CO2 and 65% humidity. 30% (v/v) 
M20a feed media was then added to the cells, and cells were incubated for 1 week at 34°C with 
shaking at 140 rpm, 5% CO2 and 70% humidity. Antibody was harvested by centrifugation at 500 g for 
30 minutes at 4°C, and filtered using a 0.22 µm steriflip filter. MabSelect SuRe resin (GE Healthcare 
Bio-sciences, Marlborough, USA) was used for purification, and antibody was eluted either with 
glycine buffer or 0.1 M sodium citrate (pH3) in the high throughput method. Desalting was then 
performed using either PD10 columns (GE Healthcare Bio-sciences) or Zeba Spin plates (ThermoFisher 
Scientific). To confirm successful purification, samples were ran on an SDS PAGE and the gels stained 
with InstantBlueTM to visualise protein bands. This process was carried out with the help of 
MedImmune protein expression team. 
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2.3.5 Phage Display Library Generation 
2.3.5.1 Stop template generation and production of uracil containing single 
stranded DNA (dU-ssDNA) 
Mutagenic primers were designed to insert stop templates into the complementarity determining 
regions (CDRs) of Glp1R0017. Mutagenesis was carried out using the QuikChange II Site-Directed 
Mutagenesis Kit (Agilent Technologies, Santa Clara, USA) according to the standard protocol.  Mutant 
DNA was used to transform Z competent CJ236 cells, which were plated onto 2xTYAGC (100 µg/ml 
ampicillin, 2% (w/v) glucose, 10 µg/ml chloramphenicol) petri dishes and incubated overnight at 37°C. 
Successful mutagenesis was confirmed by Sanger sequencing.  
Successful mutant CJ236 colonies were grown to logarithmic phase in 30 ml 2xTYAGC and infected 
with wild-type M13 KO7 helper phage using an multiplicity of infection (MOI) of 10. To allow infection 
cells were incubated at 37°C, 300 rpm for 30 minutes. After infection, media was changed to 2xTYAKU 
(100 µg/ml ampicillin, 50 µg/ml kanamycin, 0.25 µg/ml uridine), and cells were cultured overnight at 
37°C, 300 rpm. Cells were pelleted by centrifugation at 26,890 g and 2°C. 1/5 volume 20% (v/v) 
PEG8000/2.5M NaCl was added to the supernatant and incubated at room temperature for 30 
minutes to precipitate phage. Phage were pelleted by centrifugation at 11,950 g and 2°C for 10 mins, 
supernatant was decanted, before a second centrifugation at 11,950 g and 2°C for 2 mins. The 
resulting phage pellet was resuspended in 0.5 ml PBS, and any debris was pelleted in a final 
centrifugation step at 16,200 g for 5 minutes. 
dU-ssDNA was harvested from the supernatant using the E.Z.N.A® M13 DNA MiniKit (Omega Biotek, 
Norcross, USA), and eluted in 50 µl dH2O. DNA concentration was determined by measuring 
absorbance at 260nm, and the quality of dU-ssDNA harvested was examined on a 1% (w/v) TAE 
agarose gel. This process was carried out with the help of R. Fertin. 
2.3.5.2 Kunkel mutagenesis  
Kunkel mutagenesis relies upon the use of dU-ssDNA as a template, following mutagenesis, the 
product is transformed into bacteria (TG1) which contain uracil N-glycosidase which will destroy the 
template DNA, which will then be replaced by replication the mutant strand template.  
For each library a single mutagenic primer was designed to randomise blocks of up to 6 consecutive 
amino acids using NNS codons (where N = A/G/C/T, S = C/G) within degenerate oligonucleotides. 0.7 
µg of each mutagenic oligonucleotide was phosphorylated using 20 units of T4 polynucleotide kinase. 
Each reaction used 1 x TM buffer, 1 mM ATP, 5 mM DTT. Reactions were incubated at 37°C for 1 hour. 
Phosphorylation products were annealed to 20 µg template dU-ssDNA by incubation at 90C for 2 
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minutes, 50C for 3 minutes and 20C for 5 minutes. Following this, 30 units T4 DNA ligase, 30 units 
T4 DNA polymerase, 0.33 mM ATP, 0.83 mM dNTPs and 5 mM DTT were added to the reaction for 
incubation at 20°C for 3 hours. Reaction products were affinity purified using either the Roche High 
PCR Product Purification Kit or Machery-Nagel Nucleospin Gel and PCR clean up kit according to 
manufacturer’s instructions.  
2.3.5.3 Preparation of electrocompetent TG1 cells and electroporation 
TG1 cells were grown to logarithmic phase in 400 ml 2xTY media, then chilled on ice for 30 minutes 
prior to centrifugation at 2,700 g for 15 minutes at 2°C. The cell pellet was resuspended in 300 ml ice-
cold Milli-Q water. Cells were then pelleted by centrifugation at 2,700 g for 15 minutes at 2°C. The 
wash and centrifugation steps were repeated, cells were then resuspended in 50 ml Milli-Q water, and 
centrifuged in 50 ml falcon tubes at 2,210 g for 10 minutes at 4°C. The supernatant was then discarded, 
and a further 50 ml wash was completed. Cells were resuspended in the remaining liquid, to yield 2 
ml electrocompetent cells per library. Cells were kept on ice, and electroporated immediately. 
5 x 400 µl of cells were electroporated per library in electroporation cuvettes with a 0.2 cm electrode 
gap width. Electroporation settings of 2.5 kV field strength, 200  resistance, 25 µF capacitance were 
used. The time constant was approximately 5 ms. Immediately after electroporation, 1 ml 2xTYG (2% 
(w/v) glucose) was added to each cuvette, and cells were transferred to a 50 ml falcon tube, cuvettes 
then further rinsed with 1 ml 2xTYG. Cells were then incubated at 37°C, 150 rpm for 1 hour.  
The total library size was determined by plating a dilution series on 2xTYAG petri dishes. The remaining 
cells were plated on a 2xTYAG bioassay plate. Following overnight incubation at 30°C, libraries were 
scraped into 10 ml 2xTY with 17% (w/v) glycerol, and stored at -80°C.   
2.3.5.4 Library Rescue 
For each library, cells were grown to logarithmic phase in 400 ml 2xTYAG, and then infected with 
M13KO7trp helper phage at an m.o.i of 10, for 1 hour at 37°C, 150 rpm. The cells were then centrifuged 
at 2,643 g for 15 minutes at room temperature and resuspended in 400 ml 2xTYAK for overnight 
culture at 25°C, 280 rpm.  
The cells were collected by centrifugation at 10,820 g for 20 minutes at 4°C. 120 ml of chilled 20% (v/v) 
PEG8000 / 2.5 M NaCl was then added to the supernatant and incubated on ice for 1 hour. The 
bacteriophage was pelleted by centrifugation at 10,820 g for 20 minutes at 4°C, resuspended in 10 ml 
TE buffer (pH 8.0) and centrifuged at 14,460 g for 15 min at 4 ˚C. 3 ml chilled 20% (v/v) PEG8000 / 2.5 
M NaCl was added to the supernatant, then incubated on ice for 1 hour. The bacteriophage was 
pelleted by centrifugation at 14,460 g for 20 minutes at 4°C, then resuspended in 2 ml PBS. A final 
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centrifugation of 14,460 g for 10 minutes at 4°C was used to pellet bacterial debris. The bacteriophage 
in supernatant was stored at 4°C until used.  
2.3.6 Cell Based Assays 
2.3.6.1 cAMP Homogenous Time Resolved Fluorescence (HTRF) Accumulation Assay 
Control peptides and antibody were serially diluted in assay buffer, and plated using an ECHO525 
acoustic liquid handler (Labcyte, Sunnyvale, CA, USA) to give 11-point dose response curves in 384 
well plates. Overexpressing cell lines resuspended in assay buffer, at a density dependent on the 
cell line (Appendix 3), were then combined with the test compounds. For agonism experiments, 
cAMP was measured after 30 minutes of incubation at room temperature. For antagonism 
experiments, an agonist challenge was given after 15 minutes using the ECHO550 acoustic liquid 
handler (Labcyte), and samples were mixed by centrifugation at 150 g for 1 minute. After a further 
30 minute incubation at room temperature, cAMP was measured. Cellular cAMP levels were 
measured using the cAMP dynamic 2 HTRF kit (Cisbio, Codolet, France) according to the 
manufacturer’s recommendations. Plates were read on an EnVision plate reader (PerkinElmer, 
Waltham, MA, USA) after 1 hour. Non-linear regression was used to calculate EC50 and IC50 values. 
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2.4 Results 
2.4.1 Naïve Phage Display Selection of GLP1R antibodies 
Antibodies targeting GLP1R were generated using a naïve antibody phage display selection approach. 
M13 bacteriophage provide an excellent system for antibody development as the surface proteins are 
directly encoded by genes which are packaged within the bacteriophage. This attribute means that 
genes can be cloned and packaged in bacteriophage with the expressed proteins displayed on the 
surface of the phage, enabling the selection of desired genes based on the binding properties of the 
respective proteins [247]. For antibody phage display, single chain variable fragment (ScFv) 
recombinant genes are packaged into the bacteriophage. In comparison to an IgG structure, a ScFv is 
composed of VH and VL antibody domain connected by a flexible linker (Figure 2.1).  
 
Figure 2.1 Schematic diagram of IgG and ScFv structure. The variable domains from the IgG 
structure (VH and VL) are connected by a flexible linker to form a ScFv used for antibody phage 
display. 
 
For antibody phage display, bacteriophage have been engineered using phage display vectors (e.g. 
pCantab6) to contain the recombinant ScFv gene upstream of gene 3, meaning the ScFv fragment is 
fused to the pIII coat protein on the surface of bacteriophage. Large libraries of ScFv’s have been 
created by manipulating DNA, which enables selection of antibodies to ‘all’ targets [248]. ScFv’s that 
bind to the target antigen are isolated by antigen-guided selection, followed by collection and 
propagation of bound phage then repeated rounds of antigen-guided selections [247, 249] (Figure 
2.2).  
 
 
C
H
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Figure 2.2 Summary of bacteriophage display process. Bacteriophage display utilises engineered 
bacteriophage, which express ScFv’s fused to the PIII coat protein of M13 filamentous 
bacteriophage. Each bacteriophage expresses a singular ScFv determined by the phagemid 
sequence. Bacteriophage bound to the target biotinylated antigen are separated out using magnetic 
streptavidin beads, then used to infect the E. coli bacterial strain TG1. Transformed bacteria, 
containing the phagemids of interest, are then used to produce a fresh pool of bacteriophage for 
further rounds of selection. 
 
For the generation of cross-reactive human and mouse GLP1R antibodies, four naïve bacteriophage 
libraries were used; BoneMarrowVaulttrp (BMVtrp) which contains variable genes isolated from bone 
marrow, CombinedSpleentrp (CStrp) which contains variable genes isolated from a combined spleen 
library, and two semi-synthetic libraries, DP47trp  based on the VH3 framework of the DP-47 gene 
segment also known as immunoglobulin heavy variable 3-23, and Long VH CDR3trp (LH3trp) library, 
composed of ScFv’s with long CDR3 regions.  
Each of these libraries was used in a series of selections; first on 100 nmol/l biotinylated human GLP1R 
ECD, then 50 nmol/l biotinylated human GLP1R ECD, followed by cell surface selections on mouse 
GLP1R overexpressing CHO cells (Figure 2.3). Output titres were calculated at each round of selection, 
and at the third round of selection clone diversity and enrichment was assessed by sequencing (Table 
2.1). 
E. coli 
1. Block phage and beads 2. Deselect against streptavidin beads 3. Add biotinylated GLP1R ECD 
4. Add streptavidin beads 5. Elute bound phage 6. Infect bacterial cells, grow 
overnight, harvest phage.  
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Figure 2.3 Schematic representation of selection strategy used for naïve phage display. 
Selections were performed using four naïve phage display libraries: BMVtrp, CStrp, DP47trp, and 
LH3trp.  
 
 
Round of 
selection 
Output Titre (cfu/ml) Sequence 
Diversity (%) BMVtrp CStrp DP47trp LH3trp 
1 ~104 ~104 ~104 ~104 N/A 
2 104 2.4 x 104 1.7 x 104 2.3 x 104 N/A 
3 3.1 x 103 N/A 23% 
 
Tables 2.1 Output titres and sequence diversity of initial phage display selection strategy. Round 
1 of selection used 100 nmol/l biotinylated human GLP1R ECD, round 2 used 50 nmol/l 
biotinylated human GLP1R ECD, and round 3 used CHO cells overexpressing the mouse GLP1R. 
The % sequence diversity was calculated from the number of different HCDR3 sequences within 
88 clones. 
 
The output titre at each round of selection is expected to be between 103 – 106 colony forming units 
(cfu) per ml. An increase in the output titre may suggest an enrichment of binders. In contrast, when 
the output titre drops below 103 cfu/ml this indicates that the selection pressure has been too harsh, 
and the selection should be assessed. Initially following round 2 of selection (Figure 2.3), the BMVtrp, 
CStrp, and DP47trp selection outputs were pooled to save resource in selections. However, this resulted 
in a low diversity in sequencing at round 3 of selection (Table 2.1). 
To increase the chance of isolating unique clones that specifically bind to the mouse GLP1R, further 
selections were performed using the CHO mGLP1R cells. Each selection output from round 2 was used 
individually in the additional round 3 selections. Again, output titre and sequencing diversity was 
assessed for each output. Overall, sequencing diversity of clones that bind mGLP1R was increased 
(Table 2.2). 
  
Round 1
100 nmol/l GLP1R ECD 
Round 2
50 nmol/l GLP1R ECD
Round 3
mGLP1R overexpressing CHO cells
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 BMVtrp CStrp DP47trp LH3trp 
CHO mGLP1R selection. 
Output titre (cfu/ml) 
4.3 x 105 4.4 x 104 3.6 x 105 2.6 x 105 
Parental CHO selection. 
Output titre (cfu/ml) 
4 x 104 3.3 x 103 9.0 x 103 3.2 x 104 
Fold difference 10.75 13.33 40 8.13 
Sequence diversity (%) 11% 20.5% 13% 30% 
 
Tables 2.2 Output titres and sequence diversity of further phage display selections on CHO 
mGLP1R cells. As a negative control, selections were also performed on the parental CHO cell 
line. The fold difference displays the difference in output titres between parental CHO and CHO 
mGLP1R selections. 
 
2.4.2 Identification of ScFv’s of interest 
To determine the clones of interest for functional screening, binding properties of ScFv’s were 
assessed and sequencing was analysed. Binding properties of the round 3 pooled selection output 
were assessed using phage ELISA, with either hGLP1R ECD, mGLP1R overexpressing cells or hGLP1R 
overexpressing cells. Antigen-bound phage was detected with an anti-M13 antibody conjugated to 
horseradish peroxidase (HRP). A number of weak binders were detected in the cell based phage 
ELISAs, with a small signal window over the parental CHO K1 cell line. In comparison, several of the 
clones showed a robust signal with the human GLP1R ECD, indicating binding (Figure 2.4).  
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Figure 2.4 Clones of interest determined by phage ELISA.  Binding of the pooled round 3 CHO 
mGLP1R cell selection outputs to hGLP1R and mGLP1R was assessed using phage ELISA. OD 
(450 nm) is displayed for the clones which were taken forward for ScFv production.    
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Analysis of sequencing from the round 3 pooled selection output revealed three dominant clones (C03, 
A04 and B04), all of which were positive in the phage ELISA, and consequently selected for functional 
analysis. In addition, clones with specific sequences that produced a signal in the phage ELISA were 
selected for functional analysis (Table 2.3 and Figure 2.4).  
Selection description Sequencing ID No. of Sequence Copies ScFv Nickname 
R3, libraries pooled ZZ1LSB–A04 12 Glp1R0001 
R3, libraries pooled ZZ1LSB-B02 2 Glp1R0002 
R3, libraries pooled ZZ1LSB-B04 12 Glp1R0003 
R3, libraries pooled ZZ1LSB-C03 42 Glp1R0004 
R3, libraries pooled ZZ1LSB-C07 1 Glp1R0005 
R3, libraries pooled ZZ1LSB-D01 1 Glp1R0006 
R3, libraries pooled ZZ1LSB-D03 1 Glp1R0007 
R3, libraries pooled ZZ1LSB-F03 1 Glp1R0008 
R3, libraries pooled ZZ1LSB-G05 1 Glp1R0009 
R3, libraries pooled ZZ1LSB-H02 1 Glp1R0010 
R3, libraries pooled ZZ1LSB-H06 1 Glp1R0011 
R3, libraries pooled ZZ1LSB-H09 1 Glp1R0012 
R3, BMVtrp ZZ1LUF-D07 5 Glp1R0016 
R3, BMVtrp ZZ1LUF-B08 7 Glp1R0015 
R3, BMVtrp ZZ1LUF-B02 3 Glp1R0014 
R3, CStrp ZZ1LUE-B09 3 Glp1R0019 
R3, CStrp ZZ1LUE-G10 17 Glp1R0022 
R3, CStrp ZZ1LUE-D10 18 Glp1R0021 
R3, CStrp ZZ1LUE-B02 3 Glp1R0018 
R3, CStrp ZZ1LUE-A11 12 Glp1R0017 
R3, CStrp ZZ1LUE-D08 5 Glp1R0020 
R3, LH3trp ZZ1LUC-E06 6 Glp1R0025 
R3, LH3trp ZZ1LUC-H03 3 Glp1R0027 
R3, LH3trp ZZ1LUC-B06 27 Glp1R0024 
R3, LH3trp ZZ1LUC-A07 8 Glp1R0023 
R3, LH3trp ZZ1LUC-H06 3 Glp1R0028 
 
Table 2.3 Details of clones selected for ScFv purification based on ELISA and sequencing data. 
88 clones were sequenced per selection output, therefore number of sequence copies is out of 
a total of 88 possible sequences. From now on, clones will be referred to by the ScFv nickname.  
 
As the phage ELISA assay had several limitations (detailed in discussion), clones of interest from the 
extra mGLP1R cell selections were determined solely by sequencing analysis. Sequences with more 
than three replicates in the selection outputs were selected for functional analysis, with the 
hypothesis that replicated sequences have improved binding compared to unique sequences (Table 
2.3). Overall 26 ScFv clones were selected for functional analysis, and each was purified using 
immobilised metal ion affinity chromatography by the BET Team at MedImmune.   
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2.4.3 Screening of clones of interest in cAMP assays 
The ability of ScFv’s to agonise the mGLP1R and thus stimulate cAMP signalling was assessed in a cell-
based homogenous time resolved fluorescence (HTRF) assay. None of the selected ScFv’s displayed 
agonistic activity on the mGLP1R (Figure 2.5a).  
The ability of ScFv’s to antagonise GLP-1 stimulated cAMP production was also assessed. Seven unique 
ScFv’s were identified as antagonistic for the mGLP1R upon screening, of which Glp1R0017 had the 
lowest IC50 value of 238 nmol/l (Figure 2.5b, 2.5c). Based on reproducibility of cAMP antagonistic 
activity Glp1R0017, Glp1R0020, Glp1R0025 and Glp1R0015 were selected for conversion into 
humanised IgG’s (hIgG1.TM format) by the BET Team at MedImmune. Upon conversion of Glp1R0015, 
a glycosylation site was identified within the antibody framework therefore Glp1R0015 was discarded.  
Following conversion into the IgG1 format, cAMP agonistic and antagonistic activity was determined 
in the mGLP1R cell line. Again, none of the antibodies exhibited agonistic activity (Figure 2.6a). All 
three antibodies retained antagonistic activity, and increased in potency. Glp1R0017 was the most 
potent IgG, with an IC50 of 5.2 nmol/l (Figure 2.6b), and was selected as the lead antibody for further 
characterisation and lead optimisation.   
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Figure 2.5 ScFv screening in CHO mGLP1R cells reveals four clones of interest for conversion into 
IgG format. (a) Agonism activity of ScFvs is displayed as % activation of the maximal GLP-1 response. 
No agonistic activity was observed for the ScFvs screened. (b) Antagonism activity of ScFvs in initial 
screening. Antagonistic activity is displayed as % inhibition of the GLP-1 EC80 response. (c) 
Antagonism activity of selected ScFvs in second round of antagonism screening. Data are mean ± 
SD from duplicate wells. 
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Figure 2.6 IgG screening in CHO mGLP1R cells. (a) Agonism activity of IgGs displayed as % activation 
of the maximal GLP-1 response. (b) Antagonism activity of IgGs displayed as % inhibition of the GLP-
1 EC80 response. Data are mean ± SD from duplicate wells, and the data shown are representative 
of at least three separate experiments.  
 
2.4.4 Affinity maturation of Glp1R0017 
In an attempt to improve the affinity of Glp1R0017 for the GLP1R, mutant libraries were made in the 
complementarity determining regions (CDRs) which are responsible for antigen binding.  IgG’s have 
three CDR regions in both the heavy and light chain, with the CDR3 regions often being responsible 
for stabilisation of antigen binding [250, 251]. For this reason, both CDR3 regions were targeted in our 
affinity maturation approach.  Upon comparison of the remaining CDR regions, the HCDR2 region of 
Glp1R0017 is the longest, containing 17 amino acids. This provides the highest possibility for 
mutations, and was therefore also chosen for affinity maturation. 
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In total 8 ScFv phage display libraries targeting HCDR2, HCDR3 and LCDR3 were generated. Four 
overlapping libraries were constructed in HCDR3, and two overlapping libraries were constructed in 
LCDR3 to ensure full coverage. As HCDR2 is predicted to be less critical for antigen binding, only two 
libraries were constructed in the central region of this CDR. Kunkel mutagenesis readily generates 
mutant libraries of 109 clones, which covers the theoretical diversity of randomising 6 codons. For 
each library, Kunkel mutagenesis was used to replace 6 consecutive codons with NNS codons (where 
N = A/C/G/T, S = C/G), allowing for inclusion of any amino acid at the targeted positions. Prior to use 
in phage display selections, the size and quality of each library was assessed (Table 2.4). All libraries 
were larger than 108, and therefore each library was taken forward for phage display selections.  
Each library was used in a series of selections (Figure 2.7); the first three rounds were against 
biotinylated human GLP1R ECD at 20 nmol/l, then 5 nmol/l and 1 nmol/l. Output titres were calculated 
for each round of selection (Table 2.5). Sequencing assessment at round 3 showed all the clones in 
library HCDR3.3 were the parental Glp1R0017, consequently this library was discarded.  For the fourth 
round of selection, using mGLP1R overexpressing CHO cells, the HCDR2 libraries were pooled due to 
the lower sequence diversity. The HCDR3.1 and HCDR3.2 libraries were also pooled. 
 
Library Total size 
(from 
counting) 
No. of stop 
templates 
No. of 
poor 
sequences 
No. of 
frameshifts 
No. of 
uniques 
Actual 
Library 
Size 
HCDR2.1 5.2 x 109 20/88 4/88 2/88 58/88 3.4 x 109 
HCDR2.2 1.7 x 1010 24/88 1/88 7/88 53/88 1 x 1010 
HCDR3.1 3.6 x 109 50/88 4/88 18/88 16/88 6.6 x 108 
HCDR3.2 9.3 x 108 54/88 2/88 12/88 19/88 2 x 108 
HCDR3.3 6.3 x 109 22/88 6/88 13/88 47/88 3.4 x 109 
HCDR3.4 8.3 x 109 36/88 3/88 22/88 25/88 2.4 x 109 
LCDR3.1 3.8 x 109 35/88 14/88 7/88 21/88 9 x 108 
LCDR3.2 1.4 x 109 26/88 12/88 9/88 38/88 6 x 108 
 
Table 2.4 Diversity of phage display libraries generated for affinity maturation of Glp1R0017. To 
assess the quality of libraries generated for affinity maturation, the size was determined by 
counting, and then 88 colonies from each library were picked for sequencing to assess diversity. 
The column displaying the number of stop templates shows the number of sequences that 
contained a stop codon within the CDR. The actual library size was calculated using the proportion 
of unique sequences within the total library size.   
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 Output Titre (cfu/ml) Sequence Diversity (%)  
R1 R2 R3 R4 R5 R3 R5 
HCDR2.1 7.9 x 105 4.0 x 105 4.5 x 105 
6.6 x 104 1.2 x 105 
36% 
25% 
HCDR2.2 5.6 x 107 1.1 x 106 4.4 x 105 27% 
HCDR3.1 5.6 x 106 1.4 x 106 5.6 x 105 
7.4 x 104 7.4 x 105 
39% 
/ 
HCDR3.2 3.3 x 105 4.8 x 105 2.0 x 105 20% 
HCDR3.3 1.9 x 106 5.5 x 105 2.5 x 105 / / 0% / 
HCDR3.4 1.7 x 106 2.6 x 105 2.9 x 105 4.2 x 104 8.0 x 104 73% 61% 
LCDR3.1 5.1 x 107 2.6 x 106 9.9 x 105 6.6 x 104 4.2 x 105 36% 68% 
LCDR3.2 9.4 x 106 3.2 x 105 1.4 x 105 3.3 x 104 4.9 x 104 84% 93% 
 
Tables 2.5 Output titres and sequence diversity of selections from affinity maturation of 
Glp1R0017. Rounds 1, 2 and 3 of selection used 20 nmol/l, 5 nmol/l and 1 nmol/l of biotinylated 
human GLP1R ECD respectively. Round 4 of selection was performed on mGLP1R overexpressing 
CHO cells. In the fifth round of selection 100 pmol/l biotinylated human GLP1R ECD was used. The 
% sequence diversity was calculated from the number of unique sequences within 44 clones. The 
sequencing diversity of the HCDR3.1/HCDR3.2 pooled library was not assessed at round 5 due to a 
lack of signal window over the negative control selection. 
 
 
To further push the selections, a fifth round of selection was performed against biotinylated human 
GLP1R ECD at 100 pmol/l. Finally, for the sixth round of selection, all libraries were pooled, and used 
in ‘competitive’ phage display selections with 50 pmol/l biotinylated human GLP1R ECD (Figure 2.7). 
To describe briefly, antigen-bound phage were competed off by overnight incubation with a 10 – 105 
molar excess of Glp1R0017. Output titres for these ‘competitive’ selections ranged from 7 x 103 to 5 x 
104, and sequencing diversity was assessed.  
Sequencing data from round 3, 5 and 6 selection outputs were combined, and potential clones of 
interest were selected based either on the number of copies within different rounds of selection, or 
observation of a shorter recurring sequence between different clones (Table 2.6). The amino acid 
sequence has not been shown due to MedImmune confidentiality. Seventeen clones of interest were 
identified (Glp1R0037 – Glp1R0054), and then converted into the IgG1 format for functional screening. 
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Figure 2.7 Schematic representation of selection strategy used for Glp1R0017 affinity 
maturation. Selections were performed using libraries over HCDR2, HCDR3 and LCDR3. 
Libraries were pooled at the stages indicated. The ‘competitive’ selection used 50 pmol/l 
biotinylated human GLP1R ECD, and antigen-bound phage were competed off by overnight 
incubation with a 10 – 105 molar excess of Glp1R0017.   
 
  
  
Round 1
20 nmol/l GLP1R ECD
Round 2
5 nmol/l GLP1R ECD
Round 3
1 nmol/l GLP1R ECD
Round 4
mGLP1R overexpressing CHO cells
* HCDR2 libraries pooled     ** HCDR3.1 and HCDR3.2 pooled
Round 5 
100 pmol/l GLP1R ECD
Round 6
'Competitive' selection
*** All libraries pooled
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Table 2.6 Details of clones selected for IgG purification from Glp1R0017 affinity maturation. 44 
clones were sequenced per selection output, therefore number of sequence copies is out of a total 
of 44 possible sequences. From now on, clones will be referred to by the IgG nickname.  
Sequencing ID CDR region Reason for selection IgG Nickname 
ZZ1YAG-F08 LCDR3.1 2 copies in round 5 output Glp1R0052 
ZZ1YAG-A06 LCDR3.2 2 copies in round 5 output Glp1R0050 
ZZ1YAG-A04 LCDR3.2 EDL replicated Glp1R0049 
ZZ1YAG-G04 LCDR3.2 HLHV replicated Glp1R0054 
ZZ1YAG-B11 LCDR3.1 RDLRT duplicated Glp1R0039 
ZZ1YAG-G06 LCDR3.1 4 copies of SWSD Glp1R0040 
ZZ1YAG-G10 LCDR3.1 QELD duplicated Glp1R0053 
ZZ1YAH-G04 HCDR2 2 copies in round 3 output 
3 copies in round 5 output 
1 copy in round 6 output 
Glp1R0044 
ZZ1YAH-E05 HCDR2 2 copies in round 3 output 
4 copies in round 5 output 
Glp1R0042 
ZZ1YAH-H02 HCDR2 1 copy in round 3 output 
1 copy in round 5 output 
Glp1R0046 
ZZ1YAH-F06 HCDR3 2 copies in round 5 output  
(4 copies of VGPL) 
Glp1R0043 
ZZ1YAH-C08 HCDR3 2 copies in round 5 output  
(3 copies of GYPRD) 
Glp1R0041 
ZZ1YAH-H08 HCDR3 2 copies in round 5 output  
(3 copies of SEI) 
Glp1R0048 
ZZ1YAH-H06 HCDR3 2 copies in round 5 output  
(4 copies of MGFP) 
Glp1R0047 
ZZ1YA9-G11 HCDR3 11 copies in round 6 output Glp1R0045 
ZZ1YA9-A04 HCDR2 3 copies in round 6 output Glp1R0037 
ZZ1YA9-A08 HCDR3 2 copies in round 6 output Glp1R0038 
 
2.4.5 Screening of Glp1R0017 affinity maturation products 
Glp1R0039 failed to convert into the IgG1 format, therefore only sixteen of the seventeen affinity 
maturation products were screened for functional activity on both the mGLP1R and hGLP1R. Firstly it 
was confirmed that none of the affinity maturation products showed agonism in the mGLP1R or 
hGLP1R cell line (data not shown).  
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When antagonistic activity was assessed on mGLP1R, all of the affinity maturation productions 
displayed antagonistic activity (Figure 2.8a), with all of the IC50 values being within 2-fold of Glp1R0017 
activity (Table 2.7). This suggests that affinity maturation was unsuccessful. However, when 
antagonistic activity was assessed in the hGLP1R cell line, the majority of affinity maturation products 
showed a greater than 2-fold improvement in IC50 (Figure 2.8b and Table 2.7). The two antibodies with 
the largest improvement in affinity were Glp1R0047 (hGLP1R IC50 = 7.9 nmol/l) and Glp1R0048 
(hGLP1R IC50 = 7.2 nmol/l). It should be noted that Glp1R0017 has approximately a 10-fold lower IC50 
value on the human GLP1R compared to the mouse GLP1R, therefore the affinity improved antibodies 
remain in the nanomolar affinity range.   
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Figure 2.8 Antagonistic activity of Glp1R0017 affinity maturation products in mGLP1R and hGLP1R 
expressing cells. (a) Antagonism activity of IgGs in mGLP1R expressing cells displayed as % inhibition 
of the GLP-1 EC80 response. (b) Antagonism activity of IgGs in hGLP1R expressing cells displayed as 
% inhibition of the GLP-1 EC80 response. Data are mean ± SD from duplicate wells, and the data 
shown are representative of at least two independent experiments. 
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 Average IC50 (mol/l) Fold improvement over Glp1R0017 
 Mouse GLP1R Human GLP1R Mouse GLP1R Human GLP1R 
Glp1R0017 2.15E-09 4.97E-08 1.00 1.00 
Glp1R0037 2.43E-09 1.14E-08 0.89 4.35 
Glp1R0038 1.33E-09 8.9E-09 1.62 5.59 
Glp1R0040 2.08E-09 1.13E-08 1.04 4.40 
Glp1R0041 3.31E-09 1.31E-08 0.65 3.81 
Glp1R0042 2.14E-09 1.04E-08 1.01 4.78 
Glp1R0043 2.77E-09 1.07E-08 0.78 4.64 
Glp1R0044 2.30E-09 1.15E-08 0.94 4.34 
Glp1R0045 / / / / 
Glp1R0046 2.68E-09 6.68E-08 0.80 0.74 
Glp1R0047 1.60E-09 7.88E-09 1.35 6.31 
Glp1R0048 2.09E-09 7.23E-09 1.03 6.87 
Glp1R0049 5.02E-09 2.15E-08 0.43 2.32 
Glp1R0050 1.92E-09 9.22E-09 1.12 5.39 
Glp1R0051 1.82E-09 3.01E-08 1.18 1.65 
Glp1R0052 2.03E-09 2.51E-08 1.06 1.98 
Glp1R0053 4.59E-09 2.98E-08 0.47 1.67 
Glp1R0054 7.42E-09 2.35E-08 0.29 2.12 
 
Table 2.7 Average IC50 values of affinity maturation products on mouse and human GLP1R, 
together with fold improvement over the Glp1R0017 IC50. The average IC50 value was determined 
from n=3 for the mouse GLP1R cell line, and n=2 for the human GLP1R cell line.  
 
To increase the chance of isolating an antibody with increased potency for both the mGLP1R and 
hGLP1R, more clones were selected for screening from the fifth round of phage display selection. The 
round 5 selection outputs were chosen as the output titre window at this round, when using 100 
pmol/l of the biotinylated human GLP1R ECD, remained high. This demonstrates that ScFv’s were 
binding to 100 pmol/l of the antigen. In comparison, the lowest concentration of the ECD used in naïve 
phage display to select Glp1R0017 was 50 nmol/l. This observed binding to 100 pmol/l of antigen 
suggested that antibodies would be present in the round 5 output that bind to the antigen with a 
higher affinity than Glp1R0017.  
To screen clones from the round 5 output, the heavy and light chain variable fragments from each 
library were cloned into IgG expression vectors. Sequences of the cloning products were then 
determined, 44 new unique clones were found with mutations in the heavy chain, and 65 unique 
clones were found with mutations in the light chain. A high-throughput expression and purification 
method was then used to harvest a total of 109 new antibodies in the IgG1 format for screening (in 
collaboration with the BET Team, MedImmune).  
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Screening was performed for antagonism of both the mGLP1R and hGLP1R. The mean IC50 values were 
calculated, followed by the fold improvement over Glp1R0017 IC50. Within this set of screening, the 
antagonistic activity of the affinity maturation products clustered around a 2-fold improvement on 
the hGLP1R when compared to Glp1R0017 (Figure 2.9). On the mGLP1R, antagonistic activity showed 
little improvement compared to Glp1R0017 with the maximal fold improvement being 2.1-fold.  
Overall this affinity maturation approach was not able to significantly improve the potency of 
Glp1R0017 for mGLP1R, therefore Glp1R0017 was scaled up and taken forward for further 
characterisation (Chapter 3).  
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Figure 2.9 Summary of affinity maturation fold improvements in antagonistic activity. IC50 values 
from at least two independent experiments were averaged, and the fold improvement over 
Glp1R0017 calculated. Green points display summary data from the initial round of screening, blue 
points display summary data from the second round of screening. Overall the affinity maturation 
products showed a greater improvement in antagonism of hGLP1R compared to mGLP1R. 
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2.5 Discussion 
2.5.1 Phage Display for Antibody Production 
In this study, a monoclonal antibody to GLP1R with antagonistic activity has been developed using 
naïve phage display. Within the phage display selection process, human GLP1R ECD and mouse GLP1R 
expressing CHO cells were used as antigen in subsequent rounds of selection. This has enabled the 
production of an antibody with antagonistic activity on both the human and mouse GLP1R (Figure 2.8 
and Table 2.7).  
Whilst this work was being completed, Novo Nordisk published a mouse GLP1R selective antibody 
(7F38A2), complementing the human/monkey GLP1R antibody (mAb3F52) [252]. The ability of 
mAb3F52 to block activation of the human GLP1R in vitro was also demonstrated during the course of 
this study [253]. In contrast, antagonistic activity of the mouse GLP1R specific antibody (7F38A2) has 
not yet been shown, the main use of 7F38A2 is immunostaining.  
When Glp1R0017 is compared to the alternative GLP1R antibodies, mAb3F52 and 7F38A2 [116, 252, 
253], the cross-species reactivity is the main advantage. This is likely due to the use of phage display 
selection strategy used for antibody generation, which made use of both human GLP1R ECD and 
mouse GLP1R overexpressing cells. The use of different antigens in subsequent rounds of phage 
display selection, offers the possibility of yielding cross-reactive antibodies which would be impossible 
to achieve by hybridoma [254].  Several other comparisons can be made between phage display and 
the hybridoma approach for antibody generation. One key benefit of phage display is that antibodies 
of similar affinity to hybridoma antibodies can be produced, without the use of animals. This also 
means that antibodies can be produced for toxins and non-immunogenic molecules [255-258].  In 
comparison with the hybridoma approach, the recombinant nature of phage display means the 
antibody-encoding gene sequence is readily accessible, and can be cloned into a human IgG backbone 
reducing any immunogenicity effects when used therapeutically. A further benefit is that phage 
display can be more easily automated than hybridoma work, and the time-frame for producing a panel 
of antibodies of interest is much shorter. After Glp1R0017 selection via phage display, the ScFv was 
converted into an IgG1 format, and has subsequently been characterised (Chapter 3).  
Selections using phage display can lead to the production of large panels of antibodies, meaning there 
is a need for high throughput screening techniques to be in place alongside phage display to select 
clones of interest. In this study, clones of interest were determined based on phage ELISA activity 
(Figure 2.4), and assessment of sequencing (Tables 2.3 and 2.6). The signal windows observed in the 
cell based phage ELISA were small (Figure 2.4), indicating that this technique requires further 
optimisation before being used routinely as an initial screen for binding.  Possible suggestions for 
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improvement of the assay include; a change in culturing conditions of the cells or an increase in cell 
plating density, allowing cells to become confluent prior to use in the assay, alternatively a change in 
blocking solution to bovine serum albumin may help decrease cell death.  
In this study, sequencing assessment was successful in isolating clones of interest, with Glp1R0017 
originally being isolated due to having 12 copies of the sequence within 88 clones from the round 3 
selection output (Table 2.3). However, an initial optimised screen to confirm ScFv binding to the GLP1R 
would have been useful to give confidence in the choice of selection products for functional screening. 
As the phage ELISA using the human GLP1R ECD gave a larger signal window, a phage ELISA on both 
the mouse and human GLP1R ECD could be considered for initial screening.  
2.5.2 Affinity maturation approaches using phage display 
The nanomolar potency of Glp1R0017 was surprising considering this antibody was isolated directly 
from naïve phage display. However, affinity maturation approaches have the capability to improve 
affinity to the picomolar and even femtomolar range [259-261]. This is another advantage when 
comparing phage display to hybridoma, as the affinity gained in a hybridoma approach is limited to 
approximately 100 picomolar due to B cell physiology [262].  
With the aim of improving the affinity, and thereby potency of Glp1R0017 for both the human and 
mouse GLP1R, Glp1R0017 mutant libraries were generated in which the CDR’s were targeted by 
Kunkel mutagenesis (Table 2.4). The resultant libraries were used in a selection strategy with increased 
stringency, using lower concentrations of human GLP1R ECD at each round (Figure 2.7 and Table 2.5). 
To improve affinity on the mouse GLP1R, mGLP1R overexpressing cells were used at round 4 of 
selection (Figure 2.7), however availability of biotinylated mouse GLP1R ECD could have improved the 
affinity maturation strategy used.  
The maximal improvement in potency was observed on the human GLP1R, with Glp1R0048 showing 
a 6.9-fold improvement in potency when compared to Glp1R0017 (Table 2.7). This could be explained 
by the dominance of human GLP1R ECD within our affinity maturation approach giving a bias towards 
increased affinity for the human GLP1R. As this improvement in potency was less than 10-fold, the 
characterisation of Glp1R0048 as an alternative GLP1R antibody was not pursued. Of note, Glp1R0048 
was produced by affinity maturation of HCDR3, which is thought to be the most important in 
determining antibody binding [250, 251]. In comparison, only a minor improvement in potency was 
observed on the mouse GLP1R. This lack of improvement in potency meant that the affinity of 
improved clones was not measured by kinetics. 
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When considering future affinity maturation of Glp1R0017, it will be important to have a target 
potency in mind. An increase in potency for both the human and mouse GLP1R is desired, for in vitro 
signalling experiments, and pre-clinical studies in mice. A picomolar affinity is regularly achievable 
using phage display for affinity maturation, which would hopefully give a potency in line with the range 
of exendin 9-39 in our cAMP assays (Human GLP1R IC50 = 16.2 nmol/l; Mouse GLP1R IC50 = 1.09 nmol/l). 
Exendin 9-39 is currently being investigated clinically for the therapeutic treatment of congenital 
hyperinsulinemia, and post-bariatric hypoglycaemia [241, 242]. Should a GLP1R antagonistic antibody 
be developed into a clinically relevant agent, for example to provide an improved alternative to 
exendin 9-39 in the treatment of post-bariatric hypoglycaemia, increased affinity for the human GLP1R 
would be desirable. 
A number of approaches can be used for further affinity maturation, which will be discussed and 
described below. One potential strategy could be to combine Glp1R0048 with the most improved 
HCDR2 mutant sequence and most improved LCDR3 mutant sequence. Alternatively, a new panel of 
antibodies for screening could be generated from our selection outputs, by combining a selection of 
the highest affinity mutant heavy chains with a selection of the highest affinity mutant light chains, 
and vice versa. These combination approaches provide the potential to generate new antibodies that 
have the additive or synergistic affinities of the contributing heavy and light chains.  
In this study, the affinity maturation approach was to target the CDR regions independently of each 
other. One other approach involving the CDR’s is CDR walking, in which CDRs are optimised 
sequentially [260]. This method has the potential to give a better result, however due to the staggered 
approach of sequential library generation and phage display, it would take longer to produce a final 
affinity improved antibody.  
Often affinity maturation strategies target the CDR regions, which is beneficial because the framework 
remains unaffected, meaning the antibody stability should be unchanged [263]. Other affinity 
maturation approaches do exist, for example chain shuffling in which the VH or VL gene is replaced 
with a repertoire of V genes [259, 264]. Another approach is the use of focused mutagenesis then 
recombination of the best mutants. In this approach, each residue within the CDR’s is mutated one at 
a time, creating libraries in which each clone has a single amino acid change in one of the CDR 
positions. Following initial screening, the recombination of the best mutants enables the production 
of affinity matured clones without the use of large libraries which are generated when complete CDRs 
are randomised [265].  
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2.5.3 Affinity maturation approaches using alternative display platforms  
Alternative platforms are available for affinity maturation of antibodies including yeast display and 
ribosome display, both of which could be utilised for Glp1R0017 affinity maturation.  
Yeast display is analogous to phage display in ways, and can be used in affinity maturation. One 
limitation of phage display, is the unpredictable expression bias of Escherichia coli for eukaryotic 
proteins which may explain why a single amino acid change within a CDR can eliminate expression 
[266]. A further limitation of phage display is that clones may appear in the output due to factors other 
than antigen binding, such as increased infectivity of phage or reduced host toxicity [259, 267]. Yeast 
display overcomes some of these limitations, as the endoplasmic reticulum within Saccharomyces 
cerevisiae is very similar to that in mammalian cells overcoming any library bias which may be 
observed in phage display, and enabling post-translational modifications. When considering the 
number of displayed ScFv’s, each yeast cell is able to display large numbers of ScFvs fused to cell 
surface anchor proteins such as adhesion receptors, whereas bacteriophage express a single ScFv per 
bacteriophage [268]. Yeast display is also compatible with flow cytometry for cell sorting, which allows 
for the easy isolation of mutants with increased binding affinity [269]. This technique has been used 
successfully to generate antibodies with femtomolar affinity [261].  
Ribosome display has also been developed as a technique to generate and affinity mature antibodies. 
In comparison to phage display, ribosome display is performed entirely in vitro without the use of any 
cells. In principal, the encoding gene sequence (mRNA) and ScFv peptide are linked together in a 
ribosomal complex. The ScFv library is translated and transcribed in vitro, and as the mRNA does not 
contain a stop codon, mRNA-ribosome-ScFv complexes are formed. These are the complexes used in 
selection against the immobilised target. Following ScFv binding, the mRNA is isolated, purified and 
used in subsequent rounds of selection. In error prone ribosome display libraries, prior to subsequent 
rounds of selection, mutations are introduced into the mRNA using low-fidelity DNA polymerase for 
amplification resulting in error prone PCR. This gives the advantage of directed evolution at each 
round of ribosome display. In the case of optimising insulin antibodies, ribosome display was used to 
improve affinity by up to 40-fold [270]. Thus, this approach to affinity maturation could be helpful in 
optimising Glp1R0017. 
2.5.4 Affinity maturation approaches using computational methods  
Aside from the alternative display platforms discussed above, the advent of bioinformatics means that 
in silico modelling can be used to assist the process of affinity maturation. For example, structural 
knowledge of the lead antibody could be used to give a more informed approach to affinity 
maturation.  
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Indeed, crystal structures of antibody:antigen or ScFv:antigen complexes can be used to reveal the 
residues within the CDR that appear to be important for binding, then phage display libraries can be 
made around these residues [271]. A more in silico based approach is to first identify residues 
important for binding using structural data, then use computational protein design to alter the residue 
type and conformations at the selected positions. Computational power allows all possible 
combinations of mutations to be modelled, and binding properties to be predicted. A selection of the 
best mutants can then be constructed to determine the actual binding properties [272].  
When 3D structures are not available for the antibody of interest, a combination of phage display and 
computational approaches can be sought. For example, one could first target the CDR3 regions for 
affinity maturation using phage display, and screen the outputs for affinity. Those with the best 
improvement in affinity can then be modelled computationally for binding to the epitope, again 
mutations in the ScFv can be made, and the effect predicted [251].  
These approaches rely on some level of structural knowledge about the epitope. As there are now 
structures available for the GLP1R [85, 86, 273], computational modelling could be used for epitope 
mapping of Glp1R0017, and subsequent determination of the residues important for binding. This 
could be extremely helpful in providing a more targeted approach to affinity maturation of Glp1R0017.  
It would also be helpful to determine the structure of Glp1R0017.  
2.5.5 Summary 
Overall in this chapter, a GLP1R antagonistic antibody with nanomolar potency has been generated 
using naïve phage display. We have demonstrated that Glp1R0017 has cross-species reactivity, with 
antagonism of both the mouse and human GLP1R being observed. Attempts were made to improve 
the affinity of Glp1R0017 by randomising sections of the CDR regions, and using the resulting libraries 
in phage display. However, within the time frame of this study only a slight improvement in Glp1R0017 
potency for the human GLP1R was observed, with no improvement in potency on the mouse GLP1R. 
Alternative affinity maturation approaches have been discussed which may be considered for future 
affinity maturation of Glp1R0017. Glp1R0017 has since been scaled up, and characterised in more 
depth, which will be detailed in chapter 3. 
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Chapter 3. Characterisation of Glp1R0017, a GLP1R antagonistic 
antibody 
3.1 Introduction 
3.1.1 GLP1R Signalling Pathways 
To characterise the monoclonal GLP1R antagonistic antibody generated in Chapter 3, several GLP1R 
signalling pathways have been assessed including cAMP, Ca2+, and β-arrestin signalling. It is well known 
that the GLP1R is a Gαs coupled GPCR within the secretin (class B) family of GPCRs, thus the canonical 
signalling pathway leads to generation of cyclic AMP (cAMP) via adenylate cyclase [89, 274]. 
Downstream, cAMP leads to activation of protein kinase A (PKA) and exchange protein directly 
activated by cAMP (Epac), which together have several downstream effects in cells, including the 
triggering of insulin granule exocytosis from pancreatic beta cells [90, 91]. 
There are also suggestions that GLP1R can couple to Gαq resulting in elevation of cytosolic [Ca2+]. The 
binding of Gαq to GLP-1 activated GLP1R was first observed by western blotting of CHO cells 
overexpressing the GLP1R, and led to the suggestion that GLP1R may also signal via the Gαq coupled 
pathway [275]. Gαq signalling leads to activation of phospholipase C (PLC) which breaks down 
phosphatidylinositol-4,5-bisphosphate (PIP2) into inositol-1,4,5-triphosphate (IP3) and diacylglycerol 
(DAG) [276]. Downstream, IP3 causes an increase in cytosolic calcium, which together with DAG 
activates protein kinase C which then phosphorylates extracellular signal-regulated kinase (ERK) [277, 
278]. Dose-dependent increases in intracellular calcium following GLP1R stimulation have indeed 
been observed using both GLP-1 and GLP-1 mimetics in GLP1R overexpressing cell lines, indicating that 
the GLP1R signals via Gαq in addition to Gαs [279, 280]. It has even been proposed that this Gαq signalling 
is responsible for agonist induced internalisation of the GLP1R [279]. 
Further evidence suggests the GLP1R can signal using G protein independent pathways, including β-
arrestin signalling. Historically it was thought that β-arrestin binding was solely responsible for 
mediating receptor internalisation via endocytosis, however more recently β-arrestin induced 
signalling pathways have been described, such as phosphorylation of ERK1/2 and other kinases [281, 
282]. A direct interaction of β-arrestin 1 with the GLP1R has been observed in the rat INS-1 pancreatic 
beta cell line, and an interaction of GLP1R with β-arrestin 2 has also been demonstrated [283, 284].  
The functional role of β-arrestin recruitment to the GLP1R is unclear. In terms of GLP1R internalisation; 
β-arrestin 1 depletion does not affect GLP1R endocytosis, whereas enhancement of β-arrestin 2 action 
increases GLP1R endocytosis [283, 284]. When considering signalling pathways, β-arrestin 1 signalling 
upon acute GLP1R stimulation potentiates glucose stimulated insulin secretion, and regulates beta-
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cell apoptosis [283, 285]. However, prolonged GLP1R exposure to agonist, leads to β-arrestin induced 
receptor endocytosis and desensitisation of the GLP1R, reducing insulin secretion [286].  
Interest surrounds the field of GLP1R signalling bias due to the desire for development of new 
treatments for T2D. As mentioned previously, GLP-1 mimetics are available for treatment of T2D, but 
there is always a need for drugs with improved therapeutic efficacy. One strategy for this is to develop 
drugs that exploit the GLP1R signalling bias in a differing fashion to those drugs already on the market. 
For example, a biased agonist with reduced β-arrestin1 recruitment and signalling has recently been 
described, which when tested in vivo was more effective at correcting hyperglycaemia when used at 
sub-maximal concentrations compared to exendin-4 [280].  
3.1.2 GLP1R Physiology 
The downstream effects of GLP-1 signalling vary dependent upon the cell type in which GLP1R is 
expressed. As described in chapter 1, GLP1R is expressed in many different tissues. In the pancreas, 
GLP-1 modulates insulin, glucagon and somatostatin secretion from the islets of Langerhans. GLP1R 
activation in the β-cell leads to increased glucose stimulated insulin secretion, decreased apoptosis, 
and increased proliferation [98]. A subset of α cells express GLP1R [93], and GLP-1 inhibits glucagon 
secretion from the α cells. However, whether this is a direct or an indirect mechanism remains 
controversial [101, 287, 288].  In the δ cells, GLP-1 causes somatostatin secretion which in turn inhibits 
glucagon secretion from α cells [101, 289]. Together, GLP-1 actions on the pancreas are responsible 
for regulating glucose levels in the ‘incretin effect’. 
In extra-pancreatic tissue, GLP-1 has several other effects [47]. In the kidney, GLP-1 stimulates 
natriuresis, however whether this is a direct or indirect effect is unknown [290]. GLP1R activation in 
the central nervous system and brain leads to decreased food intake, increased neuroprotection and 
increased neurogenesis [98].  
GLP-1 also has a range of actions in the cardiovascular system, some of which include modulation of 
heart rate, and cardio-protection in myocardial ischaemia. Considerable uncertainty surrounds 
whether these cardiac effects are mediated via a direct or indirect mechanism, most likely both direct 
and indirect signalling are involved [124, 238]. The exact location of cardiac GLP1R remains to be 
elucidated, mRNA transcripts of GLP1R have been detected in human hearts however location of the 
GLP1R protein by immunostaining remains unclear, with further research required to determine the 
GLP1R positive cell-type [117].  
For the characterisation of Glp1R0017 in vivo, the effect on GLP-1 regulated glucose levels were 
determined, which is mainly controlled by pancreatic actions of GLP-1.     
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3.2 Aims 
To characterise the newly developed GLP1R antibody, Glp1R0017, by: 
a) Determining the specificity for GLP1R, and any cross-species reactivity. 
 
b) Assessing inhibition of GLP1R alternative signalling pathways. 
 
c) Assessing inhibition of endogenous levels of GLP1R in INS-1 832/3 cells. 
 
d) Assessing the use in immunostaining of GLP1R. 
 
e) Assessing inhibition of GLP1R in vivo using glucose tolerance tests to monitor incretin effects 
on glucose regulation.  
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3.3 Methods 
3.3.1 Solutions and Compounds 
Standard saline solution contained (mmol/l) 138 NaCl, 4.5 KCl, 4.2 NaHCO3, 1.2 NaH2PO4, 2.6 CaCl2, 
1.2 MgCl2, 10 HEPES. Krebs-Ringer Buffer (KRB) contained (mmol/l) 120 NaCl, 3.5 KCl, 1.2 KH2PO4, 1.2 
MgSO4, 2.5 CaCl2, 25 NaHCO3 (pH 7.2). Assay buffer for calcium measurements and ligand-binding 
assays was Hanks’ balanced salt solution supplemented with 25 mmol/l HEPES and 0.1% (w/v) bovine 
serum albumin (BSA) (pH 7.4); for the cAMP homogenous time-resolved fluorescence (HTRF) assay, 
the buffer was supplemented with 0.5 mmol/l 3-isobutyl-1-methylxanthine (IBMX). 
Unless stated otherwise, chemicals were obtained from Sigma-Aldrich (Poole, UK), and peptides were 
purchased from Bachem (Bubendorf, Switzerland). The following stocks were dissolved in dimethyl 
sulfoxide (DMSO): 10 mmol/l forskolin, 100 mmol/l IBMX, 136 µmol/l exendin (9-39) acetate salt, 150 
µmol/l GIP (1-42), and 285 µmol/l glucagon (1-29). GLP-1 (7-36) was diluted in water to 100 µmol/l.  
3.3.2 Cell Culture 
All cell lines were maintained at 37°C with 5% CO2. Chinese Hamster Ovary (CHO) K1 cells were 
maintained in Nutrient Mixture F-12 Ham, and Human embryonic kidney (HEK) 293 cells were 
maintained in DMEM with 1000 mg/ml glucose; both of these medias were supplemented with 10% 
FBS, 0.1 units/l penicillin, 0.1 µg/l streptomycin and 2 mmol/l L-glutamine.  
INS-1 832/3 cells were cultured in RPMI 1640 Media with GlutaMAX supplement (ThermoFisher 
Scientific), 10% FBS, 10 mmol/l HEPES, 50 µmol/l β-mercaptoethanol, 1 mmol/l sodium pyruvate and 
penicillin/streptomycin [291].  
Stably transfected cell lines overexpressing GPCRs of interest were generated at AstraZeneca 
(Gothenburg, Sweden) or MedImmune (Cambridge, UK). For experimental use these overexpressing 
cell lines were thawed from liquid nitrogen stocks directly into assay buffer. 
3.3.3 Cell Based Assays 
3.3.3.1 cAMP Homogenous Time Resolved Fluorescence (HTRF) Accumulation Assay 
Control peptides and antibody were serially diluted in assay buffer, and plated using an ECHO525 
acoustic liquid handler (Labcyte, Sunnyvale, CA, USA) to give 11-point dose response curves in 384 
well plates. Overexpressing cell lines resuspended in assay buffer, at a density dependent on the 
cell line (Appendix 3), were then combined with the test compounds. For agonism experiments, 
cAMP was measured after 30 minutes of incubation at room temperature. For antagonism 
experiments, an agonist challenge was given after 15 minutes using the ECHO550 acoustic liquid 
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handler (Labcyte), and samples were mixed by centrifugation at 150 g for 1 minute. After a further 
30 minute incubation at room temperature, cAMP was measured. Cellular cAMP levels were 
measured using the cAMP dynamic 2 HTRF kit (Cisbio, Codolet, France) according to the 
manufacturer’s recommendations. Plates were read on an EnVision plate reader (PerkinElmer, 
Waltham, MA, USA) after 1 hour. Non-linear regression was used to calculate EC50 and IC50 values. 
3.3.3.2 cAMP FRET Imaging 
A fluorescence resonance energy transfer (FRET)-based sensor, Epac2-camps, was used for single cell 
measurements of cAMP in INS-1 832/3 cells. Cells were seeded into 35 mm plastic dishes, after 24 
hours cells were transfected with 3 µg Epac2-camps DNA probe using 3 µl lipofectamine 2000. 
Following 24 hours cells were trypsinised, and re-seeded onto matrigel-coated 35 mm glass bottomed 
dishes for imaging 24 – 48 hours later. During imaging, solutions were continually perfused at 
approximately 1 ml/minute. For experiments to determine antagonism, cells were pre-incubated with 
100 µmol/l Glp1R0017 for 15 minutes prior to imaging. 
An inverted microscope (IX71; Olympus, Southend on Sea, UK) with a x40 oil immersion objective was 
used to visualise cells. Cells were excited at 435 nm (200 – 225 ms excitations) every 5 seconds using 
a Xenon arc lamp coupled to a monochromator (Cairn Research, Faversham, UK) and controlled by 
MetaFluor software (Molecular Devices). Cyan fluorescent protein (CFP) emission (470 nm) and yellow 
fluorescent protein (YFP) emission (535 nm) were monitored using an Optosplit II beam splitter (Cairn 
Research) and an Orca-ER digital camera (Hamamatsu, Welwyn Garden City, UK). Emissions were 
expressed as CFP/YFP fluorescence ratio, and a sliding average across 30 seconds was used for 
smoothening data. Responses were calculated as maximum ratio during test reagent application 
minus maximum ratio at baseline immediately prior to reagent application. Overall changes in CFP/YFP 
emission ratio was calculated as mean ± SEM. Statistical significance was assessed by one-way ANOVA 
with a post-hoc Bonferroni test. 
3.3.3.3 Calcium Measurements 
CHO cells overexpressing human GLP1R were seeded into black poly-D-lysine coated 384 well plates 
(Greiner Bio-One, Stonehouse, UK) at 15,000 cells/well. The following day, cells were washed with 
assay buffer then loaded with Fluo-4 NW containing 2.5 mmol/l probenecid (Thermo Fisher Scientific) 
for 30 minutes at 37°C then 15 minutes at room temperature. After loading, antibody was added to 
cells for 15 minutes at room temperature, prior to adding GLP-1. The FLIPR Tetra (Molecular Devices, 
Wokingham, UK) was used to record fluorescence every 0.5 seconds for 1 minute after agonist 
addition, then every 3 seconds for 4 minutes. Responses were normalised to the vehicle control, and 
average responses were calculated by subtracting basal fluorescence from peak intensity. 
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3.3.3.4 Insulin Secretion Assay 
INS-1 832/3 cells were seeded in 24-well plates at 500,000 cells/well, and used for insulin secretion 
after 24 hours. Cells were washed thoroughly in PBS before being incubated in KRB containing 0.2% 
BSA with or without Glp1R0017 for 1 hour at 37°C in 5% CO2. Test reagents diluted in KRB were then 
added to cells, and incubated for a further 2 hours. After incubation the supernatant fractions were 
collected and centrifuged at 4°C to remove cell debris. Insulin was then measured in the supernatant 
fractions by the Core Biochemical Assay Laboratory (Cambridge Biomedical Campus, Cambridge, UK), 
using a rat insulin assay (Meso Scale Discovery, Gaithersburg, MD, USA). 
3.3.3.5 Receptor Ligand Binding Assay 
AlexaFluor647 tagged GLP‐1 (Cambridge Research Biochemicals, Billingham, UK) was serially diluted 
and combined with GLP1R overexpressing CHO cell lines seeded in black clear bottomed 384 well 
plates at 1000 cells/well. The cells were then incubated +/- 0.5 µmol/l Exendin‐4 overnight at 4°C in 
the dark. The following morning, fluorescence was measured using the FL3 (650-690 nm) emission 
channel on a mirrorball system (TTP Labtech, Melbourn, UK). FL3 total readings (median fluorescence 
per event x count) were plotted.  
3.3.3.6 Nano-Glo® Live Cell Assay for Beta-Arrestin Measurements  
NanoBiT® technology was used to measure protein-protein interactions between beta-arrestin 1 or 2 
and GPCRs of interest. Firstly, GPCRs of interest were cloned into the pBiT1.1-C[TK/LgBiT] vector using 
Xho1 and EcoR1 as the restriction enzymes. The pBiT2.1-N[TK/SmBiT] vector was used to express 
SmBiT at the N terminal of beta-arrestin 1 and beta-arrestin 2. Successful cloning was verified by 
Sanger sequencing prior to using the constructs in the assay. 
HEK293 cells were seeded into 96 well plates at 20,000 cells/well. The following day, cells were 
transfected with NanoBiT constructs using 50 ng of each relevant construct per well with 0.5 – 1 µl 
Lipofectamine 2000. After overnight incubation, media was replaced with 100 µl OptiMEM Reduced 
Serum Media, and cells were incubated at 37°C for 30 minutes prior to the start of the assay. The 
Nano-Glo® Live Cell Substrate was then diluted 20-fold with Nano-Glo® LCS Dilution Buffer to make 
the Nano-Glo® Live Cell Reagent. Luminescence measurements were made on the Tecan SparkTM 10M 
multimode microplate reader, at 37°C with 5% CO2. After the first 5 minutes, 25 µl of Nano-Glo® Live 
Cell Reagent was added to cells and luminescence was monitored for 10 minutes prior to ligand 
addition. Luminescence was then measured every 30 seconds for 1 hour.  
For antagonist experiments, the antagonist or control antibodies were diluted in OptiMEM and 
incubated with cells for the 30 minutes prior to luminescence measurement. To check that antagonists 
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had no effect on beta-arrestin recruitment, the antagonist was also added to wells at the point of 
ligand addition. 
3.3.4 Animal Studies 
All experimental procedures were approved by local ethical review bodies and were performed in 
accordance with the Animal (Scientific Procedures) Act 1986, Home Office guidelines, local 
establishment guidelines and Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines. 
Experiments performed using my personal licence (I290CEFFE), under a number of Home Office 
Project Licenses. C57/Bl6 mice were purchased from Charles River UK. Mice were group-housed in 
individually ventilated cages, with ad libitum access to chow diet and water unless otherwise stated. 
Animals were euthanized by cervical dislocation, unless otherwise stated. 
3.3.4.1 Transgenic mice  
Transgenic mice were generated by F. Reimann, in which the expression of cre-recombinase is driven 
by the glp1r promoter [93]. Expression of cre-recombinase is responsible for reporter gene activation. 
The cre-recombinase recognises loxP sites surrounding a stop codon in front of the reporter gene, 
then deletes the ‘floxed’ stop codon. Consequently, the reporter protein is only produced in cells 
which express the gene of interest. However, once the reporter gene is expressed it is under the 
control of a constitutively active rosa26 promoter, meaning after initial activation each cell will 
continue to produce the reporter protein independent of cre-recombinase. The fluorescent reporter 
proteins used in this study are enhanced yellow fluorescent protein (EYFP), tandem red fluorescent 
protein (tdRFP) [292] and the fluorescent calcium indicator GCaMP3 [293].   
GLP1R knockout mice were kindly provided under license from D.Drucker (Lunenfeld-Tanenbaum 
Research Institute, Toronto, ON, Canada). Briefly, these mice have a deletion of the two exons 
encoding the first and third transmembrane domain of GLP1R, resulting in an absence of the GLP1R 
[294]. 
3.3.4.2 Immunostaining  
Tissue for immunostaining was fixed in 4% (w/v) paraformaldehyde (PFA) overnight, and subsequently 
dehydrated using a gradient of 15% then 30% (w/v) sucrose. For processing, tissue was frozen in 
optimal cutting temperature embedding media (VWR Chemicals, Radnor, PA, USA). 6-10 μm sections 
were sliced on the cryostat, and mounted onto Superfrost Plus glass slides (Thermo Fisher Scientific).  
Slides were incubated for 1 hour in blocking solution containing 5% (v/v) donkey or goat serum, 0.05% 
(v/v) Tween-20 and 1% (w/v) BSA. Slides were then stained overnight with primary antisera of interest 
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in the same blocking solution (Appendix 4). After washing in blocking solution, slides were incubated 
with appropriate secondary antisera diluted 1:300 and Hoescht diluted 1:1300 for 1 hour. Negative 
control slides were stained in parallel with only secondary antisera. Finally, coverslips were mounted 
with hydromount (National Diagnostics, Atlanta, GA, USA) and DABCO. 
Brain tissue was collected from mice perfused in situ with 4% (w/v) PFA and stored in 4% PFA, 30% 
(w/v) sucrose prior to sectioning on a freezing microtome (Leica) into 5 subsets of 25 μm slices. 
Following slicing, slides were stored in ethylene glycol based cryoprotectant. For immunofluorescent 
staining, antigen retrieval was performed using sodium citrate buffer, and sections were stained in 
suspension using a method similar to that described above, however blocking solution did not contain 
BSA.  
Slides were imaged using confocal microscopy (TCS SP8; Leica, Wetzlar, Germany) or automated 
widefield microscopy (Axio Scan.Z1, Zeiss, Oberkochen, Germany). Images displayed are either 
confocal slices or Z-stacks, quantification of cell number and co-localisation was performed using 
either Image J or HALO software (Indica Labs, Corrales, USA). 
3.3.4.3 Single-dose pharmacokinetics study 
The pharmacokinetic profile of Glp1R0017, administered via intraperitoneal or subcutaneous 
injection, was assessed in two groups of six male C57/Bl6 mice randomised according to body weight 
(13 weeks old, mean weight 29.1 ± 0.2 g). Blood samples were collected in EDTA capillary tubes, using 
a sparse sampling approach, at 0.5, 1, 2, 4 and 7 hours after injection, then every 24 hours for 5 days. 
At the 120 hour endpoint, animals were terminally anaesthetised by isoflurane inhalation, blood 
samples were collected via cardiac puncture, and death was confirmed using cervical dislocation. 
Plasma samples were obtained by centrifugation, and the plasma antibody concentration was 
assessed using a Gyrolab assay, according to manufacturer’s instructions (Gyros, Uppsala, Sweden). 
Briefly, this procedure is based on a sequential flow-through sandwich method. Firstly, the analyte 
was captured using a biotinylated idiotype antibody against IgG1 (MedImmune, Cambridge, UK). An 
Alexa-labelled sheep anti-human IgG (The Binding Site, Birmingham, UK) was then added to detect 
the bound captured analyte. Fluorescence was measured using the Gyrolab Workstation, which is 
directly proportional to the amount of analyte in the plasma sample. This work was carried out with 
the help of L. Liang and S. Madalli. 
3.3.4.4 Glucose Tolerance Tests (GTTs) 
Antibody effect on glucose tolerance was assessed by either intraperitoneal glucose tolerance tests 
(IPGTTs) or oral glucose tolerance tests (OGTTs). All GTTs were performed in 10 week old male C57/Bl6 
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mice randomised according to body weight, after a 6 hour fast. Groups of eight mice were used, 
which was pre-determined by power analysis where the effect size set at 15%, with 80% power and 
significance <0.05. Animals were dosed subcutaneously either with antibody or saline 24 hours prior 
to the GTTs. 
In the IPGTT, 0.1 mg/kg liraglutide (Victoza; Novo Nordisk, Gatwick, UK) or vehicle was dosed by 
subcutaneous injection 2 hours prior to intraperitoneal glucose administration (2 g/kg). Blood 
glucose was measured using a hand-held glucometer (AlphaTrak; Zoetis, London, UK) in tail-prick 
blood samples at −120, 0, 15, 30, 45, 60, 90 and 120 minutes relative to the glucose challenge. In the 
OGTT the same glucose challenge (2 g/kg) was administered via oral gavage, and blood glucose was 
measured at 0, 15, 30, 45, 60, 90 and 120 minutes relative to the glucose challenge. The area under 
the curve (AUC) between 0 and 120 minutes was calculated, and used for analysis. Statistical 
significance was assessed by one-way ANOVA with post-hoc Bonferroni test. This work was carried 
out with the help of L. Liang and the core team at the MedImmune animal facility. 
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3.4 Results 
3.4.1 Glp1R0017 exhibits cross-species antagonistic activity for GLP1R 
As the GLP1R is primarily recognised as a Gαs coupled GPCR, the antagonistic ability of Glp1R0017 was 
initially assessed in cAMP based HTRF assays.  
For assessment of cross-species reactivity, CHO cells overexpressing mouse, rat, human, dog or 
cynomolgus monkey GLP1R were used. To find an appropriate agonist challenge for use in the 
antagonistic assays, GLP-1 agonist activity was first investigated in each of these cell lines (in 
collaboration with J. Naylor at MedImmune). Dose-response curves of GLP-1 revealed the EC50 values 
ranged from 0.7 pmol/l to 6.07 pmol/l in the cynomolgus monkey and dog GLP1R cell lines respectively 
(Figure 3.1, Table 3.1). The concentration of agonist challenge used in the antagonistic assays ranged 
between EC55 to EC80 (Figure 3.1). Glp1R0017 antagonism of the GLP1R was observed in each species 
assessed, and IC50 values were calculated (Figure 3.2a). The IC50 values ranged from 5.2 to 43 nmol/l 
in the mouse and human GLP1R cell lines respectively (Table 3.1).  
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Figure 3.1 Agonistic activity of GLP-1 in GLP1R overexpressing cell lines. The dose response curves 
of cAMP stimulation by GLP-1 in CHO cells overexpressing mouse GLP1R (a), human GLP1R (b), rat 
GLP1R (c), cyno GLP1R (d), and dog GLP1R (e) are displayed. For each cell line, the concentration of 
GLP-1 used as the agonist challenge in antagonistic cAMP assays is marked by a dotted line. Data 
displayed are n3 for each cell line.  
 
  
63 
 
 
Table 3.1 Summary of GLP-1 and Glp1R0017 activity in each of the GLP1R overexpressing CHO cell 
lines. The mean EC50 values are displayed for GLP-1, along with the mean IC50 values for Glp1R0017. 
 
Mouse 
GLP1R 
Human 
GLP1R 
Rat 
GLP1R 
Cyno 
GLP1R 
Dog 
GLP1R 
GLP-1 EC50 (mol/l) 3.92E-12 1.45E-12 4.51E-12 7.05E-13 6.07E-12 
Glp1R0017 IC50 (mol/l) 5.21E-09  4.33E-08 5.3E-09 8.99E-09 11.7E-09 
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Figure 3.2 Antagonistic activity of Glp1R0017 in GLP1R, GIPR, GLP2R and GCGR overexpressing 
cell lines. (a) Antagonistic profiles of Glp1R0017 in CHO cells overexpressing mouse, human, rat, 
cynomolgus monkey, or dog GLP1R. (b) Antagonistic profiles of Glp1R0017 and the antagonistic 
GIPR antibody Gipg013 in CHO cells overexpressing human GIPR, and HEK293 cells overexpressing 
mouse GIPR. (c) Antagonistic profile of Glp1R0017 in HEK293 cells overexpressing human GLP2R. 
(d) Antagonistic profiles of Glp1R0017 and the glucagon receptor partial antagonist des-His1-[Glu9]-
glucagon (1–29) amide in CHO cells overexpressing human, mouse or rat GCGR. Values have been 
normalised to the maximum activity of each receptor, defined by the total cellular cAMP production 
in the absence of peptide/IgG. Data are mean ± SE from duplicate wells, and the data shown are 
representative of at least three separate experiments.  
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The observed differences in IC50 values of Glp1R0017 and EC50 values of GLP-1 between different cell 
lines may be affected by differing levels of GLP1R overexpression. This was investigated by monitoring 
AlexaFluor647 tagged GLP-1 binding to each of the overexpressing cell lines. Measurements of the 
fluorescent max for each cell line suggested that the rat GLP1R cell line most highly expressed GLP1R, 
whereas the mouse GLP1R expresses very low levels of GLP1R which were undetectable in this 
receptor ligand binding assay (Figure 3.3).  
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Cell Line
Mean SD Mean SD
Human GLP1R 480000 170000 1.57E-09 8.42E-10
Rat GLP1R 1800000 690000 2.21E-09 5.71E-10
Cyno GLP1R 940000 77000 1.48E-09 4.46E-10
Mouse GLP1R
Dog GLP1R 51000 7500 2.11E-09 1.54E-09
Fluorescent Max KD
Below limits of detection
 
Figure 3.3 AlexaFluor647 tagged GLP-1 binding to GLP1R overexpressing CHO cells indicates level 
of GLP1R overexpression. Representative AlexaFluor647 GLP-1 binding curves (n=3) are displayed 
for CHO cells overexpressing human GLP1R (a), rat GLP1R (b), cyno GLP1R (c), and dog GLP1R with 
zoom inset (d). The mean fluorescent max (FL max) and KD for each cell line are tabulated (e). Non-
linear binding curves were plotted with non-specific binding and background constrained to 0.  
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3.4.2 Glp1R0017 is a specific, competitive antagonist for GLP1R 
To determine the specificity of Glp1R0017 for GLP1R, the ability to antagonise related class B GPCR’s 
was measured in the cAMP based HTRF assays. No antagonistic activity was observed in cells 
overexpressing the GIPR, GLP2R or glucagon receptor (GCGR) (Figure 3.2b-d). This suggested that 
Glp1R0017 displays specificity for antagonism of the GLP1R. 
For downstream application, Glp1R0017 was likely to be used in the mouse to investigate GLP1R 
function in more detail. Therefore, the in vitro pharmacology of Glp1R0017 antagonistic activity was 
investigated in more detail on the mouse GLP1R. Schild regression analysis was used to determine 
whether Glp1R0017 displays competitive antagonism for the GLP1R. The effect of increasing 
concentrations of Glp1R0017 on GLP-1 dose response curves was assessed, and revealed the maximal 
cAMP response to GLP-1 was not reduced by increasing Glp1R0017 concentrations (Figure 3.4a). This 
suggested that Glp1R0017 antagonism is not insurmountable. The same was observed for the small 
peptide antagonist, exendin 9-39 (Figure 3.4b). When the Schild regression line was plotted, the slope 
gradient for Glp1R0017 was 0.56, and the calculated dissociation constant was 466 pmol/l. Exendin 
9–39 had a slope gradient of 0.89 and a calculated dissociation constant of 315 pmol/l (Figure 3.4c).  
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Figure 3.4 Schild Regression Analysis of Glp1R0017 and exendin 9-39 antagonism of the mouse 
GLP1R. (a) GLP-1 dose response curves in the presence of varying concentrations of Glp1R0017. (b) 
GLP-1 dose response curves in the presence of varying concentration of exendin9-39. Data are 
mean ± SE from duplicate wells, and are representative of at least three independent experiments. 
(c) Schild regression analysis of GLP-1 dose response curves in the presence of Glp1R0017 or 
exendin9-39. Dose ratio (DR) is the ratio of apparent GLP-1 EC50 in the presence of the antagonist 
at a set concentration, over the GLP-1 EC50 in the absence of antagonist. Points from three 
independent experiments are plotted with the 95% confidence interval band for each line. 
Dissociation constants of 466 pmol/l for Glp1R0017, and 315 pmol/l for exendin 9–39 are yielded 
from the x-axis intersect of the lines. 
 
3.4.3 Glp1R0017 also inhibits alternative signalling pathways downstream of the 
GLP1R 
In addition to signalling via cAMP, GLP1R has also been shown to stimulate Gαq coupled pathways, 
leading to increases in cytosolic Ca2+. The ability of GLP-1 to stimulate intracellular Ca2+ in CHO cells 
overexpressing mouse GLP1R or human GLP1R was first assessed. No Ca2+ response was observed in 
the mouse GLP1R overexpressing cell line (data not shown). The dose response curve of GLP-1 in 
human GLP1R cells showed GLP-1 stimulates an increase in intracellular Ca2+ at concentrations greater 
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than 556 nmol/l. The dose-response curve was significantly right shifted when compared to the dose-
response seen in the cAMP assays, even at the maximal GLP-1 concentration of 5 µmol/l the dose-
response curve had not reached plateau (Figure 3.5a).  
Glp1R0017 at 1 µmol/l successfully inhibited the 5 µmol/l GLP-1 induced intracellular calcium response 
in the human GLP1R overexpressing CHO cells (Figure 3.5b, c). In contrast, an isotype control antibody 
(R347) had no effect on the calcium response (Figure 3.5b, c). This suggested the Glp1R0017 inhibitory 
effect was specifically due to GLP1R binding.  
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Figure 3.5 Glp1R0017 inhibits GLP-1 induced intracellular calcium responses from the human 
GLP1R. (a) GLP-1 dose response curve showing intracellular calcium responses, calculated by 
subtracting basal fluorescence at 19 s from peak intensity. Data are mean ± SEM, n=2.  (b) 
Representative intracellular calcium responses of CHO cells overexpressing human GLP1R, 
measured in relative fluorescent units (RFU). All traces have been normalised (norm.) to the vehicle 
control response. (c) Mean intracellular calcium responses were calculated as in (a). Data are mean 
± SD, n=16 wells (eight wells from each of two independent experiments). Statistical significance 
was assessed by one-way ANOVA with post hoc Bonferroni test. ***p<0.001  
 
GLP1R signalling via the β-arrestins has also been observed in the literature. Therefore, the 
recruitment of β-arrestin 1 and β-arrestin 2 to the human GLP1R was determined, followed by the 
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ability of Glp1R0017 to inhibit β-arrestin recruitment. This was investigated using the Nano-Glo® live 
cell assay system in transiently transfected HEK293 cells, with an increase in luciferase activity 
indicating β-arrestin binding to the GLP1R. A pilot dose-response curve of GLP-1 showed that at 
concentrations greater than 10 nmol/l GLP-1 stimulates β-arrestin 1 and β-arrestin 2 recruitment to 
the GLP1R (Figure 3.6).  
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Figure 3.6 GLP1R signalling via beta-arrestin 1 and beta-arrestin 2. (a) Real-time beta arrestin 1 
responses to a dose titration of GLP-1. The beta-arrestin is tagged with the small part of 
nanoluciferase, and GLP1R is tagged with the large part of nanoluciferase, an increase in luciferase 
activity represents recruitment of beta-arrestin to the GLP1R. (b) Area under curve (AUC) summary 
data displays GLP-1 dose response curve for beta-arrestin 1 recruitment. (c) Real-time beta arrestin 
2 responses to a dose titration of GLP-1. (d) Area under curve (AUC) summary data displays GLP-1 
dose response curve for beta-arrestin 2 recruitment.  This was a pilot experiment to determine the 
dose of GLP-1 required for beta-arrestin recruitment, data are mean ± SEM (n=1 from 3 wells).  
 
Pre-incubation of cells with 1 µmol/l Glp1R0017 prior to use in the assay had varying effects on GLP-1 
induced β-arrestin 1 and β-arrestin 2 recruitment, dependent on the GLP-1 concentration. When 
Glp1R0017 and GLP-1 were used at equimolar concentrations, no effect was seen on recruitment of 
the β-arrestins. 10-fold excess of Glp1R0017 slightly reduced recruitment of both β-arrestins, however 
when the area under the curve (AUC) was calculated, the Glp1R0017 effect was not significant. When 
Glp1R0017 was used at 100-fold excess, GLP-1 stimulated β-arrestin recruitment was inhibited (Figure 
3.7a-d). Use of an isotype control antibody (NIP228) showed that the inhibitory effect was specific for 
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Glp1R0017 (Figure 3.7e, f). When either Glp1R0017 or the isotype control antibody was added at the 
time of ligand addition, no β-arrestin recruitment was observed (data not shown). 
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Figure 3.7 GLP1R signalling via beta-arrestin 1 and beta-arrestin 2 is inhibited by Glp1R0017 pre-
incubation. Example real-time beta arrestin responses to a dose titration of GLP-1 +/- 1 µmol/l 
Glp1R0017 are displayed for beta-arrestin 1 (a) and beta-arrestin 2 (b).  Area under curve (AUC) 
summary data +/- 1 µmol/l Glp1R0017 (n=3) displayed for beta-arrestin 1 recruitment (c) and beta-
arrestin 2 recruitment (d). AUC summary data +/-  1 µmol/l NIP228 (n=3) displayed for beta-arrestin 
1 recruitment (e) and beta-arrestin 2 recruitment (f). AUC has been calculated using the 5 minutes 
prior to ligand addition as the baseline value. Data are mean ± SEM. Data was log10 transformed for 
normality. Following this statistical significance was assessed by one-way ANOVA with post hoc 
Bonferroni test, ***p<0.001. 
 
3.4.4 Glp1R0017 inhibits GLP1R at natural levels in the INS-1 832/3 cells 
To determine whether Glp1R0017 could inhibit the GLP1R when expressed at natural levels, the rat 
pancreatic beta cell line INS-1 832/3 was used. Firstly, the antagonism of GLP-1 induced cAMP 
responses was measured by live cell imaging. Briefly, INS-1 832/3 cells were transfected with Epac2-
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camps, a FRET-based cAMP sensor [295], and then the CFP/YFP ratio was recorded over time. GLP-1 
at 100 nmol/l stimulated an increase in cAMP (Figure 3.8a). However, when 1 µmol/l Glp1R0017 was 
incubated with cells prior to live-cell imaging, the cAMP response was reduced (Figure 3.8b). Overall, 
the cAMP response was reduced by 64%. In contrast, Glp1R0017 pre-incubation had no effect on the 
responses to forskolin/IBMX (Figure 3.8c). 
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Figure 3.8 Glp1R0017 reduces GLP-1-stimulated cAMP in INS-1 832/3 cells. (a) Example trace of 
changes in cAMP concentration in response to GLP-1 receptor activation. INS-1 832/3 cells were 
transfected with Epac2-camps, to enable measurement of cAMP by FRET. Cells were then perfused 
with GLP-1 (100 nmol/l) followed by forskolin/IBMX (F/I; 10 μmol/l or 100 μmol/l), as indicated. (b) 
Example trace demonstrating the effect of 15 minute pre-incubation of cells with 1 µmol/l 
Glp1R0017 (c) Mean changes in the CFP/YFP emission ratio. Data are mean ± SEM; n=19 for 
antibody-treated cells, and n=26 for cells without antibody (monitored in 9–11 independent 
experiments per condition). Statistical significance was assessed by one-way ANOVA with post hoc 
Bonferroni test. ***p<0.001. 
 
As the INS-1 832/3 cells are a pancreatic beta cell line, this enabled the Glp1R0017 effect on insulin 
secretion to be investigated. The potentiation of insulin secretion by GLP-1 requires the presence of 
glucose, therefore the concentration of basal glucose to use was first assessed. Insulin secretion in the 
presence of 8.3 mmol/l glucose or 16.7 mmol/l glucose was compared. 16.7 mmol/l glucose increased 
basal insulin secretion, and GLP-1 potentiated insulin secretion was only observed at a significant level 
with 100 nmol/l GLP-1. In comparison, when 8.3 mmol/l glucose was used as basal glucose, significant 
increases in insulin secretion were observed with both 10 and 100 nmol/l GLP-1 (Figure 3.9a).   
Glp1R0017 reduced GLP-1 stimulated insulin secretion, but had no effect on GIP stimulated insulin 
secretion (Figure 3.9b). Interestingly, Glp1R0017 was only able to reduce GLP-1 stimulated insulin 
secretion to basal levels when used at a 10-fold excess.  When used at equimolar concentrations, the 
insulin secretion was only partially reduced. Of note, Glp1R0017 also significantly reduced the 8.3 
mmol/l glucose induced insulin secretion. Upon further investigation, 8.3 mmol/l glucose was shown 
to stimulate GLP-1 secretion from INS-1 832/3 cells (Figure 3.9c). This basal level of GLP-1 secretion 
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likely explains why Glp1R0017 reduced insulin secretion at 8.3 mmol/l glucose without the addition of 
exogenous GLP-1.  
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Figure 3.9 Glp1R0017 reduces GLP-1 induced insulin secretion in INS-1 832/3 cells. Insulin 
secretion is expressed relative to secretion in 8.3 mmol/l glucose, all data are mean ± SEM. (a) 8.3 
mmol/l glucose and 16.7 mmol/l glucose were assessed as basal glucose concentrations for 
investigating GLP-1 induced insulin secretion. n=6 wells (from 2 independent experiments). 
Statistical significance was assessed by one-way ANOVA with post hoc Bonferroni test. (b) Effect of 
Glp1R0017 on GLP-1 and GIP stimulated insulin secretion. n=9–18 wells (from 3–6 independent 
experiments). Statistical significance was assessed by one-way ANOVA with post hoc Bonferroni 
test. (c) GLP-1 secretion from INS-1 832/2 cells stimulated by glucose. n=9 wells (from 3 
independent experiments). A two-tailed unpaired t-test was used to assess statistical significance. 
*p<0.05, **p<0.01, ***p<0.001. 
 
3.4.5 Glp1R0017 can be used to immunostain GLP1R from mouse tissue 
In addition to the use of Glp1R0017 as a GLP1R antagonist, the ability of Glp1R0017 to immunostain 
GLP1R in mouse tissue was also investigated. Initially, pancreas tissue was used to test the antibody, 
due to the high levels of GLP1R expression within pancreatic islets. Tissue was collected from Glp1r-
Cre/ROSA26-tdRFP mice [93] so that colocalisation of Glp1R0017 with GLP1R could be determined. 
Tissue from Glp1r−/− mice [294] was also used as a negative control. 
Immunostaining of Glp1r-Cre/ROSA26-tdRFP tissue revealed that Glp1R0017 bound to cells expressing 
the tandem red fluorescent protein (tdRFP) (Figure 3.10a). In contrast, no immunostaining with 
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Glp1R0017 was observed in the Glp1r−/− (Figure 3.10b). This again suggested that Glp1R0017 is specific 
for the GLP1R.  
The ability of Glp1R0017 to immunostain GLP1R was further assessed in the arcuate nucleus region of 
the hypothalamus, where GLP1R expression is thought to play a role in controlling food intake [94, 
107, 125].  Similar to staining in the pancreas tissue, Glp1R0017 immunostaining overlapped with 
tdRFP staining for the GLP1R (Figure 3.10c). Overall, these immunostaining results gave confidence 
that administration of Glp1R0017 to mice would lead to GLP1R binding in vivo.  
 
Figure 3.10 Glp1R0017 immunostains GLP1R in mouse pancreas and brain tissue. (a) 
Representative pancreas islet section from Glp1r-Cre/ROSA26-tdRFP tissue immunostained for RFP 
(white), insulin (green) and GLP1R using Glp1R0017 (pink). Overlay is seen in bottom right panel. 
Nuclei were visualised with Hoechst stain. Scale bars, 20 µm. (b) Representative pancreas islet 
section from Glp1r-−/− tissue immunostained for glucagon (white), insulin (green) and GLP1R (pink). 
Scale bars, 20 µm. Overlay is seen in bottom right panel. (c) Representative hypothalamic section 
from Glp1r-Cre/ROSA26-tdRFP tissue immunostained for RFP (red) and GLP1R (white). Nuclei were 
visualised with Hoechst stain (blue). Scale bars, 100 µm. Overlay is seen in right hand-side panel. 
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3.4.6 Glp1R0017 inhibits the GLP-1 incretin effect in vivo 
Prior to use in any functional studies in vivo, the pharmacokinetic profile of Glp1R0017 was 
determined. Glp1R0017 was dosed to mice at 19.2 mg/kg either using an intraperitoneal route or 
subcutaneous route, following which the pharmacokinetic profile of Glp1R0017 was compared 
between the different administration routes, over a period of 5 days.  
The intraperitoneal dosing of Glp1R0017 reached maximal concentration (Cmax) 4 hours after dosing, 
whereas Glp1R0017 dosed via subcutaneous injection reached Cmax 24 hours post-dosing. The values 
of Cmax were similar in both groups; 2.1 µmol/l for the intraperitoneal dosing, and 1.7 µmol/l for the 
subcutaneous dosing. By 120 hours post-injection, the plasma concentration of Glp1R0017 was 0.9 
µmol/l for the intraperitoneally dosed group, and 1 µmol/l for the subcutaneously dosed group (Figure 
3.11). This indicated that Glp1R0017 is relatively stable when dosed to mice, and consequently could 
be used for sub-chronic studies of GLP1R blockade. For functional experiments performed within this 
study, subcutaneous dosing was used 24 hours prior to the start of experiments. 
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Figure 3.11 Pharmacokinetic analysis of Glp1R0017 over a 5 day timecourse. Glp1R0017 was dosed 
at 19.2 mg/kg to two groups (n=6) either intraperitoneally or subcutaneously, and antibody 
concentration was measured in the plasma (n=3 per timepoint). One sample is missing at 0.5 hours 
in the subcutaneous group, and one sample at 72 hours in the intraperitoneal group is also missing.  
 
To investigate the effects of Glp1R0017 in vivo, glucose tolerance tests (GTTs) were used. Firstly, the 
ability of Glp1R0017 to block the glucose lowering effects of liraglutide, a GLP-1 mimetic, was assessed 
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using intraperitoneal GTTs (IPGTTs). Subsequently, the ability of Glp1R0017 to block the incretin 
actions of endogenous GLP-1 was determined using oral GTTs (OGTTs). 
Results from the IPGTT showed that Glp1R0017 dose-dependently reversed the actions of liraglutide 
on glucose tolerance (Figure 3.12a, b). When the AUC of the vehicle control group was compared with 
the AUC of the highest concentration of Glp1R0017 group, no significant difference was found (Figure 
3.12b). This indicates that at 19.2 mg/kg Glp1R0017 completely abolishes the effect of liraglutide on 
glucose tolerance. This set of data provided the first indication that Glp1R0017 can inhibit the GLP1R 
in vivo. 
To assess possible compensation of one incretin for the other within OGTTs, Glp1R0017 was dosed 
alone (9.6 mg/kg) or in combination with Gipg013 (100 mg/kg), which is a GIPR antagonistic antibody, 
previously produced at MedImmune [164]. When Gipg013 was dosed alone, no difference in glucose 
tolerance was observed. In contrast, individual dosing of Glp1R0017 slightly reduced glucose tolerance 
when compared to the isotype antibody control group. When Glp1R0017 was dosed together with 
Gipg013, the glucose tolerance was even further reduced (Figure 3.12c, d). This demonstrated that 
both antibodies could inhibit the glucose lowering actions of their respective endogenous incretin 
hormones, most probably via inhibition of glucose stimulated insulin secretion. 
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Figure 3.12 Glp1R0017 blocks the effect of liraglutide and endogenous GLP-1 on glucose 
tolerance. All data displayed are mean ± SEM (n=8). (a) 24 hours after antibody dosing, and 2 hours 
after liraglutide treatment (0.1 mg/kg) intraperitoneal glucose tolerance tests (2 g/kg) were 
performed. The groups were; vehicle only (blue), liraglutide only (red) and liraglutide plus 19.2 
mg/kg (green), 6.4 mg/kg (purple) and 3.1 mg/kg (orange) Glp1R0017. (b) AUC of glucose 
concentration between 0 and 120 minutes is displayed. Comparisons were made with the 
liraglutide-only group, and statistical significance was assessed by one-way ANOVA with post hoc 
Dunnett’s test. (c) Oral glucose tolerance tests (2 g/kg) performed 24 hours after antibody dosing. 
The groups were; isotype control (blue), Glp1R0017 at 9.6 mg/kg (red), Gipg013 at 100 mg/kg 
(green), Glp1R0017 and Gipg013 (purple). The double-treatment group was compared with single-
treatment groups, and statistical significance assessed by two-way ANOVA with post hoc Dunnett’s 
test. *’s indicate significant differences with the Glp1R0017 only group, #’s indicate significant 
differences with the Gipg013 group. (d) AUC of glucose concentration between 0 and 120 minutes 
is displayed. Comparisons were made with the isotype control group, and statistical significance 
assessed by one-way ANOVA with post hoc Dunnett’s test. *p<0.05, **p<0.01, ***p<0.001 
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3.5 Discussion 
3.5.1 Characterisation of Glp1R0017 using cell based assays 
Glp1R0017 was characterised in this study using a range of in vitro assays, both with overexpressing 
cell lines and the INS-1 832/3 cell line modelling endogenously expressed GLP1R. These experiments 
served as a pre-requisite to in vivo work, and were used to show the specific inhibition of GLP1R caused 
by Glp1R0017. In future studies, it will be possible to use Glp1R0017 as a tool for in vitro inhibition of 
the GLP1R. 
The use of cAMP HTRF based assays allowed for cross-species reactivity, and cross-receptor reactivity 
to be assessed. Glp1R0017 is specific for the GLP1R (Figure 3.2b-d), and has antagonistic activity across 
the multiple species characterised (Figure 3.2a). In comparison to the GLP1R antibodies recently 
produced by Novo Nordirsk [116, 252, 253] (described in Chapter 2), Glp1R0017 produced here is 
advantageous in terms of cross-species reactivity, and the ability to block GLP1R in vivo. The specificity 
observed provides a major advantage when Glp1R0017 is compared to the peptide antagonist exendin 
9-39 which has been shown to have some off-target effects [121, 243, 244]. However, it must be noted 
that a limited range of GPCR’s were investigated here for off-target responses, meaning potential 
interactions with unknown targets cannot be excluded.  
Schild regression analysis of Glp1R0017 in the mouse GLP1R overexpressing cell line allowed for the 
investigation of Glp1R0017 mode of antagonism. Antagonism of the GLP1R by Glp1R0017 was found 
to be surmountable, in that the maximal cAMP response was still achieved with increased competing 
concentrations of GLP-1 (Figure 3.4a). This led to the suggestion that Glp1R0017 is a competitive 
antagonist for the GLP1R. However, for this to be true it is expected that the slope of the Schild 
regression plot would be equal to one. In this case, the slope of the Schild plots for both Glp1R0017 
and exendin 9-39 was not equal to one (Figure 3.4c). One possible reason for this is a disequilibrium 
between agonist and antagonist at the time of cell lysis and measurement of cAMP. Alternatively, the 
inhibition may not be as simple as a competition for the same binding site on the receptor. The 
calculated dissociation constant should therefore only be taken as an estimate.  
For further investigation, structural studies would be incredibly helpful in determining whether the 
Glp1R0017 epitope is the same as the GLP-1 binding site. Recent structural studies have shown GLP-1 
binding within the transmembrane domain and in the large N terminal extracellular domain of GLP1R 
[85-87]. As Glp1R0017 is larger in size than GLP-1, and was selected via binding to the extracellular 
domain of GLP1R, it is unlikely that Glp1R0017 shares the exact same binding site as GLP-1. Rather 
than binding to the transmembrane domain and extracellular domain, it is predicted that Glp1R0017 
binds only to the extracellular domain of GLP1R.  
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When the alternative signalling pathways downstream of GLP1R were investigated, increased 
intracellular Ca2+ was observed in GLP-1 stimulated human GLP1R overexpressing cells (Figure 3.5a) 
but not in mouse GLP1R overexpressing cells. This increase in intracellular Ca2+ was abolished by pre-
incubation of cells with Glp1R0017 (Figure 3.5b, c). Within published data, GLP1R signalling via 
intracellular Ca2+ has been investigated in most detail in human GLP1R overexpressing cells [279, 280], 
although coupling to Gαq has also been observed in cells overexpressing the rat GLP1R [275]. The lack 
of signalling in the mouse GLP1R overexpressing cell line observed here, may be due to the much 
lower levels of mouse GLP1R overexpression when compared to human GLP1R overexpression. When 
levels of GLP1R overexpression were measured using fluorescently tagged GLP-1, the levels of mouse 
GLP1R in the overexpressed cell line were below the limits of detection (Figure 3.3e). Despite this, the 
mouse GLP1R overexpressing cell line was successfully used in the cAMP assays.  
A comparison of the GLP-1 dose response curves for intracellular Ca2+ and cAMP in the human GLP1R 
overexpressing cell line shows that the GLP-1 dose response for intracellular Ca2+ is right shifted 
compared to the cAMP response which had an EC50 in the nanomolar range. As the Ca2+ response was 
not saturated at the top concentration of GLP-1, an EC50 cannot be accurately defined, but appears to 
be in the micromolar range. This suggests that although some GLP1R signalling is via intracellular Ca2+, 
the main signalling pathway is Gαs coupled with cAMP as the main signalling molecule. The in vivo role 
of GLP1R signalling via Ca2+ is debatable as GLP-1 is only found within the picomolar range in plasma 
[296]. Glp1R0017 was able to inhibit intracellular Ca2+ signalling without being in molar excess (Figure 
3.5b, c). 
Within literature, it has also been proposed that GLP1R signals via β-arrestin, therefore recruitment 
of β-arrestin was investigated in cells transiently transfected with the human GLP1R. GLP-1 dose 
response curves from a pilot study showed that both β-arrestins are recruited to the GLP1R (Figure 
3.6). The GLP-1 dose response curves for β-arrestin recruitment gave an EC50 of 3 nmol/l for β-
arrestin1, and 120 pmol/l for β-arrestin2. This assay used transiently transfected cells, whereas the 
cAMP assay used stable cell lines, therefore the EC50 values should not be directly compared. The 
importance of GLP1R signalling via β-arrestin in vivo is interesting to consider from a drug 
development point of view, as it is thought that GLP-1 mimetics that exhibit biased agonism have 
differing therapeutic efficiency [280, 286]. Glp1R0017 inhibited GLP-1 stimulated recruitment of both 
β-arrestins, however only when used at 100-fold excess of the GLP-1 concentration (Figure 3.7a-d).  
Before moving on to in vivo work, the INS-1 832/3 cell line was used to study Glp1R0017 inhibition of 
endogenous expression levels of GLP1R. Glp1R0017 inhibited both GLP-1 stimulated cAMP signalling, 
and insulin secretion from this cell line (Figure 3.8, 3.9). However, Glp1R0017 also reduced insulin 
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secretion stimulated from 8.3 mmol/l glucose alone (Figure 3.9b). This led to the incidental finding 
that 8.3 mmol/l glucose stimulated GLP-1 secretion from the INS-1 832/3 cells (Figure 3.9c), which 
probably explains why Glp1R0017 reduces the insulin secretion when cells are stimulated with 8.3 
mmol/l glucose alone. Glp1R0017 had no effect on insulin secretion stimulated with 10 nmol/l GIP 
(Figure 3.9b). However due to the glucose stimulated GLP-1 secretion, antibody off-target effects 
could not be investigated using submaximal concentrations of GIP or other Gαs coupled stimuli. 
The observation of GLP-1 secretion from the INS-1 832/3 cells was surprising as the cell line is 
described as a pancreatic beta cell line [291, 297]. The INS-1 832/3 cells were created by transfecting 
INS-1 cells with the human insulin gene, and isolating the clones of interest which were highly 
responsive to a change in glucose concentration [297]. Originally the INS-1 cells were isolated from a 
radiation induced insulinoma tumour, raising the possibility that the parental INS-1 cells may not have 
been clonal pancreatic beta cells, and instead a mixture of pancreatic endocrine cells [298]. As GLP-1 
secretion from pancreatic alpha cells has been observed elsewhere [299, 300], the hypothesis that the 
INS-1 832/3 cells are not clonal could explain why GLP-1 secretion was observed upon stimulation with 
8.3 mmol/l glucose. Alternatively, genetic drift observed in all cell lines over time [301], may 
contribute to the explanation for GLP-1 secretion in 8.3 mmol/l glucose. 
Overall, the combination of in vitro signalling data suggested that Glp1R0017 is a competitive 
antagonist that specifically targets the GLP1R, across multiple species. 
3.5.2 Use of Glp1R0017 for immunostaining 
Alongside the characterisation of Glp1R0017 in cell based assays, the antibody was successfully used 
for immunostaining of mouse tissue highly expressing the GLP1R in the pancreas and arcuate nucleus. 
Due to the limited availability of tissue from Glp1r−/− mice, only pancreas staining was used as a 
negative control to show that Glp1R0017 immunostaining was specific for the GLP1R (Figure 3.10). 
The staining of pancreatic tissue can be compared with staining using 7F38A2; both antibodies 
specifically immunostained GLP1R on the beta cells within the islets of Langerhans [252]. As described 
earlier, GLP1R expression is not limited to the pancreas, and is widely distributed in a number of 
different tissues, likely at varying levels [93, 98]. Therefore, in future work with Glp1R0017 it will be 
important to assess immunostaining in areas such as the kidney and heart, where GLP1R is expressed 
at lower levels. Due to the lower expression of antigen, it is expected that optimisation of the 
immunostaining procedure will be necessary, perhaps using antigen retrieval methods or increased 
concentrations of antibody. 
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The cross-species reactivity of Glp1R0017, demonstrated in a range of species-specific GLP1R 
overexpressing cell lines (Figure 3.2a), suggests that Glp1R0017 will be suitable for immunostaining 
GLP1R tissue from a range of species. It is hoped that this would complement human and monkey 
GLP1R immunostaining observed with the previously published GLP1R antibody, MAb 3F52, which has 
been used to map GLP1R expression in the primate brain [116, 302]. Compared with both MAb 3F52 
and 7F38A2, Glp1R0017 produced and characterised in this study has the main advantage of cross-
species reactivity. Glp1R0017 provides an additional tool for the field of GLP1R research, and the study 
of GLP1R physiology in rodents and other species (cynomolgus monkey, dog and human).  
3.5.3 Characterisation of in vivo GLP1R inhibition using Glp1R0017  
The pharmacokinetic study of Glp1R0017 showed stability over a 5-day period, by 120 hours post 
administration the concentration of Glp1R0017 in the plasma had approximately halved (Figure 3.11), 
leading to the estimation that Glp1R0017 half-life in mice is around 120 hours. To determine the actual 
biological half-life of Glp1R0017, an extended pharmacokinetic study of Glp1R0017 is required. The 
expected half-life for antibodies in the human IgG1 format is approximately 10 days [164, 303]. This 
extended stability when compared to the peptide antagonist, exendin 9-39, gives Glp1R0017 a 
competitive advantage. With repeated doses, Glp1R0017 could be used to study the effects of chronic 
GLP1R inhibition.  
In this study, rather than using long term studies, the effects of acute administration of Glp1R0017 to 
mice were investigated. Glp1R0017 when dosed 24 hours prior to an IPGTT, dose dependently 
reversed the effects of liraglutide on glucose tolerance (Figure 3.12a, b). The ability of Glp1R0017 to 
inhibit GLP1R in vivo could give rise to a range of further studies. For example, GLP-1 containing dual 
or triple agonists could be characterised in more detail, alternatively GLP1R physiology could be 
studied in more depth.  
OGTTs were used to assess whether Glp1R0017 could inhibit the endogenous GLP-1 effects on glucose 
tolerance. The availability of both Glp1R0017, along with Gipg013 as a GIPR antagonistic antibody 
meant that the actions of both incretin hormones could be inhibited [164]. The OGTT results produced 
here can be compared with glucose tolerance of Glp1r−/− and Gipr−/− mice. The results are comparable, 
as both the single antibody treated groups had mild effects on glucose tolerance (Figure 3.12c,d), 
similar to the glucose tolerance of individual receptor knockouts [294, 304]. In contrast, the 
combination of Glp1R0017 and Gipg013 had a significant effect on oral glucose tolerance. This 
supports the hypothesis that the incretin hormones are able to compensate for each other, as was 
proposed in studies using both single and double incretin receptor knockout mice [305].  
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Gipg013 dosed independently had no significant effect on oral glucose tolerance, whereas Glp1R0017 
caused a small but significant increase in plasma glucose levels in the OGTT (Figure 3.12c, d). This 
suggests that the role of GLP-1 in insulin secretion is potentially more important than GIP in the 
C57/Bl6 mouse model. This contrasts with other studies using the single and double incretin hormone 
receptor knockout mouse models, which concluded GIP was more important than GLP-1 for the 
incretin effect [305].  
Overall, cohesive conclusions cannot be made regarding which incretin hormone is the most 
important. However, the data confirms there is a compensatory effect upon inhibition of either of the 
incretin hormones, and demonstrates Glp1R0017 can be used to inhibit GLP1R in vivo.  
3.5.4 Possible future uses of Glp1R0017  
As Glp1R0017 can be used to inhibit both the actions of exogenously added GLP-1 mimetics, along 
with endogenously secreted GLP-1, the possible applications of Glp1R0017 are broad. Firstly, 
Glp1R0017 could be used to investigate GLP-1 mimetics, and GLP-1 containing dual or triple agonists 
in more depth. Secondly, Glp1R0017 could be used to study GLP1R physiology, such as the importance 
of the GLP1R after gastric bypass surgery. Finally, there is also the possibility of using Glp1R0017 
therapeutically for the treatment of patients with hypoglycaemia.  
GLP-1 mimetics within the clinic for type 2 diabetes treatment have varying beneficial effects within 
the cardiovascular system, such as reducing the number of cardiovascular events observed in high risk 
patients [113-115]. Despite this, the molecular mechanism for cardio-protection remains unclear 
[288]. As Glp1R0017 is a specific antagonist of the GLP1R, there is the possibility of using Glp1R0017 
to study whether the cardiac effects of GLP-1 mimetics are directly dependent on the GLP1R or 
independent. Both in vivo and ex vivo experiments could be used, for example cardiac telemetry could 
be used to monitor cardiovascular parameters such as heart rate and blood pressure in rodents, 
alternatively ex vivo experiments using langendorff perfusion set-ups could also be useful. 
GLP-1 containing dual and triple agonists are an emerging therapeutic for the treatment of type 2 
diabetes, with several molecules currently being tested in clinical trials [232]. The concept for these 
unimolecular dual or triple agonists is based upon the observation that gastric bypass surgery is the 
most effective single treatment for type 2 diabetes [225]. Clearly gastric bypass surgery alters a 
number of molecular pathways, thus the multi-agonists are trying to mimic the effects of gastric 
bypass [231]. In development of these unimolecular multi-agonists, the balance of the different 
components is particularly important [291, 306]. For this purpose, Glp1R0017 could be useful for 
investigating the importance of GLP-1 within the GLP-1 containing dual or triple agonists.  
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When considering the use of Glp1R0017 for studying physiology, Glp1R0017 may be used for the 
pharmacological inhibition of GLP1R in studies looking at the molecular mechanisms of GLP-1. 
Additionally, Glp1R0017 could be used to confirm the location of the GLP1R in extra-pancreatic tissues 
[93]. Of particular interest is determining the importance of GLP-1 signalling for the metabolic effects 
of gastric bypass surgery. Following gastric bypass, secretion of enteroendocrine hormones is vastly 
different to pre-surgery. Increased secretion of GLP-1, along with anorexic peptides oxyntomodulin, 
and peptide YY is observed [307, 308]. On the other hand, there is reduced secretion of GIP and ghrelin 
[307, 309]. There is debate surrounding whether the remission of type 2 diabetes is solely due to a 
change in gastrointestinal factors or due to caloric restriction [231]. The use of Glp1R0017 in rodent 
studies could complement studies performed with exendin 9-39 [310, 311], and shed more light on 
the importance of increased GLP-1 signalling for the beneficial metabolic effects of gastric bypass 
surgery.  
Surgery on the gastrointestinal tract is not only used for the treatment of obesity and type 2 diabetes, 
lean patients can also undergo gastrectomy as a means for treating cancer. For the lean population of 
patients, significant deleterious effects are observed in the long term, with a high prevalence of 
“dumping syndrome” [312].  This leads to a poor quality of life, symptoms for early dumping syndrome 
occur within 30 minutes of eating a meal, and include diarrhoea, abdominal cramping and nausea. 
Late dumping syndrome occurs 2-3 hours after a meal, with patients showing signs of hypoglycaemia 
such as faintness, hunger and dizziness [312]. One possible cause of this is increased levels of GLP-1 
post-prandially [313, 314]. Clinical studies using infusions of exendin 9-39 are in progress, and may 
reveal that antagonism of the GLP1R is a potential therapeutic strategy for treatment of patients with 
“dumping syndrome” (unpublished, Gribble lab).  
Bariatric surgery can occasionally give rise to the metabolic disorder post-bariatric hypoglycaemia, 
which is characterised by symptomatic post-prandial hypoglycaemia. Blockade of the GLP1R by 
infusion of exendin 9-39 prevents this hypoglycaemia, suggesting that GLP1R antagonism may be 
beneficial therapeutically for treatment of patients with post-bariatric hypoglycaemia [242]. A further 
cause of hypoglycaemia is congenital hyperinsulinism, this is the most common cause of 
hypoglycaemia in children. Briefly, congenital hyperinsulinism is defined by the pancreatic beta cells 
secreting insulin even when plasma glucose concentrations are low [315].  Pre-clinical and clinical data 
supports GLP1R antagonism as a therapeutic strategy for treating this group [241, 316, 317].   
Together, this collection of studies shows there is a small but significant population of people for which 
a GLP1R antagonistic antibody could be used therapeutically to inhibit the GLP1R, and prevent 
hypoglycaemia.  
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3.5.5 Summary 
In summary, Glp1R0017 has been characterised in considerable detail within this chapter. Glp1R0017 
specifically antagonises all GLP1R signalling pathways investigated, and has cross-species reactivity 
across a range of species. In addition to this, Glp1R0017 can be used to stain GLP1R in mouse tissue, 
and holds the possibility of being used for immunostaining tissue from other species. Glp1R0017 also 
has the ability to inhibit GLP1R in vivo in mouse models.  
Glp1R0017 provides a new method for blockade of GLP1R over several days in a range of species. 
Transient and/or age-restricted GLP1R blockade can be achieved using Glp1R0017, complementing 
studies using Glp1r−/−  mice. Glp1R0017 may also have advantages when compared to exendin 9-39, 
particularly in terms of the longer half-life, and when it is important to exclude cross-reactivity with 
related GPCRs. 
Glp1R0017 provides a novel tool for investigating the GLP-1 component of emerging unimolecular 
dual agonists for type 2 diabetes treatment, and for further understanding GLP1R physiology. Aside 
from acting as a tool, there is also prospect for using a GLP1R antagonistic antibody therapeutically 
for the treatment of patients with postprandial hypoglycaemia. 
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Chapter 4. Localisation and characterisation of glucose-dependent 
insulinotropic polypeptide receptor (GIPR) expressing cells 
4.1 Introduction  
4.1.1 Therapeutic Relevance of GIPR 
The GIPR is an incretin hormone receptor, similar to GLP1R, with specificity for the ‘ugly duckling’ 
incretin hormone GIP (described in detail in chapter 1). However, unlike the GLP1R, agonism of the 
GIPR has not been successfully exploited therapeutically for the treatment of type 2 diabetes [169]. 
When the incretin effects of GLP-1 and GIP were compared in patients with type 2 diabetes during a 
hyperglycaemic clamp, GIP failed to induce insulin secretion [318]. Consequently, in comparison to 
the GLP1R, less research has been performed to date on the GIPR.  
Recently, the combination of GIPR agonism with GLP1R agonism has been described as beneficial. In 
pre-clinical studies, unimolecular dual agonists for GIPR and GLP1R have increased efficacy when 
compared to GLP-1 agonists [48]. 
Contrary to the initial ideas surrounding therapeutic targeting of the GIPR, the idea of GIPR 
antagonism for therapeutic treatment of type 2 diabetes has also been postulated [169]. This is 
because insulin secretion is not the only therapeutically relevant function of the GIPR. Other functions 
of GIPR agonism include increased glucagon secretion in euglycaemia and hypoglycaemia [319, 320], 
along with effects on adiposity such as stimulation of lipoprotein lipase (LPL) activity and increased 
triacylglycerol (TAG) uptake [176]. The suggestion of using GIPR antagonism therapeutically is centred 
around the hypothesis that GIPR antagonism could reduce body fat, and limit hyperglucagonemia in 
patients [169]. Safety of GIP(3-30)NH2 as a GIPR antagonist has recently been demonstrated in healthy 
humans, along with an observation of decreased GIP-induced insulin, and block of GIP induced 
increases in adipose tissue blood flow [321, 322]. Whether GIPR antagonism is a practical therapeutic 
strategy for type 2 diabetes remains to be elucidated. 
4.1.2 Location of GIPR 
As described in chapter 1, GIPR expression is not limited to the pancreas; peripherally mRNA 
expression has been detected by in situ hybridisation in the gut, adipose tissue, heart, pituitary gland 
and inner layers of the adrenal cortex [149]. A combination of in situ hybridisation and radioligand 
binding studies have also shown central expression of the GIPR, with expression in a number of areas 
including the cerebral cortex, hippocampus, lateral septal nucleus and olfactory bulb [149, 161]. Aside 
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from these early studies, there has been very little investigation into the actions and location of central 
GIPR.  
GIPR antibody availability is a limiting factor for the investigation of GIPR protein localisation. Limited 
antibodies are available for immunostaining, and the resulting images are varying in quality [162, 163]. 
Although GIPR antagonistic antibodies have been produced, these do not appear to work in 
immunostaining [164].  
To circumvent this problem, we have produced a lineage tracing transgenic mouse model to identify 
GIPR containing cells. This approach is comparable to that previously used within our lab to identify 
the location of GLP1R expressing cells [93].  
4.1.3 The role of GIPR in obesity 
Dietary fat is one of the main stimulants for GIP secretion [323, 324]. In addition to this, it has been 
observed that high fat diet (HFD) and obesity are linked with hypersecretion of GIP, and increased 
fasting levels of GIP [182, 323, 325-327]. The underlying mechanism for this GIP hypersecretion in the 
obese state is unclear; hyperplasia of the GIP-secretory K cells may form a partial explanation [327], 
other suggestions include decreased feedback inhibition of the K cells due to insulin sensitivity [325]. 
More recently, increased expression of the transcription factors regulatory factor X6 (Rfx6) and 
pancreatic and duodenal homeobox 1 (Pdx1) have been observed in the K cells of HFD induced obese 
mice, leading to the suggestion that these transcription factors are important for GIP hypersecretion 
in obesity [137].  
In humans, an elevated level of GIP in the plasma appears to be associated with an unhealthy fat 
distribution in men [328]. Not only does HFD induce hypersecretion of GIP, GIPR sensitivity also 
appears to be improved in islets from HFD fed mice. Isolated islets from HFD fed mice have significantly 
improved GIP induced insulin secretion compared with islets from mice fed with chow diet, while there 
is no difference in GIPR expression [329]. Together, the above data suggests that GIP may have a 
physiologically important role in obesity. 
Further evidence pointing to the importance of GIP in obesity has been found using global and tissue-
specific GIPR knock out mouse models. To model obesity in mouse models, mice are either fed with 
HFD, or Lepob/ob mice are used which have a mutation in the leptin gene, meaning hunger is not 
inhibited, and mice become obese with increased adipose tissue [330].  
Global knockout of the GIPR gives protection from HFD induced obesity. When the GIPR-/- mice were 
crossed with Lepob/ob mice, a decrease in body weight and fat mass was observed in comparison with 
the single mutant Lepob/ob mice. Thus, the GIPR is clearly important in the control of obesity, with GIP 
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being a ‘key molecule linking overnutrition to obesity’. Upon further investigation it was found that 
the GIPR-/- resistance to obesity was due to increased energy expenditure. The underlying mechanism 
was investigated using a peripheral based approach, focusing on the adipocyte effects of GIP.  The 
GIPR-/- mice display decreased acyl CoA:diacylglycerol transferase (Dgat1) expression in the 
adipocytes. As Dgat1 is involved in triglyceride synthesis, a decrease in Dgat1 suggests decreased 
triglyceride synthesis, meaning the GIPR-/- adipocytes store less nutrients than WT mice fed with the 
same HFD [182].  
GIPR knockout restricted to the adipose tissue (GIPRadipo-/-) also leads to reduced body weight gain on 
HFD compared with WT mice. In contrast to the global GIPR-/- mouse, no significant differences in 
energy expenditure were observed in GIPRadipo-/- mice compared to WT mice. The differences observed 
in body weight corresponded to a change in lean mass rather than fat mass, with a reduction in liver 
volume and fat content [185].   
As GIPR is expressed in the brain, it is thought that there may also be some central effects of GIP that 
regulate energy expenditure or food intake in obesity. Central administration of GIP to rats for 4 days 
(2 nmol/day) decreases body weight gain compared to control groups, and alters expression of 
hypothalamic genes involved in energy regulation [331]. In mice, a intracerebroventricular (ICV) single 
high dose (6nmol) of GIP was found to decrease food intake, without any change in body weight over 
24 hours [332]. 
The role of GIPR in obesity still requires some further investigation. To add to the field, we have used 
the newly developed GIPR transgenic mouse model in combination with adeno-associated virus (AAV) 
technology to study the acute effects of both hypothalamic GIPR ablation and GIPR activation.  
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4.2 Aims 
To identify and characterise cells expressing the GIPR by: 
a) Immunostaining of peripheral tissues including the pancreas, adipose tissue, duodenum and 
nodose ganglia from Gipr-Cre x Rosa26-EYFP/RFP mice. 
 
b) Immunostaining of coronal sections from perfuse fixed brains from Gipr-Cre x Rosa26-
EYFP/GCamp3 mice. 
 
c) Ablating hypothalamic GIPR positive neurons using AAV-flex-taCasp3-TEVp and characterising 
the effects on food intake.  
 
d) Activating hypothalamic GIPR positive neurons using AAV-hSyn-DIO-hM3D(Gq)-mCherry in 
combination with clozapine-N-oxide (CNO) and characterising the effects on food intake. 
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4.3 Methods 
4.3.1 Animal Studies 
All experimental procedures were approved by local ethical review bodies and were performed in 
accordance with the Animal (Scientific Procedures) Act 1986, Home Office guidelines, local 
establishment guidelines and Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines. 
Experiments performed using my personal licence (I290CEFFE), under a number of Home Office 
Project Licenses. C57/Bl6 mice were purchased from Charles River UK. Mice were group-housed in 
individually ventilated cages, with ad libitum access to chow diet and water unless otherwise stated. 
Animals were euthanized by cervical dislocation, unless otherwise stated. 
4.3.2 Transgenic mice  
Transgenic mice were generated by F. Reimann, in which the expression of cre-recombinase is driven 
by the gipr promoter (unpublished). Expression of cre-recombinase is responsible for reporter gene 
activation. The cre-recombinase recognises loxP sites surrounding a stop codon in front of the reporter 
gene, then deletes the ‘floxed’ stop codon. Consequently, the reporter protein is only produced in 
cells which express the gene of interest. However, once the reporter gene is expressed it is under the 
control of a constitutively active rosa26 promoter, meaning after initial activation each cell will 
continue to produce the reporter protein independent of cre-recombinase. The fluorescent reporter 
proteins used in this study are enhanced yellow fluorescent protein (EYFP), tandem red fluorescent 
protein (tdRFP) [292] and the fluorescent calcium indicator GCaMP3 [293].   
4.3.3 Immunostaining  
Immunostaining was performed as described in chapter 3. For 3,3'-diaminobenzidine (DAB) 
immunohistochemistry of brain tissue, slices were washed in PBS, then incubated with 0.5% (v/v) 
hydrogen peroxide for 15 minutes to block endogenous peroxidase activity. Following further 
washing, slices were blocked for 1 hour in 5% donkey serum, 0.3% (v/v) Tween-20, then incubated 
with primary antibody overnight at 4°C with gentle agitation. The sections were then washed with 
0.1% (v/v) PBS-Tween20, and incubated with biotinylated donkey anti-goat IgG (1:400) in 0.3% (v/v) 
PBS-Tween20. After a further washing, sections were incubated with avidin-biotin complex (Vector 
Laboratories Inc., Burlingame, USA), washed a final time, then staining was developed using DAB as 
the substrate (Abcam). Slides were incubated for up to 10 minutes with DAB, then washed in PBS 
before mounting onto Superfrost Plus glass slides (VWR). Finally, slides were dried and dehydrated 
using an ethanol gradient, and coverslips applied with pertex mounting media (CellPath).   
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Slides were imaged using confocal microscopy (TCS SP8; Leica, Wetzlar, Germany) or automated 
widefield microscopy (Axio Scan.Z1, Zeiss, Oberkochen, Germany). Images displayed are either 
confocal slices or Z-stacks, quantification of cell number and co-localisation was performed using 
either Image J or HALO software (Indica Labs, Corrales, USA). 
4.3.4 Intracerebroventricular Surgery 
All surgery, and subsequent feeding studies were performed under a Home Office Project License held 
by C. Blouet (PC02F3663), and surgery was kindly completed by C. Blouet as a Personal Licensee 
(I3AC7C9CD).  
Surgery was carried out in 6-10 week old male mice under isofluorane anesthesia, and all animals 
received Metacam prior to the surgery and 24 hours after surgery. A bilateral steel guide cannulae 
(Plastics One) was stereotaxically implanted as previously described [333], and positioned 1 mm above 
the arcuate region of the hypothalamus (ARH) (A/P: −1.1 mm, D/V: −5.9 mm, lateral: +0.4 mm from 
Bregma). Beveled stainless steel injectors (33 gauge) that extended 1 mm from the tip of the guide 
were used for injections of viruses at 100 nl/min, 500 nl/side. AAV-hSyn-DIO-hM3D(Gq)-mCherry was 
used to study GIPR activation, and AAV-flex-taCasp3-TEVp was used to study GIPR ablation. All animals 
were given at least a 3 week recovery period, during which they were acclimatized to handling and 
body weight was monitored. 
4.3.5 Mouse feeding studies 
Feeding studies were run together with T. Darwish (I562DDDFF), under the Home Office Project 
License held by C. Blouet (PC02F3663). To monitor food intake, mice were single housed for up to 48 
hours, then returned to their group housing conditions. Aggressive behaviour was monitored, and no 
problems were encountered with re-grouping animals. Food intake was measured over 24 hours, 
either with ad lib feeding, or following a 24 hour fast. Acute food intake was also measured after 
intraperitoneal injection of clozapine N-oxide (1 mg/kg), this was either with ad lib feeding or following 
a fast of up to 10 hours. Mice were fed with either standard chow, or 45% high fat diet (D12451, 
Research Diets). 
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4.4 Results 
Identification and characterisation of GIPR expressing cells has been enabled by the generation of a 
novel transgenic mouse by F. Reimann and I. Zvetkova. A lineage tracing approach has been utilised 
whereby GIPR expressing cells are labelled with a fluorescent reporter protein (Figure 4.1). A number 
of different fluorescent reporter lines were utilised in this study; Gipr-Cre x Rosa26-EYFP, Gipr-Cre x 
Rosa26-tdRFP, and Gipr-Cre x Rosa26-GCamp3. 
 
 
Figure 4.1 Schematic representation of transgenic mouse line used to identify cells which have 
expressed Gipr. The mouse model is a ‘knock-in’ model whereby on one copy of the Gipr gene, cre 
recombinase is expressed downstream of the Gipr promoter. Upon expression, cre recombinase 
removes the floxed ‘stop’ codon, enabling expression of the fluorescent reporter protein (e.g. EYFP). 
The fluorescent reporter is under the control of a constitutive promoter, Rosa26. 
 
4.4.1 Localisation of the GIPR in peripheral tissues 
For characterisation of the Gipr-Cre x Rosa26-reporter mice, pancreas tissue was the initial focus. 
Pancreas was collected, fixed, cryosectioned and immunostained with antibodies raised against GFP 
or RFP dependent upon the reporter protein used. The sections were costained for insulin as a marker 
for pancreatic β cells, or glucagon as a marker for pancreatic α cells (Figure 4.2). All pancreatic islets 
expressed the GIPR as expected for the incretin hormone receptor, with expression in both the β cells 
(Figure 4.2b) and α cells (Figure 4.2c). The surrounding exocrine acinar tissue also showed GIPR 
expression, in a heterogenous pattern (Figure 4.2a). This immunostaining provided confidence that 
the Gipr-Cre x Rosa26-reporter mice were successfully labelling cells which had expressed the GIPR. 
Secondary antibody only control slides were also imaged, and displayed no fluorescence.  
Following the pancreas immunostaining, other peripheral tissues were collected and assessed for GIPR 
localisation. In line with the GIPR having functions in adipose tissue, expression was observed in 
adipose tissue from both brown and white adipose tissue depots (Figure 4.3 a, b). Within interscapular 
brown adipose tissue, several multilocular adipocytes scattered throughout the tissue were stained 
with the GFP antibody, thus suggesting GIPR expression (Figure 4.3a). GIPR positive adipocytes were 
also immunostained within inguinal white adipose tissue, at what appeared to be a lower density. A 
mixture of both multilocular and unilocular adipocytes were positively stained (Figure 4.3b). Again, no 
immunostaining was observed in secondary antibody only control slides. 
X 
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GIP is secreted from enteroendocrine K cells within the small intestine, with a higher density of K cells 
in the duodenum, where GIPR expression has been reported previously [149]. We therefore examined 
GIPR expression in the duodenum of the Gipr-Cre x Rosa26-EYFP mouse model. Very few cells were 
GIPR positive within the epithelial cell layer, of interest some cells in the centre of the villus also 
appeared to stain with the GFP antibody (Figure 4.3c). In comparison, no cells were stained in the 
secondary antibody only control slides.  To identify the cell-type of these GIPR positive cells co-staining 
experiments were performed using antibodies for glucagon, 5-hydroxy tryptamine (5-HT), vimentin 
and α-smooth muscle actin (α-SMA).  
 
 
Figure 4.2 GIPR in the pancreas. Pancreas tissue from Gipr-Cre x Rosa26-EYFP mice (n=3) was 
assessed by immunohistochemistry. (a) Tile-scan of pancreatic tissue stained for GFP (green) and 
glucagon (Gcg, red) showing staining in islets and acinar tissue. (b and c) Representative pancreatic 
islet sections stained for GFP (green) and either insulin (Ins, white, (b)) or glucagon (Gcg, red, (c)). 
  
GFP (gipr) 
Gcg 
GFP (gipr) GFP (gipr) Gcg Ins 
a 
b c 
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Figure 4.3 GIPR in extra-pancreatic tissue. Extra-pancreatic tissue from Gipr-Cre x Rosa26-EYFP 
mice was also assessed by immunohistochemistry. Sections of interscapular brown adipose tissue 
(a), inguinal white adipose tissue (b) duodenum (c) and nodose ganglia (d) were co-immunostained 
for GFP (representing gipr expression), and vimentin (vim) or serotonin (5HT) as indicated.    
GFP (gipr) 
GFP (gipr) 
Vim 
GFP (gipr) 
GFP (gipr) Vim 
GFP (gipr) 5HT 
GFP (gipr) 
a b 
c 
d 
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Of the GIPR positive cells within the epithelial cell layer, a minority colocalised with glucagon stained 
cells, indicating some GIPR expression in enteroendocrine L-cells (data not shown). 5-HT staining 
revealed a higher degree of colocalisation between GIPR positive cells and 5-HT producing 
enterochromaffin cells (Figure 4.3c). To determine the identity of the GIPR positive cells within the 
centre of the villi, co-staining was performed with vimentin and α-SMA to look at cells of mesenchymal 
origin [334, 335]. Vimentin and GFP colocalisation was observed, suggesting the GIPR positive cells 
within the centre of the villi are of mesenchymal origin (Figure 4.3c). The role of the GIPR within 
mesenchymal cells, and the specific mesenchymal cell-type in which GIPR is expressed remains to be 
determined. 
The final peripheral tissue in which GIPR localisation was assessed was the nodose ganglia. Neurons 
from the nodose ganglia innervate the small intestine, as GLP1R has been identified in this tissue [93] 
expression of the GIPR was of interest. Indeed, immunostaining of tissue isolated from Gipr-Cre x 
Rosa26-EYFP mice revealed GIPR expression is found in the nodose ganglia (Figure 4.3d). No staining 
was found in the secondary antibody only control slides. 
4.4.2 Localisation of GIPR within the brain 
The GIPR is thought to play a role in regulating energy expenditure in an obese setting, and expression 
of the GIPR has previously been demonstrated in the brain. Expression of the GIPR within the 
hypothalamus would be of particular interest, as this region is known to have a role in controlling 
energy expenditure [336]. To add to the previous in situ hybridisation data set, Gipr-Cre x Rosa26-EYFP 
and Gipr-Cre x Rosa26-GCamp3 mice were used to further characterise the localisation of central GIPR.  
To gain an overview of GIPR expression throughout the mouse brain, reporter mice were perfuse fixed 
with paraformaldehyde (by E. Roth) to allow complete fixation of the brain, and then coronal sections 
were made every 25 µm. GFP was stained, and detected by DAB immunohistochemistry, representing 
GIPR expression. Secondary antibody only controls were also used, and showed no immunostaining. 
GIPR expressing neurons were examined from the olfactory bulb to the spinomedullary junction of 
the mouse brain. As described previously, GIPR expression was detected in the olfactory bulb [149, 
161]. More specifically, GIPR expression was observed in the frontal association cortex (FrA), lateral 
orbital cortex (LO), external plexiform layer (EPI) and the mitral cell layer (Mi) of the olfactory bulb, as 
depicted schematically (Figure 4.4).   
Within the nucleus of stria terminalis (BST) region of the brain GIPR expression was detected in cortex 
regions, in line with that previously published [149, 161] (Figure 4.4 and 4.5a). GIPR expression was 
also found in the medial preoptic area (MPA), medial septal nucleus (MS), dorsal part of the lateral 
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septal nucleus (LSD), and median preoptic nucleus (MnPO). It should be noted that staining in the LSD 
is similar to that observed previously [149, 161]. Surrounding the ventricle, GIPR expression was 
observed in the periventricular hypothalamic nucleus (Pe), anteroventral periventricular nucleus 
(AVPe), the anterior parvicellular part of the paraventricular hypothalamic nucleus (PaAP) and the 
dorsomedial part of the suprachiasmatic nucleus (SChDM). Additionally, within the BST region, 
densely grouped GIPR neurons were found in the subfornical organ (SFO). Of note, this expression in 
the SFO is similar to the GLP1R pattern of expression [94].  
It was particularly interesting to find GIPR expression within the hypothalamic nuclei, which has not 
previously been described. Neuronal bodies expressing the GIPR densely populated the arcuate 
nucleus (Arc) region (Figure 4.4, 4.5b). In the more caudal sections of the hypothalamus GIPR positive 
neurons were identified in the dorsal part of the dorsomedial hypothalamic nucleus (DMD) (Figure 
4.4, 4.5c). Within these sections, GIPR expression was also observed in the paraventricular thalamic 
nucleus (PV), field CA1 of the hippocampus (CA1), and the dentate gyrus (DG). The observation of GIPR 
within the hippocampus was again in line with previously published data, and gave confidence that 
the GIPR reporter mice were successfully reporting GIPR expressing cells [149].  
Finally, upon examination of the hind brain region, GIPR positive neurons were detected at high 
density within the area postrema (AP), a circumventricular part of the brain that is extensively 
vascularised, and also expresses the other incretin hormone receptor, the GLP1R [94]. GIPR expression 
was also found in the medial part of the nucleus of the solitary tract (SolM) and the hypoglossal 
nucleus (12N) (Figure 4.4, 4.5d).  
Overall, the GIPR appears to be widely distributed throughout the brain. This identification of central 
GIPR raises questions surrounding the function of GIPR in the brain. Initially we sought to find out 
whether GIP, the ligand for the GIPR, was produced centrally. Gip-Cre x Rosa26-GCamp3 transgenic 
mice were used for this purpose, which have a lineage tracing approach to label cells that produce 
GIP. Upon immunostaining of the brains from this mouse line, no expression of GFP positive cells were 
found within the brain (data not shown), thus suggesting GIP is not produced centrally. However, one 
should note that the Gip-cre model labels only 60% of GIP positive K cells in the upper small intestine 
[337]. This penetrance may mean that GIP positive cells in the brain were missed. With caution, from 
this data one would hypothesise peripheral GIP rather than centrally produced GIP acts on the central 
GIPR.  
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Figure 4.4 Schematic representation of GIPR expression 
throughout the brain. Filled red circles indicate GIPR expression, 
with the density indicating relative density of GFP-positive cells. 
Images are adapted from the Paxinos Mouse Brain Atlas, and the 
numerical values at the bottom right of each section shows the 
rostro-caudal position relative to Bregma. 
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Figure 4.5 GIPR expression in the brain. Immunostaining of Gipr-Cre x Rosa26-EYFP and Gipr-Cre x 
Rosa26-GCamp3 brain tissue showed GIPR expression throughout the brain. Example images of a 
BST section (Bregma 0.74 mm) (a), a rostral (Bregma -1.46 mm) and caudal (Bregma -1.94 mm) 
section of the hypothalamus (b and c respectively), and a hind brain section (Bregma -7.48 mm) (d) 
are displayed. Areas of interest highlights in the left hand column are magnified in the right hand 
column. 
 
c 
b 
a 
d 
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4.4.3 Ablation of hypothalamic GIPR positive cells  
Both global knockout of the GIPR, and GIPR knockout in the adipose tissue alone protect mice from 
HFD induced obesity [182, 185]. Following the identification of GIPR within the hypothalamus, we 
were interested in whether GIPR ablation in the hypothalamus had any effect on body weight or food 
intake.  
The combination of our transgenic Gipr-Cre mouse model with Cre-dependent AAV technology 
allowed for the acute manipulation of Gipr-Cre positive cells. To study the function of the GIPR positive 
cells, hypothalamic GIPR cells were ablated by ICV injection of AAV-flex-taCasp3-TEVp (Appendix 5) 
(by C. Blouet). Briefly, this virus encodes a genetically engineered caspase-3, which upon activation 
causes apoptosis, thus removing the Cre-positive neurons expressing Gipr [338]. In more detail, the 
genetically engineered caspase-3, pro-taCasp3, is activated by cleavage with Tobacco Etch Virus 
protease (TEVp) which is co-delivered by the AAV-virus. Both pro-taCasp3 and TEVp require Cre-
dependent activation [339, 340]. For the negative control group, AAV-flex-taCasp3-TEVp was injected 
into mice that were genotypically negative for Cre. 
Within this pilot study, body weight was monitored 3 times per week, while mice were fed with 
standard chow diet and subsequently 45% HFD (Figure 4.6a). 24-hour food intake was assessed in the 
GIPR ablation and control cohort of mice, along with sensitivity to leptin. At the end of the study, 
adipose tissue was collected to determine whether hypothalamic GIPR ablation had any effect on 
adipose tissue weight. Finally, brains from three of the ablation mice with the EYFP reporter were 
perfuse fixed, and immunostained with a GFP antibody to confirm GIPR ablation. 
When fed chow diet, both the GIPR ablation and control cohort gained body weight at the same rate 
(Figure 4.6b). Upon switching the diet to 45% HFD, the average increase in body weight was also the 
same between the two groups. However, when looking at the body weights of the individual mice, 
three of the ablation mice gained less body weight than the rest of the group (Figure 4.6c). No 
significant differences were observed between the ablation and control group when 24 hour food 
intake was assessed on either the chow diet and 45% HFD (Figure 4.6d, e). When mice on chow diet 
were injected with leptin, food intake was slightly decreased for both the ablation and control group, 
again with no significant difference between the two groups (Figure 4.6f). The same pattern was 
observed when mice were fed with 45% HFD; the net effect of leptin injection was a slight reduction 
in 24 hour food intake, with no significant difference in food intake between the GIPR ablation and 
control cohort (Figure 4.6g).  
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Figure 4.6 Effect of hypothalamic GIPR ablation on body weight and feeding behaviour. (a) 
Schematic representation of GIPR ablation study timeline. (b) Body weight monitored throughout 
GIPR ablation study, with a change of diet to 45% HFD indicated by the dotted line. Surgery was 
performed at day 0. (c) Changes in body weight throughout GIPR ablation study. (d) 24 hour food 
intake assessed on chow diet. (e) 24 hour food intake assessed on 45% HFD. (f) Effect of leptin 
injection on 24 hour food intake on chow diet. (g) Leptin sensitivity on 24 hour food intake on 45% 
HFD.  
Chow Diet 45% HFD 
Day 0                           53                      107 
Day 29: 24 hour 
Food Intake 
Day 50: Leptin 
sensitivity 
Day 78: 24 hour 
Food Intake 
Day 92/101: 
Leptin sensitivity 
a 
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Despite seeing no clear differences in food intake or body weight between the GIPR ablation and 
control cohort of mice, at the end of the experiment adipose tissue was collected and weighed to 
investigate whether body fat distribution was different between the groups. Epididymal and inguinal 
white adipose tissue was collected along with interscapular brown adipose tissue. For each adipose 
tissue depot no difference in weight was observed between the GIPR ablation and control group, 
meaning the total adipose tissue mass was also the same in both groups (Figure 4.7).  
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Figure 4.7 Effect of hypothalamic GIPR ablation on adipose tissue weights. Adipose tissue mass 
expressed per gram of body for (a) epididymal white adipose tissue (b) inguinal white adipose tissue 
and (c) interscapular brown adipose tissue. (d) Total adipose tissue mass expressed as percentage 
of body weight. 
 
Immunostaining of hypothalamic sections confirmed two of the three GIPR ablation brains stained 
had successful ablation of GIPR positive cells, with fewer GFP positive cells than observed in an age-
matched positive control which had not undergone surgery (Figure 4.8). To ensure this observation 
was correct, immunostaining was performed on two different days using either DAB 
immunohistochemistry, or immunofluorescent staining. For analysis, a bregma level was assigned to 
each section stained, then GIPR positive cells were counted within the arcuate nucleus. Per bregma 
level, counts have been calculated as a percentage of the total GIPR positive count in positive control 
tissue. Both methods of immunostaining indicated that ablation was successful for the mice with ID’s 
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9716 and 9797. However, ablation was not successful for the third mouse with ID 9793 (Table 4.1). Of 
the successful GIPR ablation mice, 9716 was one of the mice which gained less body weight on 45% 
HFD. The remaining six mice within the GIPR ablation cohort did not have a fluorescent reporter, 
therefore confirmation of GIPR ablation was not possible in the rest of the cohort.  
Overall, this pilot study suggests that ablation of the GIPR within the hypothalamus has no phenotypic 
effect on mice in terms of body weight, food intake, and fat mass distribution. 
a 
  Bregma Level 
Percentage of cells in positive control -1.23 -1.31 -1.43 -1.55 -1.79 
9716 37.1 10.3 42.6   71.3 
9793 51.7     180.4 240.0 
9797 45.7 93.1 35.5 25.5 52.5 
 
b 
  Bregma Level 
Percentage of cells in positive control -1.22 -1.46 -1.58 -1.7 -1.94 
9716   36.8   14.3 27.9 
9793 28.9 62.1 91.6 281.6   
9797 83.1   24.1 18.4   
 
Table 4.1 Quantification of GIPR Ablation by GFP immunostaining. The three Gipr-Cre x Rosa26-
EYFP mice used for GIPR ablation were used for confirmation of ablation by immunostaining for GFP 
(representing gipr expression). For each bregma level, the GFP cell count has been expressed as a 
percentage of total GFP cells found in control Gipr-Cre x Rosa26-EYFP brain tissue. Cells were 
stained using DAB staining (a) and immunofluorescent staining (b).  
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Figure 4.8 GIPR ablation in the arcuate nucleus. Immunostaining of Gipr-Cre x Rosa26-EYFP brain 
tissue from GIPR ablation animals (a-c), and an age matched positive control (d) showed the degree 
of GIPR ablation within the hypothalamus. Example images from bregma level -1.79 mm are 
displayed for 9716 (a), 9793 (b), 9798 (c), and the positive control which had not undergone surgery, 
456 (d). The area surrounding the third ventricle is magnified in the right hand column. 
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4.4.4 Activation of hypothalamic GIPR positive cells 
An alternative strategy for investigating the effect of GIPR positive cells in the brain is to specifically 
and acutely activate the GIPR neurons. Previously it has been seen that central administration of GIP 
can alter hypothalamic gene expression, and affect body weight gain [331]. Though these effects only 
seem to be observed when a high concentration of GIP is administered [332].  
To directly activate hypothalamic GIPR populations, without central administration of GIP, designer 
receptors exclusively activated by designer drugs (DREADD) technology was used in combination with 
the Gipr-Cre transgenic mouse model. ICV injection of AAV-hSyn-DIO-hM3D(Gq)-mCherry (Appendix 
6) meant that acute effects of GIPR activation could be monitored. Briefly, the DREADD technology 
uses mutant muscarinic GPCRs which are activated solely by CNO, an otherwise inert ligand [341]. The 
stimulatory DREADD used here, hM3D(Gq), is coupled to a Gαq pathway which consequently 
depolarises neurons upon activation. The AAV is cre-dependent meaning only cells expressing cre will 
express hM3D(Gq), hence theoretically only cells expressing GIPR will be targeted. The fusion of 
hM3D(Gq) to mCherry means that once the receptor is incorporated into a cell, expression can be 
detected by fluorescence microscopy [342-344]. 
Within this pilot study, GIPR was activated by intraperitoneal injection of CNO, and the acute effects 
on food intake were measured over the following 2 hours. Food intake was monitored when mice 
were fed with standard chow diet or 45% HFD, either ad libitum or following a day time fast of up to 
10 hours (Figure 4.9a). The experiments were performed in a blinded fashion.  
When mice were fed ad libitum, CNO had no significant effect on 2-hour food intake of standard chow 
diet or 45% HFD (Figure 4.9b, d). In contrast, following a day time fast of up to 10 hours, injection of 
CNO significantly reduced the 2-hour food intake of standard chow diet (Figure 4.9c). The same 
experiment, using 45% HFD fed mice after a day time fast, showed that CNO injection had no 
significant effect on food intake, however a trend of decreased food intake upon CNO injection seems 
to be observed (Figure 4.9e). To ensure this wasn’t an off-target effect of CNO injection, a control 
experiment was completed using mice which had no DREADD expression. CNO injections following an 
equivalent day time fast had no net effect on 2-hour food intake of chow diet (Figure 4.10).  
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Figure 4.9 Effect of acute activation of hypothalamic GIPR neurons on food intake. (a) Schematic 
representation of GIPR activation study timeline. (b) 2 hour food intake of chow diet following 
injection of CNO or DMSO to mice fed ad libitum. Food intake was measured in the light cycle. (c) 2 
hour food intake of chow diet following injection of CNO or DMSO to mice which had been fasted 
for up to 10 hours during the day. Food intake was measured in the dark cycle. (d) 2 hour food 
intake of 45% HFD following injection of CNO or DMSO to mice fed ad libitum. Food intake was 
measured in the dark cycle. (e) 2 hour food intake of 45% HFD following injection of CNO or DMSO 
to mice which had been fasted for up to 10 hours during the day. Food intake was measured in the 
dark cycle. All experiments were performed on mice that had received an ICV injection of AAV-hSyn-
DIO-hM3D(Gq)-mCherry meaning CNO administration activated the GIPR positive neurons in the 
hypothalamus. Statistical significance was assessed using a two-tailed t-test, ***p<0.001.  
 
Chow Diet 45% HFD 
Wk 0         1          2          3          4          5         6         7         8         9         10         11         12 
Ad Lib Food 
Intake 
Day Fast, 
Food Intake 
Ad Lib Food 
Intake 
a Day Fast, 
Food Intake 
104 
 
C N O D M S O
0
1
2
3
4
5
F
o
o
d
 i
n
ta
k
e
 (
k
c
a
l)
 
Figure 4.10 Negative control to determine off target effects of CNO on food intake. 2 hour food 
intake of chow diet following injection of CNO or DMSO to mice which had been fasted for up to 10 
hours during the day. Food intake was measured in the dark cycle, and experiment was performed 
on mice which had not received an ICV injection of AAV-hSyn-DIO-hM3D(Gq)-mCherry. 
 
At the end of the study, brains were harvested by perfusion fixation and stained for RFP alone or in 
combination with YFP to determine the AAV targeting success. Of the 11 mice used for the activation 
study, 4 of these were genotypically positive for either the EYFP or GCamp3, enabling colocalisation 
immunostaining experiments to be performed. Between bregma levels -1.22 mm and -1.58 mm, the 
average percentage of YFP positive cells targeted by the AAV was 11%. In contrast, the average 
percentage of off-target RFP positive cells was high at 83%. Between bregma levels -2.06 mm and -2.6 
mm, the average percentage of targeted cells was 13%, and the average off-target percentage was 
55%. In addition to this, of the 11 mice used for the study, 5 mice had RFP staining on only one side of 
the 3rd ventricle, suggesting one of the injectors could have become blocked within surgery.  
The poor colocalisation of YFP and RFP positive cells raised concerns surrounding the cre-dependent 
integration of the AAV into neurons. Therefore, a set of control experiments were kindly performed 
by A. Adriaenssens. Gipr-Cre, Agouti-related peptide (AgRP)-Cre, and Cre negative mice underwent 
surgery for ICV injections of AAV-hSyn-DIO-hM3D(Gq)-mCherry. Following recovery, the brains were 
harvested by perfuse fixation, and then immunostained for YFP and/or RFP. Within the Gipr-Cre mice, 
the average percentage of targeted cells was 19%, and the average off-target percentage was 36% 
(Figure 4.11a). AgRP is known to be localised to the arcuate nucleus [345]. Although colocalisation 
experiments could not be performed on the AgRP-Cre mice, due to a lack of fluorescent reporter 
carried in the Rosa26 locus, staining of AgRP-Cre mice for RFP revealed the AAV was only found in the 
arcuate nucleus region (Figure 4.11b). The most important observation was that no RFP staining was 
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observed in the cre negative control mouse, showing that AAV integration was dependent on cre 
expression (Figure 4.11c).  
Overall, the immunostaining results here mean conclusions surrounding the effect of GIPR activation 
on food intake should be made with caution. Further investigation will be required to understand the 
role of hypothalamic GIPR.  
 
Figure 4.11 Immunostaining of Gipr-Cre, AgRP-Cre, and Cre negative brains injected with AAV-
hSyn-DIO-hM3D(Gq)-mCherry. (a) Example image of Gipr-Cre brain slice stained for YFP (green, 
representing GIPR), and RFP (orange, representing AAV). (b) Example image of Agrp-Cre brain slice 
stained for RFP (orange, representing AAV). (c) Example image of Cre negative brain slice stained 
for RFP (orange, representing AAV). All sections also stained with Hoescht as a nuclear stain, the 
area surrounding the third ventricle is magnified in the right-hand column. 
  
c 
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a 
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4.5 Discussion 
4.5.1 Use of Gipr-Cre mice for GIPR localisation  
The Gipr-Cre mouse model used here relies on a lineage tracing approach, in which one copy of the 
Gipr promoter drives Cre recombinase expression, enabling the expression of a fluorescent reporter 
protein (Figure 4.1). The result of this is that GIPR expressing cells are fluorescently labelled, and can 
be identified without the use of GIPR antibodies, which for the purpose of immunostaining seem to 
be limited and poorly validated.  
Hence, with this novel transgenic mouse model we could identify GIPR expressing cells in both the 
periphery, and central nervous system. The limitation however, is that the lineage tracing approach 
means that cells which have expressed GIPR transiently, or within the course of development, will also 
produce the fluorescent reporter protein. To ensure GIPR expression, one useful step would have 
been to perform qPCR alongside immunostaining, though often levels of the mRNA are extremely low 
and can be hard to detect by qPCR, aside from in pancreatic tissue where GIPR is highly expressed. 
Within the pancreas, GIPR was expressed in the α and β cells of the islets, and acinar tissue in a 
heterogenous pattern (Figure 4.2). Despite GIPR expression in δ cells not being investigated by 
colocalisation with somatostatin (Sst), it has previously been shown that GIPR is ubiquitously 
expressed in pancreatic islets, with equal expression in α, β, and δ cells [346]. Even without this Sst 
costaining data we were able to conclude that reporter expression in the pancreas was as expected 
for the GIPR, suggesting that the novel transgenic mouse model accurately detects GIPR expression.  
The heterogenous expression of GIPR in the acinar tissue was initially unexpected. However, studies 
from the 1980’s and 1990’s show that GIP stimulates release of pancreatic lipase, colipase and 
amylase, which are produced in the exocrine acinar tissue [347, 348]. In addition to this, the acinar 
tissue is known to be a heterogenous population of cells [349, 350]. These previous studies could 
explain why GIPR expression was observed in a heterogenous pattern in acinar tissue.  
GIPR expression is also important within the adipose tissue, though the exact underlying functions of 
the GIPR in adipocytes remain unclear. In vitro studies using mammalian cell lines and human 
adipocytes show that GIP increases lipoprotein lipase (LPL) expression and activity, triglyceride (TG) 
accumulation, and GLUT4 expression at the plasma membrane [176, 181, 351]. Adipose specific GIPR 
knockout (GIPRadipo-/-) mice, driven by a mouse adipocyte protein 2 (aP2)-Cre line, gain less weight on 
HFD compared to wild-type mice, suggesting protection from HFD induced obesity [185]. aP2 encodes 
fatty-acid binding protein 4 (FABP4) which has a less specific pattern of expression than originally 
thought, with expression also found in macrophages [352, 353]. However, GIPR is not detected in 
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macrophages, and despite the potential caveats of GIPRadipo-/- mice, the importance of GIPR in adipose 
tissue has been clearly demonstrated [185]. In a different experimental setting, GIPR expression driven 
by the aP2 promoter on a GIPR knockout background increased weight gain on HFD, preventing the 
protection from HFD induced obesity [354].  
Staining of brown and white adipose tissue showed scattered GIPR positive adipocytes (Figure 4.3a, 
b), which provided further confirmation that the Gipr-Cre transgenic mouse line was successfully 
labelling GIPR positive cells. Within the white adipose tissue, some of the GIPR positive adipocytes 
appeared to be multilocular, which may indicate beiging of the inguinal white adipose tissue. To 
determine whether this is the case, it could be useful to stain adjacent sections with haemotoxylin 
and eosin for histological analysis of the tissue.  
GIP is produced and secreted by K cells in the duodenum, therefore expression of GIPR in the 
duodenum could indicate the presence of local signalling pathways for GIP. GIPR expression was found 
in very few epithelial cells, with more cells appearing GIPR positive in the centre of the villi (Figure 
4.3c).  
Several of the epithelial GIPR positive cells co-stained with a 5-HT antibody, suggesting the expression 
of GIPR in gut enterochromaffin (EC) cells. This observation is supported by recent qPCR analysis of EC 
cells, which showed GIPR is enriched in both small intestinal and colonic EC cells [355]. The main role 
of these EC cells is to secrete 5-HT. This 5-HT produced in the periphery is unable to cross the blood-
brain barrier, and the majority is taken up by platelets for use in blood clotting [356]. The 5-HT also 
has other gastrointestinal functions such as peristalsis, perception of pain, nausea and is thought to 
be involved in the regulation of metabolism [59-62]. Despite this the regulation of 5-HT secretion is 
poorly understood. The withstanding hypothesis is that 5-HT secretion is regulated by dietary 
nutrients and microbial metabolites [357, 358].  
Recent findings suggest that the EC cells are not directly regulated by dietary nutrients, as there is a 
lack of expression of the main nutrient receptors. Instead, the expression of GLP1R in colonic EC cells, 
combined with the observation that GLP-1 stimulates 5-HT secretion, has led to the suggestion that 
EC cell nutrient sensing is indirect via GLP-1 producing enteroendocrine L-cells [355]. The 
colocalisation of GIPR and 5-HT in the duodenum could be used to suggest a similar mechanism for 
indirect EC cell nutrient sensing in the small intestine via GIP producing K-cells. Further studies to 
investigate GIP stimulated 5-HT secretion would be needed to confirm this hypothesis. 
The GIPR positive cells in the centre of the villi colocalised with vimentin immunostaining, used as a 
marker for cells of mesenchymal origin. GIPR expression within mesenchymal cells was a new finding 
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of this study, which can be compared to GLP2R expression in sub-epithelial myofibroblasts, a cell-type 
of mesenchymal origin [198]. Before proposing a role for GIPR within the mesenchymal cells, 
confirmation of GIPR presence in this cell type by analysis of the RNA is required. GIPR expression 
within the nodose ganglia (Figure 4.3d) was also a new finding of this study, which again needs to be 
confirmed by RNA analysis.  
4.5.2 Central expression of GIPR 
The Gipr-Cre mouse model not only allowed the study of GIPR in peripheral tissues, we were also able 
to demonstrate GIPR expression throughout the brain (Figure 4.4 and 4.5). GIPR expression was 
detected in several regions of the brain, some of which were in line with previous findings. Observation 
of GIPR expression in the olfactory bulb, defined areas of the cortex, the LSD, and hippocampus gave 
confidence that the mouse model was accurately detecting GIPR expression as GIPR had previously 
been detected in these regions using in situ hybridisation [149, 161].    
Immunostaining with the YFP antibody to detect GIPR expression produced images of higher 
resolution than those previously published, meaning the location of GIPR in further areas of interest 
could be characterised. Here, for the first time, GIPR expression was identified within hypothalamic 
nuclei, in particular in the Arc and DMD. GIPR expression was also found in the BST region, the PV, DG 
and the AP. No comment can be made upon the level of GIPR expression, because once cre-
recombinase excises the ‘floxed’ stop codon in the reporter gene construct, the fluorescent reporters 
are under control of a constitutively active promoter. Immunostaining of the fluorescent reporter 
means that low and high levels of GIPR expression would both be easily detected at the same level. 
Lower limits of detection using this new mouse model could be used to explain why we were able to 
detect GIPR expression in several brain regions for the first time here. 
When comparing GIPR expression to GLP1R expression in the brain, there are a number of areas in 
which expression appears to overlap. For example, both GLP1R and GIPR expression were observed in 
the SFO, CA3 of the hippocampus, Arc, and AP [94, 359]. Of particular interest is the expression in the 
Arc and AP; when considering the function of these regions, both are thought to be important in 
controlling food intake and energy expenditure [336]. With respect to the role of GIPR in obesity, 
central GIPR in these regions may play a role. A series of experiments have been performed here with 
the Gipr-Cre mouse model to further investigate the role of hypothalamic GIPR in control of food 
intake (discussed in section 4.5.3 and 4.5.4). In addition to these, it would be interesting to further 
characterise the role of the GIPR in the AP.    
We have demonstrated GIPR expression in several locations within the brain, however as discussed 
earlier the Gipr-Cre model has limitations due to the lineage tracing nature of this approach. 
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Confirmation of Gipr expression in the brain using alternative methods will be essential to ensure the 
Gipr-Cre model is accurately reporting. However, GIPR antibodies for use in immunostaining are 
limited, and accurate qPCR of specific regions will be difficult. When EYFP positive cells were sorted 
from Gipr-Cre x Rosa26-EYFP mice, hypothalamic Gipr gene expression was detected in the EYFP 
positive population, and not in the negative population, although the levels of expression were 
extremely low compared to other neuronal and astrocyte gene markers.  
One method to confirm GIPR expression at the time of immunostaining would be to stain with a Cre 
antibody, for example that produced by Novagen which has been used to specifically stain AAV-Cre 
[360]. A further way to infer GIPR expression would be to determine if the YFP expressing cells are 
activated by ICV infusion of GIP. Experimentally, this could be performed by co-staining for c-Fos 
expression and EYFP, as c-Fos is a marker for activated cells [361]. 
Obviously, a more in-depth characterisation of these GIPR positive cells would be useful to determine 
the cell-type and possible functions. One method for this is immunostaining and colocalisation 
analysis, which has been completed for GLP1R positive cells [94]. A number of cell-type specific 
markers can be used for this purpose, for example antibodies for glial fibrilliary acidic protein 
immunostain astrocytes [362], antibodies for tyrosine hydroxylase immunostain catecholamine 
neurons [363], and parvalbumin neurons can be detected by antibodies for parvalbumin [364]. The 
main limitation of this technique is specificity and availability of antibodies.  
An alternative method which has been used within the lab is flow cytometry to sort cells positive for 
the fluorescent reporter, followed by single cell RNA sequencing. This enables sequencing of over 1000 
genes per cell, providing a better overview of GIPR positive cell-type. This approach is limited to a 
defined area, thus we have focused entirely on the hypothalamic population of GIPR positive cells. 
When this technique was used to characterise proopiomelanocortin (POMC) neurons from the 
arcuate, the clustering analysis revealed the POMC neurons are a highly heterogenous population 
[365]. When searching this dataset, GIPR expression was detected in 2 of the 163 neurons. Of these, 
one neuron was defined as a ‘canonical’ POMC neuron with high levels of the POMC gene, the other 
was an unknown cell-type with low levels of the POMC and AgRP genes [365]. 
A final stage for characterisation of the GIPR positive cells would be to determine what the neurons 
are projecting to using anterograde viral tracing vectors based on the herpes simplex virus [366]. 
Alternatively, retrograde viral tracing vectors based on the pseudorabies virus [367, 368] could be 
used to identify the neurons which project to the GIPR positive cells. 
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4.5.3 Hypothalamic GIPR ablation 
Together, use of the Gipr-Cre mouse model with Cre-dependent AAV technology allowed for acute 
manipulation of hypothalamic GIPR positive cells. The hypothalamic GIPR positive cells were either 
ablated or activated, and the effects on food intake were monitored.  
In previous studies, global GIPR knockout and adipose specific GIPR knockout gave protection from 
HFD induced obesity. The underlying mechanism for this is not clearly understood, one key difference 
between these studies is that global GIPR knockout increases energy expenditure, whereas adipose 
specific GIPR knockout has no effect on energy expenditure [182, 185]. We hypothesised that 
hypothalamic GIPR identified here may have a role in regulating either food intake or energy 
expenditure. To determine if hypothalamic GIPR knockout gives protection from HFD induced obesity, 
GIPR positive cells were ablated, and effects on body weight and food intake were monitored.  
Overall, on both chow diet and 45% HFD, hypothalamic ablation of GIPR positive cells had no effect 
on body weight or food intake (Figure 4.6). This suggests the hypothalamic GIPR is less important for 
regulating GIP effects on obesity compared to the GIPR in adipose tissue. At the end of the experiment 
no differences were observed in fat mass, but lean mass was not measured (Figure 4.7). It would have 
been useful to also assess whole body composition, for example by using a non-invasive method of 
dual-energy X-ray absorptiometry (DEXA) or time domain nuclear magnetic resonance (TD-NMR) 
[369]. 
Food intake in all the ablation experiments was assessed over a 24-hour period, however 
retrospectively it could have been useful to measure leptin sensitivity over a shorter timeframe due 
to the half-life of leptin, which in C57/Bl6 mice is 49.5 minutes [370]. For comparison, when Yan et al 
assessed food intake after a leptin dose, a dose dependent decrease in 4-hour food intake was 
observed, whereas the magnitude of this effect was decreased when food intake was measured over 
24-hours [371]. In this study, leptin was injected towards the end of the day before dark onset, which 
is also important to consider due to the nocturnal activity of mice.  
It should be noted that over the course of the ablation experiments, we identified that the automated 
lighting within the mouse-holding room was faulty, and that the room was continuously light through 
to day 64 post-surgery. The issue was fixed for the experiments on HFD. This is a major confounding 
factor of this set of experiments, meaning that the circadian rhythm of the mice will have been 
disrupted throughout this study. Therefore, for any firm conclusions to be drawn, a repeat cohort is 
required.  
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A further factor for consideration when interpreting the body weight and food intake results of the 
ablation experiments is the degree of successful ablation. Only three of the mice from the ablation 
cohort had the EYFP fluorescent reporter, therefore these were the only mice which could be used in 
immunostaining for confirmation of GIPR ablation. Of these, only 2 of the 3 mice appeared to have 
decreased GIPR positive cells in the arcuate nucleus region (Figure 4.8; Table 4.1). For the remaining 
6 mice within the ablation cohort, we have been unable to show whether GIPR ablation was successful. 
One option to prove ablation could have been to co-inject an EGFP encoding cre-dependent AAV to 
label the Cre positive cells in the reporter negative mice, this would be similar to the method used in 
the original paper that describes the use of AAV-flex-taCasp3-TEVp [340].  
As it stands, we are unsure whether the GIPR cell ablation was successful throughout the ablation 
cohort, and consequently conclusions regarding the effect of hypothalamic GIPR ablation on food 
intake and body weight cannot be drawn. If repeated, it would be useful to have all Gipr-Cre mice 
genotypically positive for the fluorescent reporter gene.  
4.5.4 Hypothalamic GIPR activation 
Conversely to the GIPR ablation study, hypothalamic GIPR positive cells were acutely activated using 
DREADD technology, and effects on short-term food intake over a 2-hour window was measured. The 
use of DREADD technology is an increasingly popular technique for genetic manipulation of selected 
populations of neurons [372].  
As briefly described earlier, the DREADD receptors have been designed so that they are specifically 
activated by CNO, an otherwise inert ligand [341]. However, over the course of our study, Gomez et 
al have shown that clozapine, a CNO metabolite [373, 374], binds with higher affinity to the DREADD 
receptors, accumulates over time, and more readily crosses the blood-brain barrier compared to CNO 
[375, 376]. Together, this suggests that following CNO injection, clozapine is the activating ligand of 
the DREADD receptors. The significance of this is currently unknown, but it should be noted that 
clozapine also has endogenous receptors which may be activated if clozapine concentrations are 
above the threshold [377]. Alternative DREADD agonists have not been characterised in vivo, thus the 
current recommendation is to continue using either CNO or clozapine for DREADD experiments with 
emphasis on the importance of negative control experiments in non-DREADD expressing animals 
[378]. 
In this study we found activation of hypothalamic GIPR positive cells by intraperitoneal injection of 
CNO led to decreased food intake of chow diet following a 10-hour day time fast (Figure 4.9c). The 
same experiment in non-DREADD expressing mice showed CNO had no effect on food intake (Figure 
4.10). This is an intriguing observation which is in line with other rodent studies in which central 
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administration of GIP decreased food intake over 24 hours [332]. Additionally, transgenic 
overexpression of GIP leads to decreased food intake of low fat and high fat diet in the dark cycle 
[379]. However, together this data doesn’t seem to fit with the knowledge that knockout of the GIPR 
protects from high fat diet induced obesity [182]. The contrasting data is rather confusing, clearly the 
role of central GIP in regulating food intake requires further investigation. One possibility is that rather 
than solely effecting food intake, GIP may play a role in determining food preference. This hypothesis 
stems from a recent publication in which it was found that although GIPR knockout mice are protected 
from weight gain on HFD, they are not protected from weight gain induced by high starch diet (HSD) 
[380].  
When interpreting the results of our study, it is important to consider the immunostaining results 
which were used for confirmation of accurate targeting of the AAV. We identified a high percentage 
(55 – 83%) of off-target cells, positive for RFP but negative for YFP. This was improved in a separate 
control cohort of mice, with an average off-target percentage of 36% (Figure 4.11a). It should be noted 
that this counting was manual, meaning error could have accumulated due to uncertainty surrounding 
the threshold at which to count a ‘positive’ cell. Despite this, there was clearly a degree of AAV off-
targeting observed. The reason for this off-targeting of the AAV is unclear, particularly as no RFP 
staining was observed in the Cre negative control, outruling the possibility of the AAV randomly 
integrating into cells in a cre-independent manner (Figure 4.11c). One possible reason is a difference 
in efficacy of the cre-dependent fluorescent reporter protein expression versus the cre-dependent 
incorporation of the AAV.  
Prior to conclusions being drawn surrounding the effect of hypothalamic GIPR activation, the effects 
on food intake found here must first be confirmed in a second cohort. It is essential that within this 
second cohort all animals express a fluorescent reporter so that AAV targeting can be assessed in the 
whole group. Following this, it could be possible to investigated food preference using specially 
designed holding cages for the mice.  
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4.5.5 Summary 
Within this chapter, a novel transgenic mouse line, Gipr-Cre, has been used to identify and 
characterise cells expressing the GIPR. Immunostaining of the pancreas and adipose tissue suggested 
that the model was successfully reporting GIPR positive cells. Additionally, GIPR was found 
sporadically in duodenal EC cells and sub-epithelial cells, nodose ganglia and in several regions of the 
brain.  
Expression of GIPR in hypothalamic nuclei was of particular interest as this central brain region plays 
a role in the control of food intake and energy expenditure. Despite our efforts to characterise the 
role of GIPR positive cells within the hypothalamus, we are currently unable to conclude with high 
confidence that acute manipulation of these GIPR positive cells effects food intake. 
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Chapter 5. Characterisation of a GLP2R variant, D470N, associated 
with Type 2 Diabetes risk 
5.1 Introduction  
5.1.1 A missense variant in GLP2R is associated with citrulline levels and type 2 
diabetes risk 
Genome wide association studies (GWAS) have been successful in the identification of genetic variants 
robustly associated with metabolite levels and disease risk. In a GWAS of metabolite levels L. Lotta, C. 
Langenberg and colleagues found a common missense variant within GLP2R (Asp470Asn; D470N; 
rs17681684) that is strongly associated with higher circulating levels of citrulline (n=30,940; p = 6.4e-
22), a biomarker of enterocyte mass [381].  
Other GWAS studies have associated the same single nucleotide polymorphism (SNP) with increased 
fasting GIP levels (p = 1.4e-9), and a nominal association with slightly lower fasting glucose has also 
been identified (p = 0.03) [382]. In addition, a GWAS of type 2 diabetes recently identified a common 
variant associated with higher diabetes risk in high linkage disequilibrium with the citrulline-raising 
allele of D470N [383]. 
The functional effect of this GLP2R mutation is not known [382], however the pattern of association 
with citrulline levels suggests it might be a gain-of-function mutation, on the basis that greater 
signalling via GLP2R would result in greater enterocyte mass. We therefore aimed to characterise the 
functional effects of the D470N mutant on GLP2R signalling.   
5.1.2 Function of intestinal GLP2R  
GLP-2 is secreted from enteroendocrine L-cells in response to dietary nutrients, alongside GLP-1 [384]. 
The gastrointestinal functions include regulation of epithelial cell proliferation and apoptosis [202]. 
Activation of the GLP2R leads to a rapid expansion of the mucosal epithelium [214], which is thought 
to be related to increased intestinal absorption of carbohydrates, amino acids and lipids [203-205]. 
Other observed effects of GLP2R activation include decreased gastrointestinal motility [206], 
decreased gut permeability, increased intestinal barrier function [207, 208], and increased visceral 
blood flow [209, 210].  A detailed review of these functions, along with the possible underlying 
mechanisms can be found elsewhere [201].  
There is contrasting evidence regarding the location of the GLP2R, with some groups arguing 
expression is found in 5-HT positive enterochromaffin cells within the epithelial lining of the intestine 
[194-196]. In contrast, other groups fail to detect GLP2R in epithelial cells. Using techniques including 
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qPCR, in situ hybridisation and receptor autoradiography these groups argue that GLP2R expression is 
either in subepithelial myofibroblasts or enteric neurons [197-200].  
Despite the lack of understanding surrounding the location of GLP2R, the gastrointestinal functions of 
GLP-2 have been utilised therapeutically. A stabilised GLP-2 analogue, teduglutide, is approved for the 
treatment of short bowel syndrome, successfully reducing malabsorption-related consequences [385-
387]. Clinical trials show that teduglutide may also be useful for treating patients with inflammatory 
bowel diseases such as Crohn’s disease [388, 389]. Additionally, one group has suggested that GLP-2 
has beneficial metabolic effects in a HFD setting [390, 391].  
For the potential next generation of GLP-2 therapeutics, co-agonists are being developed. For 
example, a GLP-2/GLP-1 dual acting agonist has recently been produced and characterised in vivo, 
demonstrating the viability of modulating metabolic and intestinotrophic factors using a single 
molecule [392].  
5.1.3 GLP2R signalling pathways 
The GLP2R belongs to the class B family of GPCR’s (as detailed in chapter 1), thus the canonical 
signalling pathway is mediated by Gαs and leads to an increase in cAMP [191]. Regarding G-protein 
independent pathways, GLP2R signalling via phosphorylation of ERK1/2 and phosphorylation of 
protein kinase B (known as Akt) has been observed in primary cultures of rodent enteric neurons. This 
phosphorylation is dependent upon phosphatidylinositol-3 kinase (PI3K), and downstream leads to an 
increase in vasoactive intestinal polypeptide (VIP) expression [192].  
In addition to this, GLP2R over-expressing cell lines show β-arrestin 2 is recruited to the GLP2R upon 
activation, however the downstream role of β-arrestin 2 is unknown. Investigation has shown that β-
arrestin 2 is not involved in agonist induced desensitisation of the GLP2R, nor the phosphorylation of 
ERK1/2 [193].  
To characterise the effect of the D470N mutation within GLP2R, we investigated the effects on 
signalling via cAMP, β-arrestin 1, β-arrestin 2 and phosphorylation of ERK1/2 (P-ERK1/2). 
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5.2 Aims 
Investigate the functional differences between wild-type (WT) GLP2R and the D470N mutant GLP2R 
by: 
a) Generation of D470N GLP2R mutant constructs using site-directed mutagenesis. 
 
b) Characterisation of canonical GLP2R signalling pathways via cAMP. 
 
c) Characterisation of alternative GLP2R signalling pathways via β-arrestin and P-ERK. 
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5.3 Methods 
GLP-2 was diluted in 50% acetic acid to form a 1 mmol/l stock solution. 
5.3.1 Molecular Biology 
Firstly, an internal ribosome entry site (IRES) and venus gene segment was inserted downstream of 
the GLP2R cDNA sequence using Gibson cloning. The IRES-Venus fragment was amplified from a 
Glucagon(GCG)-IRES-Venus plasmid using PCR, with primers that had a 19-21 basepair overlap with 
Xho1/Xba1 linearized GLP2R plasmid. The PCR product and linearized GLP2R plasmid were combined 
with Gibson cloning (New England Biolabs) which utilises 5’ exonuclease, DNA polymerase and DNA 
ligase to assemble DNA in a one-step process. Reactions were incubated at 50°C for 60 minutes, and 
resultant cloning product was used to transform One Shot® OmniMAX™ 2 T1R bacteria. DNA was 
harvested from the transformation products using the QIAprep® Spin miniprep kit, and successful 
cloning was confirmed using Apa1 restriction digest together with DNA Sanger sequencing 
(SourceBioscience).  
To generate the D470N mutant, a single point mutation was made in GLP2R-IRES-Venus in the 
pcDNA3.1 vector using the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies) 
according to the standard protocol (primers detailed in Appendix 2). One Shot® OmniMAX™ 2 T1R 
bacteria (Invitrogen) were used for transformation of the mutant product, and DNA was harvested 
from resultant colonies using a QIAprep® Spin miniprep kit. DNA Sanger sequencing 
(SourceBioscience) was used to confirm successful mutagenesis. 
5.3.2 HitHunter® cAMP Assay 
To determine differences in cAMP signalling between wild-type GLP2R and Asp470Asn (D470N) GLP2R 
a HitHunter® cAMP assay was used. CHO K1 cells were seeded into white-bottomed 96 well plates at 
20,000 cells/well. The following day, cells were transiently transfected with wild-type/mutant GLP2R 
constructs or control plasmid. 100 ng DNA was transfected per well using 1 µl lipofectamine 2000. The 
following day, cells were washed once with PBS, then incubated for 30 minutes at 37°C in PBS 
containing 0.5 mM IBMX ± ligand. Cellular cAMP levels were measured using HitHunter® cAMP assay 
according to the manufacturer’s recommendations (DiscoveRx, Fremont, CA, USA). Briefly, antibody 
reagent and lysis solutions were added to the plate, then plates were incubated for 1 hour in the dark 
on a shaker. Enzyme solution was then added to the plates, and plates were incubated for a further 
hour in the dark on a shaker. After a final 3 hours at room temperature, luminesence was measured 
on a TopCount plate reader (PerkinElmer). 
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5.3.3 Nano-Glo® Live Cell Assay for Beta-Arrestin Measurements  
Assay performed according to method described in chapter 3.  
5.3.4 ERK1/2 Phosphorylation Analysis by Western Blotting 
HEK293 cells were seeded into 6 well plates at 300,000 cells/well, and transfected the following day 
with wild-type or D470N mutant GLP2R expressing constructs using 2 µg DNA and 6 µl lipofectamine 
2000 per well. 16-24 hours post transfection, media was replaced with OptiMEM reduced serum 
media and cells were incubated at 37°C for 2 hours prior to stimulation with 1 µM GLP-2. After 5, 10, 
15, 30 or 60 minutes of treatment, cells were washed with ice-cold PBS, and lysed using RIPA lysis 
buffer (ThermoFisher Scientific) containing PhosSTOP™ and cOmplete™ protease inhibitors (Sigma-
Aldrich). Samples were then centrifuged at 13,200 rpm for 10 minutes at 4°C, and the supernatant 
used for western blotting. The protein content was determined by bicinchoninic acid (BCA) assay 
(ThermoFisher Scientific) according to the manufacturer’s protocol. 
Samples were prepared for western blotting, by mixing with 10X Bolt™ Sample Reducing Agent and 
4X Bolt™ LDS Sample Buffer, then heating samples to 85°C for 10 minutes. 8 µg of samples were loaded 
onto 4–15% precast polyacrylamide gels for electrophoresis at 150 V for 45 minutes, then transferred 
onto nitrocellulose membrane using the iBlot® Dry Blotting System iBlot (Life Technologies). 
Membranes were blocked for 1 hour using 5% (w/v) milk in tris-buffered saline (TBS) + 0.1% (v/v) 
Tween-20 (TBS-T). For protein detection, primary antibodies of interest (Appendix 4) diluted in 0.5% 
(w/v) milk TBS-T were incubated with membranes overnight at 4°C. After washing with TBS-T, goat 
anti-rabbit IgG HRP conjugated secondary antibody (1:2,500) was incubated with membranes in 1% 
(w/v) milk TBS-T for 1 hour.  Proteins were detected with Pierce™ ECL Western Blotting Substrate 
(Thermo Scientific) and imaged with a Bio-Rad ChemiDoc Imaging System.  
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5.4 Results 
5.4.1 Generation of D470N GLP2R mutant expressing constructs 
To investigate the functional differences between WT GLP2R and the D470N mutant, first GLP2R 
expressing constructs were generated. Human GLP2R cDNA within the pcDNA3.1+ vector was 
purchased, and Gibson cloning was completed to insert an internal ribosome entry site (IRES) and 
venus gene downstream of the GLP2R sequence. Briefly, primers were designed for amplification of 
the IRES-Venus fragment from a GCG-IRES-Venus plasmid within the lab. The 5’ end of each primer 
had a 19 – 21 basepair sequence complementary to the ends of Xho1 and Xba1 linearized GLP2R 
pcDNA3.1+ vector (Appendix 2). The amplified IRES-Venus fragment and linearized GLP2R vector were 
combined using Gibson cloning. Successful Gibson cloning products were determined by analysis by 
gel electrophoresis after an Apa1 restriction digest, along with DNA Sanger sequencing.  
Following this, QuikChange Lightning site directed mutagenesis was used to perform a single base 
change from GAC (encoding aspartic acid) to AAC (encoding asparagine) at amino acid position 470 
(Figure 5.1a, b). Successful mutagenesis was confirmed by DNA Sanger sequencing (Figure 5.1c), and 
the successful products were scaled up for use in functional assays. The WT and mutant GLP2R 
constructs within the pcDNA3.1+ vector were used to assess signalling by cAMP and P-ERK. 
To determine β-arrestin recruitment using NanoBiT® technology, an alternative vector was required 
for lower expression of GLP2R, and fusion of GLP2R to the Large BiT subunit of NanoBiT®. For this, 
GLP2R was cloned into the pBiT1.1_C[TK/LgBiT] vector using restriction cloning with Xho1 and EcoR1, 
followed by quick ligation. DNA Sanger sequencing was then used for confirmation of successful 
cloning.  
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Figure 5.1 Schematic depicted wild-type and mutant GLP2R sequences. (a) Wild-type GLP2R 
sequence, amino acid targeted for mutation is highlighted in yellow. (b) Mutant GLP2R sequence, 
showing D470N mutation highlighted in yellow. Primers used to introduce the mutation using 
QuikChange Lightning Site-Directed Mutagenesis are depicted, forward primer shown in green, and 
reverse primer shown in red. (c) Sequence confirmation of successfully mutagenesis, 
chromatogram depicted for clone 4 which was then sequenced in full.  
 
5.4.2 Comparison of WT and D470N GLP2R signalling via cAMP 
After generation of WT and D470N GLP2R containing constructs, these were used to assess differences 
in WT and mutant GLP2R signalling. The initial signalling pathway to be assessed was Gαs signalling via 
cAMP. CHO K1 cells were transiently transfected with WT or mutant GLP2R constructs, then after 16 
- 24 hours were treated with a dose response of GLP-2. cAMP levels were measured following 30 
minutes of GLP-2 treatment, in an end-point lysis HitHunter® cAMP assay.  
The presence of IRES-Venus within the GLP2R expressing vectors allowed transfection efficiency to be 
determined for each construct. Transfection efficiency was approximately 60 - 70%, with no 
differences between the WT and mutant constructs. Comparison of the GLP-2 dose-response in WT 
a 
b 
c 
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and mutant GLP2R expressing cells revealed no significant differences in signalling, with an almost 
overlapping dose response curve (Figure 5.2).  
 
Figure 5.2 GLP-2 dose response curves in cAMP assay for GLP2R wild-type and mutant receptors. 
The dose response curves of cAMP stimulation by GLP-2 in CHO K1 cells transiently transfected with 
either GLP2R wild-type or mutant constructs. Data has been normalised to the wild-type maximal 
and minimal response, with 100% being GLP-2 maximal stimulation of the wild-type GLP2R, and 0% 
being wild-type GLP2R cells with buffer only. Data are mean ± SEM (n=4).  
 
5.4.3 Comparison of β-arrestin recruitment to the WT and D470N GLP2R 
Aside from cAMP signalling, it is known that the WT GLP2R recruits β-arrestin 2 [193]. Therefore, 
following assessment of cAMP signalling, we investigated β-arrestin recruitment to the WT and 
mutant GLP2R. Both β-arrestin 1 and β-arrestin 2 recruitment were assessed using a Nano-Glo® live 
cell assay in transiently transfected HEK293 cells. Briefly, the recruitment of β-arrestin to GLP2R brings 
the large and small BiT subunit of NanoBiT® together, resulting in increased luciferase activity. The top 
concentrations from the GLP-2 dose response in the cAMP assay (1 – 100 nmol/l GLP-2) were chosen 
for stimulation of the GLP2R and observation of β-arrestin recruitment. 
Both β-arrestin 1 and β-arrestin 2 were recruited to the WT GLP2R upon GLP-2 stimulation, in a dose-
dependent manner (Figure 5.3a, c). The maximal luciferase activity for both β-arrestin 1 and β-arrestin 
2 recruitment to the mutant GLP2R was significantly decreased when compared to the WT GLP2R, 
indicating the extent of β-arrestin recruitment was markedly decreased (Figure 5.3b, d). The example 
traces indicate that neither β-arrestin 1 or β-arrestin 2 were recruited to the mutant GLP2R upon 
stimulation with 1 nmol/l GLP-2, however the same concentration of GLP-2 induced β-arrestin 
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recruitment to the WT GLP2R (Figure 5.3). Overall there was a significant decrease in β-arrestin 1 and 
β-arrestin 2 recruitment to the D470N GLP2R mutant (Figure 5.4).  
 
Figure 5.3 Example traces of GLP2R wild-type and mutant signalling via beta-arrestin 1 and beta-
arrestin 2. Example real-time beta arrestin responses to a dose titration of GLP-2 are displayed for 
beta-arrestin 1 (a, b) for wild-type GLP2R (a) and D470N mutant GLP2R (b). Real time beta-arrestin 
responses are also displayed for beta-arrestin 2 (c, d) for wild-type GLP2R (c) and D470N mutant 
GLP2R (d). Data are from representative experiments, and are displayed as mean ± SEM from 3 
wells. 
 
 
Figure 5.4 Summary of wild-type and mutant GLP2R beta-arrestin 1 and beta-arrestin 2 responses. 
Area under curve (AUC) summary data (n=3-4) displayed for beta-arrestin 1 recruitment (a) and 
beta-arrestin 2 recruitment (b). Individual data points are displayed, the presence of 2 populations 
within beta-arrestin 2 data is explained by a day-effect. AUC has been calculated using the 5 minutes 
prior to ligand addition as the baseline value. Data are mean ± SEM. Normal distribution of log10 
transformed data was determined by the D'Agostino & Pearson normality test. Following this 
statistical significance was assessed by one-way ANOVA with post hoc Bonferroni test. ***p<0.001, 
*p<0.05.  
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5.4.4 Comparison of WT and D470N GLP2R signalling via P-ERK 
Following the observation of decreased β-arrestin recruitment to the mutant GLP2R, we hypothesised 
that this would increase cell surface expression of the activated receptor, due to the generally 
accepted function of β-arrestin in promoting endocytosis [393].  
We further hypothesised that this increased cell surface expression may lead to prolonged GLP2R 
signalling. As the D470N mutant GLP2R is associated with increased citrulline, and one of the main 
functions of the GLP2R is regulation of epithelial cell proliferation in the small intestine, we 
investigated signalling via P-ERK, a pathway known to be involved in modulating cell proliferation 
[394]. 
To determine signalling via P-ERK, transiently transfected HEK293 cells were used, and signalling was 
detected by western blotting of stimulated and unstimulated cell lysates, for P-ERK and total ERK. To 
test the hypothesis that the mutant GLP2R would have prolonged signalling, cells were stimulated 
with 1 µmol/l GLP-2 for varying lengths of time, and cell lysates were used for western blotting. 
Initially, HEK293 cells transfected with GLP2R in the low expressing pBiT1.1_C[TK/LgBiT] vector were 
used for western blotting. However, stimulation with 1 µmol/l GLP-2 was not able to produce a P-ERK 
signal strong enough to be detected by western blotting. The bands observed were extremely faint, 
and unquantifiable above background (data not shown).  
Therefore, HEK293 cells transfected with the WT or mutant GLP2R within the pcDNA3.1 backbone 
were used. Treatment with 1 µmol/l GLP-2 produced signalling via P-ERK which appeared to peak at 
10 minutes for both the WT and mutant GLP2R (Figure 5.5). Upon observation of the western blots, 
no difference in the time-course of GLP-2 signalling via P-ERK could be seen between the WT and 
mutant GLP2R. To normalise and quantify the three independent western blots, the optical densities 
of bands were measured and expressed relative to optical density of beta-actin bands on the same 
western blot. P-ERK was then expressed relative to total ERK. This quantification confirmed that there 
was no difference in the time-course GLP-2 stimulated P-ERK signalling (Figure 5.6).  
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Figure 5.5 Western Blots demonstrating wild-type and mutant GLP2R signalling via P-ERK. 
Representative western blots of HEK293 cells transiently transfected with wild-type or mutant 
GLP2R constructs, and stimulated with 1 µmol/l GLP-2 for the times indicated above bands. Mock 
transfected cells were transfected with empty pCDNA3.1, and either untreated, or treated with 1 
ng/ml EGF. Blots are presented for P-ERK (a), total ERK (b), and beta-actin for the respective blots 
(c) and (d).  
 
 
 
Figure 5.6 Quantification of western blots to compare wild-type and mutant GLP2R signalling via 
P-ERK. Densitometry was used to measure density of each band from 3 independent western blots, 
data are mean ± SEM. Optimal density for each blot was normalised by dividing by beta-actin 
density. Following this normalised P-ERK intensity is expressed relative to total ERK intensity.  
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5.5 Discussion 
5.5.1 Mutant GLP2R displays decreased β-arrestin recruitment  
Upon investigation of WT and D470N mutant GLP2R downstream signalling pathways, no differences 
were observed in the canonical cAMP signalling or P-ERK signalling. However, we observed decreased 
β-arrestin recruitment to the D470N mutant GLP2R (Figure 5.3, 5.4). 
We were able to demonstrate binding of both β-arrestin 1 and β-arrestin 2 to the WT GLP2R. It appears 
that this is the first report of GLP2R association with β-arrestin 1, with the β-arrestin 2 recruitment 
being in line with previous findings [193]. In comparison to the WT receptor, both β-arrestin 1 and β-
arrestin 2 binding to the mutant GLP2R were decreased. 
It is generally accepted that β-arrestins are involved in mediating endocytosis [393], though for GLP2R 
it seems this may not be the case. Deletion studies, in which different portions of the GLP2R C terminal 
tail were deleted have shown that this portion of the GLP2R is required for binding to β-arrestin 2. 
However, the truncated receptors still undergo agonist induced endocytosis, with a more rapid 
recovery of cell surface expression following endocytosis. This suggests β-arrestin 2 is not required for 
GLP2R endocytosis, a clathrin- and dynamin-independent, lipid-raft-dependent process [193, 395].  
The function of β-arrestin 2 binding to the GLP2R is currently undefined. One suggestion is that GLP2R 
bound β-arrestin 2 regulates intracellular signalling and trafficking downstream of endocytosis [193]. 
The other β-arrestin, β-arrestin 1 may well be involved in regulating GLP2R endocytosis. 
5.5.2 Consequences of decreased β-arrestin recruitment to the mutant GLP2R 
To investigate the consequences of decreased β-arrestin recruitment to the mutant GLP2R, the time-
course of ERK phosphorylation was assessed. No differences were observed between the WT and 
mutant GLP2R (Figure 5.5, 5.6).  
Upon reflection, the optimal experimental conditions may not have been used to test the hypothesis 
that decreased β-arrestin recruitment would lead to increased cell surface expression of GLP2R, thus 
prolonged signalling via P-ERK. GLP2R was transfected into cells using a high expressing construct with 
a CMV promoter, which may overwrite any slight differences in surface expression produced by 
decreased β-arrestin recruitment. Perhaps a lower level of expression is required to observe any 
differences related to increased cell surface expression. However, detection of P-ERK by western 
blotting was not sensitive enough to allow for measurement of P-ERK in the lower expressing cells. 
Further optimisation of this technique may be required to increase sensitivity. Alternatively, one could 
look at cAMP signalling at different timepoints using the low expressing constructs. Though the P-ERK 
experiments suggest that decreased β-arrestin recruitment has no effect on prolonged GLP2R 
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activation, to confirm this cAMP signalling should be assessed as the better-defined signalling pathway 
of the GLP2R.    
One possible reason to explain the P-ERK results could be related to the location of the endogenous 
GLP2R. P-ERK signalling is a well-known pathway for the control of proliferation [394], and GLP-2 
stimulates P-ERK [192]. However, in vivo, if the GLP2R is expressed on enteric neurons rather than 
endothelial cells [197-200], one would hypothesise that GLP-2 has an indirect role in stimulating 
endothelial cell proliferation, indirect of P-ERK stimulation.  
A potential mechanism for the proliferative actions of GLP-2 could be GLP2R activation on the enteric 
neurons leading to cAMP stimulation. Downstream, one could hypothesise this leads to release of an 
intermediate factor such as a growth factor, which then causes proliferation of the endothelial cells. 
Similar indirect effects of GLP-2 on intestinal growth have previously been reported, requiring insulin-
like growth factor-I (IGF-I) [396]. Therefore, prolonged cAMP stimulation could be more relevant to 
the gain of function effect observed by increased citrulline in people with the D470N mutant.  
Interestingly, progressive truncation of the C terminal tail of GLP2R reduces cell surface receptor 
expression, and decreases cAMP signalling. However, when the expression level of WT GLP2R is 
matched to the truncated GLP2R, the truncated forms of GLP2R produce more cAMP per receptor 
[193].  It appears that the GLP2R C-terminal tail responsible for β-arrestin recruitment in some way 
interferes with Gαs coupling. We hypothesize the failure of D470N GLP2R mutants to recruit β-arrestin 
may enhance or prolong cAMP signalling independently of cell surface receptor expression. In future 
experiments, the time-course of cAMP signalling in WT and mutant D470N GLP2R cells will be 
investigated.  
5.5.3 Future investigations of the D470N mutant GLP2R 
In addition to investigating the time course of cAMP signalling in WT and mutant GLP2R cells, the cell 
surface expression of the GLP2R could be assessed, along with any effects on the proliferative actions 
of GLP-2.  
To assess cell surface expression, a labelled version of the GLP2R would need to be used. For example, 
a FLAG tag could be used, similar to in previous settings [193]. The combination of a FLAG tagged WT 
and mutant GLP2R with techniques such as immunostaining could be helpful for determining cell 
surface expression. Alternatively, the availability of GLP2R antibodies or fluorescently tagged GLP-2 
could be useful for looking at GLP2R cell surface expression. 
To determine effects of mutant GLP2R on the proliferative action of GLP-2 in vitro may be more 
difficult. Transiently transfected cell lines could be used in a scratch wound assay to assess 
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proliferation, however this is not necessarily the best model as it does not represent the endogenous 
setting. A cell line expressing endogenous levels of the GLP2R may be helpful, although this again does 
not represent the endogenous setting where GLP2R is likely on the enteric neurons rather than 
endothelial cells [197-200]. Perhaps biopsies from patients displaying the GLP2R mutation could be 
useful to assess intestinal morphology histologically, which would then give an indication of 
differences in proliferative actions of GLP-2.  
5.5.4 Summary 
In summary, the functional effects of the D470N mutation within GLP2R were characterised in a 
variety of downstream signalling assays. Interest in this mutant arose from GWAS studies in which the 
D470N GLP2R mutant was found to be associated with higher circulating citrulline levels (C. 
Langenberg and L. Lotta), and increased risk of type 2 diabetes.  
Characterisation of D470N GLP2R, and comparison with the WT receptor showed there was no 
difference in cAMP signalling after 30 minutes stimulation with a dose response of GLP-2. The D470N 
GLP2R mutant had decreased β-arrestin recruitment, however the physiological effect of this is 
currently unknown and requires further investigation. No differences were observed in the time-
frame of P-ERK signalling. As a next step possible differences in the time-course of cAMP signalling are 
to be assessed.
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Chapter 6. General Discussion 
6.1 Summary  
The aims of this thesis focused on generation of tools to characterise the expression and function of 
gut hormone receptors in more depth. For this purpose, three parallel projects have been undertaken; 
an antagonistic antibody has been developed for GLP1R, a novel GIPR transgenic mouse model has 
been used to characterise GIPR expression, and mutant GLP2R expressing vectors have been 
generated to understand effects of a common missense mutation in the GLP2R associated with type 
2 diabetes.  
In this chapter, the overall results from each of the above projects are summarised and put into 
context with the wider field. The key findings are schematically depicted in figure 6.1.  Alongside this, 
future directions and possible therapeutic implications are discussed.  
 
 
 
Figure 6.1 Summary of key findings throughout thesis.  A schematic representation of key findings 
for research on the gut hormones GLP-1, GIP and GLP-2.  
 
6.2 Glp1R0017 enables controlled blockade of the GLP1R over several days 
In chapter 2, a new monoclonal antagonistic antibody for the GLP1R, Glp1R0017, was identified using 
naïve phage display libraries. Several studies have focused on the function of the GLP1R, due to it’s 
therapeutic importance in the treatment of type 2 diabetes [237]. Pharmacologically, the GLP1R has 
been studied using exendin 9-39 as a peptide antagonist for GLP1R [239]. However, questions have 
been raised surrounding the specificity of exendin 9-39 [121, 243, 244]. When considering the location 
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of the GLP1R, rather than using antibodies, a transgenic mouse model expressing fluorescent 
reporters downstream of the Glp1r promoter seems to give the most detailed characterisation of 
GLP1R [93]. The generation of Glp1R0017 provides a new tool for the field studying the function of 
GLP1R. 
Upon characterisation of Glp1R0017, detailed in chapter 3, specificity for the GLP1R was confirmed, 
and cross-species reactivity was defined. Although we have indicated specificity of Glp1R0017 for 
GLP1R using overexpressing cell lines expressing closely related GPCR’s, we cannot exclude potential 
interactions with unknown targets. Use of the INS-1 832/3 cell line to assess off-target effects of 
Glp1R0017 was limited upon discovery that GLP-1 is secreted from this cell line in the presence of 8.3 
mmol/l glucose. To add to our research, it would be interesting to assess Glp1R0017 effects on glucose 
stimulated insulin secretion from isolated islets, however this would not necessarily enable us to 
assess off-target effects as there are claims that GLP-1 is secreted from α-cells within pancreatic islets 
[397]. 
Further characterisation, in an in vivo setting using a mouse model, showed that Glp1R0017 inhibits 
GLP-1 mediated incretin effects on glucose tolerance, and has an extended half-life in comparison to 
exendin 9-39 which may be beneficial in certain in vivo studies. In comparison to mAb3F52 and 
7F38A2, two antibodies developed and characterised by Novo Nordisk during the course of this PhD 
[116, 252, 253], Glp1R0017 has the major advantage of having cross-species reactivity, likely due to 
the selection approach using both human GLP1R ECD and mouse GLP1R overexpressing cells as the 
target antigens. 
6.2.1 Future directions for Glp1R0017  
Glp1R0017 has been characterised in substantial detail within chapter 3, however more experiments 
can be thought of for further characterisation of the antibody. For example, western blotting is the 
method used previously, by Panjwani and colleagues, that showed a number of commercially available 
antibodies were unspecific for GLP1R [92]. The use of Glp1R0017 for western blotting of the GLP1R 
has not been detailed here, initial attempts using cell lysates from the mouse and human GLP1R 
overexpressing cell lines were unsuccessful with an absence of bands on the blots. Optimisation of 
this technique is required to determine if Glp1R0017 is able to detect GLP1R by western blotting. 
Other groups are interested in using Glp1R0017 for western blotting, and will hopefully be able to 
optimise this technique. 
In vivo, following a short pharmacokinetic study we characterised Glp1R0017 effects on metabolism 
by using glucose tolerance tests. We found that Glp1R0017 dose-dependently reversed the actions of 
liraglutide on glucose tolerance, and decreased glucose tolerance in an OGTT in C57Bl6 wild-type mice. 
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Other published glucose tolerance studies also measure insulin levels to give a more complete picture 
of glucose metabolism. Retrospectively, it could have been interesting to measure insulin in our 
glucose tolerance tests. Additionally, to confirm that Glp1R0017 is specific for GLP1R in an in vivo 
setting, one could make use of the GLP1R knock-out model [294], and test the effects of Glp1R0017 
in glucose tolerance.  
It is hoped that Glp1R0017 provides a new tool to the field for answering currently unanswered 
questions surrounding GLP1R physiology. For example, Glp1R0017 is currently being used to assess 
the importance of GLP-1 in controlling glucose tolerance and weight loss following vertical sleeve 
gastrectomy in mice. The long half-life of Glp1R0017 means that a weekly injection is able to block the 
GLP1R, in comparison this study would be impossible using exendin 9-39 due to its short half-life. The 
GLP1R knock-out mouse would also not be suitable for this type of study as the mice are thought to 
have adaptations to the knock-out during the course of development, including compensatory 
increases in GIP secretion and responsiveness to GIP in terms of insulin secretion [398]. This form of 
experiment shows the key benefits of using a GLP1R antagonistic antibody to study GLP1R physiology, 
and will hopefully reveal new findings surrounding the importance of GLP-1 post bariatric surgery. 
In the longer term one could postulate that a GLP1R antagonistic antibody, may be therapeutically 
beneficial for patients suffering from post-prandial hypoglycaemia.  There are two main groups of 
patients which suffer with this; one being patients with “dumping syndrome” which often occurs in 
lean patients that undergo gastrectomy to treat cancer, the other group is patients with the metabolic 
disorder “post-bariatric hypoglycaemia” which occasionally happens in patients that have undergone 
bariatric surgery [242, 312]. Studies are currently ongoing using exendin 9-39 infusions, with promising 
results that GLP1R blockade is a potential therapeutic strategy for treating these patients. Using this 
previously published data it is exciting to hypothesise that a GLP1R antagonistic antibody may also be 
beneficial therapeutically, and the longer half-life may provide an important advantage in comparison 
to exendin 9-39.  
6.3 GIPR transgenic mice reveal previously unknown central GIPR localisation 
The GIPR is particularly interesting due to it’s possible role in the control of obesity which has been 
postulated from a range of studies in both mice and humans [182, 185, 328]. Prior to this study, the 
limited availability of GIPR antibodies meant that the majority of knowledge surrounding GIPR location 
was from early studies using in situ hybridisation and radioligand binding with low resolution [149, 
161]. Here, in chapter 4, a new transgenic mouse model expressing fluorescent reporters downstream 
of the Gipr promoter was used to identify cells expressing the GIPR. This led to a more detailed 
description of GIPR location, particularly with regards to central expression of the GIPR. 
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The technique of using transgenic mouse models to label cells of interest has been used widely within 
the Gribble/Reimann lab, with focus on characterising either enteroendocrine cells [81] or cells 
expressing receptors for enteroendocrine hormones [93]. The GIPR transgenic mouse line can be 
directly compared with a GLP1R transgenic model previously used in the lab to characterise GLP1R 
expression [93]. Another line of interest relevant for this project is the GIP-cre mouse model, it will be 
interesting to compare the expression of GIP and GIPR [337]. When comparing these expression 
patterns, the percentage cre penetrance of both lines should be taken into account. Flow cytometry 
experiments using a GIP antibody and tdRFP labelled ‘GIP’ cells showed that the GIP-cre model only 
labels 60% of GIP positive K cells in the upper small intestine [337]. Unfortunately, due to the lack of 
suitable GIPR antibodies, we have been unable to assess the degree to which the GIPR transgenic 
mouse line successfully labels GIPR positive cells, which is a limitation to this study.  
Here we have used the GIPR mouse model to assess GIPR location by immunohistochemistry, though 
this is not the only potential use of the model. The transgenic mice enable study of cells of interest 
using a variety of techniques including isolation of cells by flow cytometry followed by genomic 
analysis [399], and single-cell imaging [400, 401].  
In peripheral tissues, we found that GIPR was present in pancreatic islets and exocrine acinar tissue. 
Expression of GIPR in the acinar tissue was initially unexpected, however a role for GIP in the 
regulation of digestive enzymes from acinar tissue has been previously suggested [347, 348]. GIPR was 
also found in both white and brown adipose tissue depots, which is in line with the knowledge that 
GIPR in adipose tissue is important for storage of fats and may play a role in the regulation of HFD 
induced obesity [176, 181, 185, 351]. In the duodenum, a population of epithelial GIPR positive cells 
appeared to be enterochromaffin cells. Most of the GIPR expression was found in cells in the centre 
of the villi, which are thought to be of mesenchymal origin. GIPR was also detected in the nodose 
ganglia, where a population of cells are also GLP1R positive. It could be interesting to see if the GIPR 
positive cells in the nodose ganglia are also GLP1R positive, which could now be performed with the 
use of Glp1R0017 described in chapters 3 and 4. 
Clearly, there are still outstanding tissues for characterisation of GIPR expression or lack of. So far, 
each tissue assessed has had some form of GIPR expression, therefore it would be useful to find a 
completely GIPR negative tissue. GIPR expression in the liver is of particular interest, as the            
GIPRadipo-/- mice have decreased liver volume and fat content but the reason for this is unknown [185].  
Collaborators are also using our GIPR transgenic line to assess GIPR expression in the bones where GIP 
is thought to promote bone formation [402].   
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The most interesting results from the study of GIPR expression was the observation of GIPR in the 
hypothalamus, an area of the brain involved in the regulation of food intake. We tried to characterise 
the role of GIPR within the hypothalamus, however more investigation is required. The main 
observation was that upon activation of the GIPR positive hypothalamic cells there was a decrease in 
acute food intake of chow diet following a 10-hour day time fast. 
6.3.1 Future directions for understanding GIPR biology using GIPR transgenic mice 
The GIPR transgenic mouse model used here to label GIPR positive cells, adds to the field of GIPR 
research providing a new tool for studying GIPR localisation and the function of GIPR positive cells. As 
Gipr-Cre x Rosa26-GCamp3 mice have been bred within the lab, the techniques to study GIPR positive 
cells are not limited to immunostaining. GCamp3 is a fluorescent indicator of intracellular calcium, 
which combines calmodulin (a Ca2+ sensitive protein) with a modified GFP [293]. Combined with the 
advancements in hypothalamic neuronal culture [403], this means that the calcium responses of GIPR 
positive cells in primary neuronal cultures can be studied. This could be used in part to further 
characterise the function of hypothalamic GIPR neurons. Alternatively, rather than imaging individual 
neurons, one could utilise organotypic brain slice acute preparations or cultures [404, 405] in which 
the exact location of responding GIPR positive cells could be determined. These studies should be 
completed alongside further in vivo studies to understand the physiology of hypothalamic GIPR 
positive neurons. 
As discussed earlier in chapter 4, the GIPR transgenic mouse model used in this study relies on a 
lineage tracing approach. Although this technique circumvents the need for antibodies to describe the 
location of GIPR positive cells, GIPR antibodies would have been useful for full validation of the 
transgenic mouse line. One possibility for future development would be to use an inducible system to 
label GIPR cells. For example, Cre-ERT2 and tetracycline-inducible expression systems (‘Tet-on’) are 
currently being investigated in the lab for labelling glucagon expressing cells and insulin-like peptide 
5 expressing cells. Briefly, the Cre-ERT2 system requires the addition of tamoxifen for activation of Cre 
[406], and consequently the fluorescent reporter would only be present if cre was expressed at the 
time of tamoxifen injection. For the Tet-on system, expression of a reverse tetracycline transactivator 
(rtTA) is driven by the promoter of interest which activates tetracycline responsive elements (Tre) 
when bound to tetracycline, or doxycycline [407]. For labelling cells of interest, fluorescent reporters 
are under the control of Tre activation (e.g. Tre-GFP). Both of these methods would provide the 
advantage that the fluorescent reporters are only expressed in cells that transcribe the gene of 
interest during the time of treatment.  
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6.4 The common missense GLP2R mutation, D470N, has decreased β-arrestin binding 
The third gut hormone receptor investigated here was the GLP2R. In contrast to GLP1R and GIPR, the 
GLP2R is not an incretin hormone receptor. GLP-2 is a gut hormone, related to GLP-1 in that it is 
processed from the same proglucagon gene, and is co-released from enteroendocrine L cells alongside 
GLP-1 [384]. The main gastrointestinal function of GLP-2 appears to be the regulation of epithelial cell 
proliferation and apoptosis [202, 214]. 
As the final part of this thesis, the functional implications of a common missense GLP2R mutation, 
D470N, associated with type 2 diabetes were investigated. For this purpose, site directed mutagenesis 
was used to mutate the GLP2R expressing construct. Mammalian cell lines were then transfected with 
either WT or mutant GLP2R, and signalling was investigated. The mutant GLP2R displayed decreased 
β-arrestin binding compared to the WT receptor, however there was no difference in cAMP signalling 
or the timecourse of ERK phosphorylation. The relevance of decreased β-arrestin binding is currently 
unknown. 
6.4.1 Future directions of GLP2R research 
The major next step for the GLP2R research project is to determine whether decreased β-arrestin 
binding to the mutant GLP2R results in any differences in the time course of cAMP signalling 
downstream of receptor activation. There is good evidence in the field that GLP2R activation 
stimulates growth factor release (e.g. IGF-1) from sub-epithelial cells in the intestinal wall, which 
regulate proliferation of the epithelial cell layer [396]. Rather than searching for possible changes in 
proliferation signals directly downstream of the mutant GLP2R, one can postulate that decreased β-
arrestin binding would alter the time-course of primary cAMP signalling, which may affect growth 
factor release. In our findings there was no difference between the WT and mutant GLP2R 
accumulated cAMP response at 30 minutes, however a range of time points will now be investigated 
in more detail.  
Therapeutically, without knowing the function of decreased β-arrestin binding to the mutant GLP2R, 
it is difficult to postulate whether type 2 diabetes patients with the mutant GLP2R should be treated 
any differently to patients with a WT GLP2R. Currently there are no treatments for type 2 diabetes 
solely based on the GLP2R, though there are some indications that GLP2 is beneficial for glucose 
metabolism in an obese state [408].    
As an aside to research on the D470N GLP2R mutant, the Gribble/Reimann group could also contribute 
to the field of GLP2R research in which there is debate surrounding GLP2R location [194-200]. It would 
be particularly helpful to clarify if the GLP2R is expressed on enteric neurons or on enterochromaffin 
cells. Using the expertise within the lab a GLP2R lineage tracing transgenic mouse line, similar to the 
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Gipr-Cre model, could be generated circumventing the need to use GLP2R specific antibodies for 
studies of GLP2R location.  
6.5 Overall therapeutic implications of gut hormone research  
There has been a surge in interest surrounding gut hormone research in recent years, due to the 
success of targeting the enteroendocrine hormone GLP-1 for the treatment of type 2 diabetes [47]. 
Of increasing therapeutic interest is the use of unimolecular agonists that target multiple pathways 
simultaneously, which is in part based on the knowledge that gastric bypass surgery can cause the 
rapid resolution of type 2 diabetes [225]. It is known that this surgery does not simply alter one 
pathway, but triggers a range of physiological changes including an alteration of several gut hormones 
[231].  
A lot of these dual agonists contain a central GLP-1 component due to the success of established GLP-
1 mimetics as treatments. A variety of dual, and even triple agonists have been developed; 
unimolecular agonists targeting either 2 or 3 different pathways. Of relevance to the research carried 
out in this thesis are the GLP-1/GIP and GLP-1/GLP-2 dual peptides.  
The GLP-1/GIP dual peptide is based upon the premise that both the GLP-1 and GIP components would 
target pancreatic β-cells increasing glucose stimulated insulin secretion, meaning lower doses of the 
GLP-1 receptor ligand would be required for the same efficacy on insulin secretion. The hypothesis 
followed that these lower doses would reduce any GLP-1 gastrointestinal side effects [48]. Concerns 
were initially raised as the role of GIP in regulating weight gain is unclear, with GIPR knockout animals 
being protected from HFD induced obesity [182]. However, the GLP-1/GIP dual peptide has proved 
successful in pre-clinical models with synergistic effects on body weight reduction and insulinotropic 
effects. The GLP-1/GIP dual peptide is now in clinical trials [232]. 
The GLP-1/GLP-2 dual peptide was developed to investigate whether the beneficial effects of GLP-1 
agonism and GLP-2 agonism could be combined into a single molecule. Results show that the GLP-
1/GLP-2 dual peptide can both improve glucose tolerance and increase gut volume, suggesting that 
the novel concept of combining GLP-1 and GLP-2 agonism could be used to treat both type 2 diabetes 
and short bowel syndrome [392]. However, our data showing the GLP2R polymorphism D470N is 
associated with increased enterocyte mass and increased risk of type 2 diabetes, questions whether 
a GLP-1/GLP-2 dual peptide which increases gut volume would be useful for treatment of type 2 
diabetes.  
In the development of these unimolecular dual acting peptides, the balance of agonism is often 
important. With regards to the research performed within this thesis, Glp1R0017 could be a useful 
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tool in the development of GLP-1 containing dual agonists to determine the importance of the GLP-1 
component.  
6.6 Conclusion 
Together, the data presented in this thesis has demonstrated the applicability of biological and 
molecular tools for the characterisation of gut hormone receptors. A new antagonistic antibody 
targeting the GLP1R has been developed and characterised in depth, which is now available for use in 
collaborative projects to further understand GLP1R physiology. A new transgenic mouse model has 
been used to determine the location of cells expressing GIPR, and central GIPR expression was 
revealed which may play a role in the control of food intake. Finally, the signalling defects in a common 
missense GLP2R mutant, associated with type 2 diabetes, have been defined. It is hoped that the 
contributions made within this thesis will be helpful for further understanding gut hormone receptor 
physiology, which will be critical in the development of new therapeutics for type 2 diabetes. 
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8. Appendix 
Appendix 1 – Plasmid Map for pCantab6 
 
 
 
 
  
4.6 kB 
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Appendix 2– Primer Details 
 
Primers for V fragment cloning into 
IgG expression vectors 
 
AF16 (for VH) CTCTCCACAGGCGCGCACTCCGAGGTGCAGCTGGTGCAG 
RH100 (for VH) CGAGACGGTGACCGTGGTCCC 
AF31 (for VL) CTCTCCACAGGCGTGCACTCCCAGTCTGTGCTGACTCAGCC 
AF26 (for VL) CTATTCCTTAATTAAGTTAGATCTATTCTGACTCACCTAGGACG
GTGACCTTGGTCCCTCC 
GLP2R Cloning Primers  
GLP2R_IRESVenus_GibsonF GGAAGAGAGTGAGATCTAGCGCTGCTAGCCACCGTAC 
GLP2R_IRESVenus_GibsonR GGGTTTAAACGGGCCCTCTAGTTACTTGTACAGCTC 
GLP2R_D470N_SDM_F TGTGTCCTGGGGAAGAACTTCCGGTTCCTAG 
GLP2R_D470N_SDM_R CTAGGAACCGGAAGTTCTTCCCCAGGACACA 
GLP2R_Barr_Xho1_Rev CACCGCTCGAGGCGATCTCACTCTCTTCCAG 
GLP2R Sequencing Primers  
pCDNA3.1+_1_F GACGGATCGGGAGATCTCCC 
pCDNA3.1+_2_F GTTCCCATAGTAACGCCAATAGGG 
GLP2R_1_F GGCTCAGTACAAACAGGCATGTC 
GLP2R_2_F CGCGCAACTACATCCACATGAAC 
GLP2R_3_F GAGGACCCATGATGCTCTGTGT 
GLP2R_4_F GAAGGCTGAGCTGCGGAAATAC 
IRES_1_F gcggctagtactccggtattgc 
IRES_2_F ggctgcttatggtgacaat 
Venus_1_F ggcatcaaggccaacttcaag 
pCDNA3.1+_3 GCATCGCATTGTCTGAGTAGGTG 
pCDNA3.1+_4 CGCCCTGATAGACGGTTTTTCG 
pCDNA3.1+_5 GTCAGCAACCATAGTCCCGC 
pCDNA3.1+_6 CAGCTGTGCTCGACGTTGTCAC 
pCDNA3.1+_7 GGCCGCTTTTCTGGATTCATC 
pCDNA3.1+_8 GGGATCTCATGCTGGAGTTCTTC 
pCDNA3.1+_9 CGCAGGAAAGAACATGTGAGC 
pCDNA3.1+_10 GCGCCTTATCCGGTAACTATCG 
pCDNA3.1+_11 GTGAGGCACCTATCTCAGCGATC 
pCDNA3.1+_12 CTGAGAATAGTGTATGCGGCGAC 
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Appendix 3 – Cell Seeding Densities for cAMP HTRF Assay  
 
Cell Line  Plating density (cells/ml) Plating density (cells/well) 
Mouse GLP1R (CHO mGLP1 clone A10) 8e5 4000 
Human GLP1R (CHO K1 3xVIP c2.6GLP-1) 2e5 1000 
Rat GLP1R (CHO/Flp In rat GLP1) 16e5 8000 
Cyno GLP1R (CHO Jump In cyno GLP-1R) 2e5 1000 
Dog GLP1R (CHO dog GLP1 clone B9) 8e5 4000 
Mouse GIPR (HEK 293s mouse GIPR) 3e5 1500 
Human GIPR (CHO K1 hGIPR low 
expressing pool C3) 
4e5 2000 
Human GLP2R (HEK293s pcDNA3 
hGLP2R cB12) 
3e5 1500 
Mouse GCGR (CHO K1 Jump In mGR 5:1) 8e5 4000 
Human GCGR (CHO K1 3xVIP c2.6 hGR 
C12) 
1e5 500 
Rat GCGR (CHO K1 2.6 RGR C8) 4e5 2000 
 
 
 
 
Appendix 4 – Antibody Details  
 
  Dilution Source 
dsRed 1/1,000 – 1/500 Clontech, #632496 
GFP 1/1,000 Abcam #5450 
Insulin 1/100 Abcam, #7842 
Proglucagon 1/100 Santa Cruz, #sc-7782 
Serotonin (5-HT) 1/10,000 Immunostar, #20080 
Vimentin 1/200 Abcam, #92547 
Phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204)  
1/1,000 – 1/500 Cell Signalling, #9101 
p44/42 MAPK (Erk1/2) (137F5) 1/1,000 Cell Signalling, #4695 
B-actin 1/10,000 Abcam, #8227 
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Appendix 5 – AAV-flex-taCasp3-TEVp plasmid map  
 
 
 
Appendix 6 – AAV-hSyn-DIO-hM3D(Gq)-mCherry plasmid map  
 
 
